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Abstract 
 
Background 
Half of older people in hospital have a pre-admission medicine prescribed that is 
potentially inappropriate. Deprescribing research has historically focused on the 
primary care setting. The aim of this thesis was to develop a practitioner behaviour 
change intervention for enhancing deprescribing in the hospital setting. 
 
Methods 
Underpinned by behavioural science, the research programme comprised four 
empirical studies: evaluation of existing hospital deprescribing activity; survey of 
patients’ and carers’ attitudes towards deprescribing; focus groups with geriatricians 
and pharmacists to identify key barriers and enablers to address in an intervention; 
expert panel consensus study to select Behaviour Change techniques (BCTs) for 
the intervention. 
 
Results 
Deprescribing in hospital occurred for 0.6% of pre-admission medicines, of which 
84.1% was reactive in response to harm and 15.9% proactive to prevent harm. 
Deprescribing in hospital was acceptable to patients and carers: 97.4% and 76.3% 
respectively were willing to accept a doctor’s deprescribing proposition. 
Geriatricians and pharmacists described several existing deprescribing enablers in 
hospital including alignment with their generalist role/knowledge and routine patient 
monitoring. 
Key barriers to deprescribing were a misconception of patients’ and carers’ 
resistance to deprescribing, pharmacists’ perception that deprescribing is riskier 
than continuing to prescribe, pharmacists’ working patterns limiting capacity to 
support deprescribing and it being a low hospital priority. Introduction of incentives 
to deprescribe was an enabler. 
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Six BCTs were selected and characterised to address the key barriers and enabler: 
social comparison (two distinct characterisations); salience of consequences; pros 
and cons; restructure the physical environment; action planning. 
 
Conclusion 
There is significant scope to increase deprescribing in hospital and this is 
acceptable to patients and carers. The behavioural intervention to enhance 
geriatrician and pharmacist led deprescribing requires modelling to determine the 
optimal configuration of BCTs. Subsequent testing of the intervention is necessary 
to determine efficacy at enhancing deprescribing and impact on patient outcomes.  
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Chapter 1 Background 
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1.1 Ageing 
Advances in healthcare and improvements in living conditions have contributed to 
populations in Western countries living longer(1), with average life expectancy being 
80 years, relative to 50 years in the early 1900s(2). This trend is set to continue, 
with a rise in the proportion of people aged ≥80 years being the primary factor 
contributing to the United Kingdom’s (UK) 15% projected population increase over 
the next 25 years(3). This rise in people living into old age represents a significant 
achievement in Western medicine, but has evoked a substantial change in 
population health needs. 
The mainstay of current health problems in Western countries are non-
communicable, long-term conditions that are associated with ageing. Approximately 
15 million people in England are living with at least one long-term condition and a 
further 1.9 million are living with several, which is termed multi-morbidity(4). 
This increase in patients with multi-morbidity imposes significant resource and 
economic costs on health systems. UK survey data captured in 2009 reported 
people living with long term conditions accounted for 50% of general practitioner 
(GP) consultations, 64% of outpatient appointments and 70% of hospital bed 
days(4). Similar data have been reported in the United States of America (USA), 
which associated the number of morbidities a patient has with the degree of 
healthcare recourse utilisation(5). Unsurprisingly given the acknowledged 
population trends, substantial increases in demand on health systems for treating 
long-term conditions are predicted(2,6). 
Management of the majority of long-term conditions requires pharmacological 
treatment in order to alleviate symptoms and/or halt disease progression(7,8). It is 
therefore unsurprising that older people are the population in receipt of the largest 
number of prescribed medicines(9). The total number of prescription items 
dispensed in England in 2016 was 1,104.2 million, equating to an average of 20.0 
items per head of population(10). The majority (61%) of medicines in England are 
prescribed for people aged 60 and over. 
 
1.2 Polypharmacy 
Polypharmacy is most frequently defined in terms of a numerical threshold for the 
number of prescribed medicines. Five or more medicines is the most widely 
reported threshold(9), however, there is variation in how it is applied with some 
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studies defining it as the use of at least three medicines, while others have reported 
it as a minimum of 10 prescribed medicines(11,12). 
An evaluation of prescribing indicates that the proportion of patients receiving 
polypharmacy, defined as ≥5 medicines, increased by almost 50% between 1995 
and 2010 to 20% of adults(13). Moreover, the proportion of patients prescribed ≥10 
medicines increased from 1.9% to 5.8%. Proportions are larger for institutionalised 
patients such as those living in care homes, with a cross-sectional study reporting 
that one third of nursing home residents are in receipt of ≥10 prescribed medicines 
(14). 
Continuing trends in population ageing are predicted to result in both an increase in 
the proportion of patients receiving polypharmacy and in the number of medicines 
prescribed per patient. Polypharmacy has been described as both a positive for it’s 
contribution to healthy ageing, and a potentially serious problem arising from the 
risks associated with concomitant use of medication(9,15). A report commissioned 
by the King’s Fund determined that polypharmacy was a “necessary evil, that for 
many patients is required to improve clinical outcomes”(9). This view accords with 
associations between polypharmacy and a reduction in some adverse outcomes 
such as hospitalisation described in the literature for patients with multi-
morbidity(16). There is a place for polypharmacy in instances where the benefits 
outweigh the risks and it is deemed appropriate. However, there is also a need to 
acknowledge and distinguish between appropriate and inappropriate polypharmacy, 
where the risks of concomitant medication use outweigh the intended benefits. 
 
1.2.1 Appropriate Polypharmacy 
Polypharmacy is ‘appropriate’ when prescribing of several medications is indicated 
and collectively, the intended benefits of each medication outweigh the risks. 
Prescribing should therefore be underpinned by evidence of benefits, achieve 
improvements in health status and sustain or improve quality of life(11,17). For 
example, the national body which publishes health and social care guidance in 
England recommends prescribing five medicines for secondary prevention of 
cardiovascular events following a myocardial infarction(18). Patients who were 
previously medication naïve are therefore prescribed a polypharmacy regimen post-
implementation of these recommendations. However, this regimen is appropriate 
and is underpinned by evidence demonstrating significant health benefits. 
4 
 
Appropriate polypharmacy requires ongoing monitoring to identify any changes in 
circumstances that indicate that some or all of the prescribed medicines are no 
longer appropriate. For example, development of a new condition such as age 
associated renal impairment should trigger a medication review(19). 
 
1.2.2 Inappropriate polypharmacy 
The intended benefits and risks offered by a medication are important 
considerations at initial prescribing and subsequent medication reviews(20,21). 
Medicines that offer an individual patient more risks than benefits, including those 
without an evidence-based indication, are inappropriate. This determination is 
specific to a patient’s individual circumstances, and considers factors such as multi-
morbidity, suitability of concomitant medication prescribing and quality of life. 
Additionally, any prescribing of more medicines than are clinically necessary is 
considered inappropriate polypharmacy, given that each additional unnecessary 
medicine brings additional risks in the absence of any additional benefits(22). 
Inappropriate polypharmacy increases the risk of iatrogenic harm, which is harm 
resulting from a healthcare intervention(23). Harms associated with inappropriate 
polypharmacy are well documented and include adverse drug events (ADEs) such 
as side effects which can lead to adverse outcomes including morbidity, 
hospitalisation and mortality(24,25). Resultant harms may also contribute to 
intentional medication non-adherence, for example a patient may choose to take 
less medication than prescribed in order to limit exposure(26). Patients may not be 
able to identify the problematic medication, and may therefore decide not to take 
some or all of their medications as prescribed, including those that are appropriate, 
which may directly lead to adverse outcomes. 
ADEs are an established and frequently preventable cause of hospitalisation. A 
prospective analysis at two UK hospitals over six months in 2011/12 evaluated 
18,820 admissions to determine the causes(27). ADEs accounted for 6.5% of all 
unplanned admissions, representing an annual cost of £466m to the National Health 
Service (NHS) in England. The average age of patients admitted with ADEs was 76 
years and significantly higher than the 66 years for patients admitted for other 
reasons. Almost three quarters of ADE admissions were categorised as possibly or 
definitely avoidable(27). Similarly, a prospective multi-centre study in the 
Netherlands reported that 5.6% of all admissions were medication related(28), of 
which 7.2% required treatment in an intensive care unit, representing significant 
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clinical and economic implications. Gastrointestinal bleeding, constipation and 
diarrhoea were the most frequently reported ADEs leading to the admission(28). 
The economic costs of preventable ADE related admissions to hospital are 
motivating factors for this healthcare setting contributing to the development and 
implementation of strategies to address inappropriate polypharmacy(29). 
 
1.2.2.1 Potentially inappropriate medicines 
Quantifying the prevalence of inappropriate medication prescribing in large-scale 
studies is challenging due to the individualised nature of a medicine being 
inappropriate for a given patient. Validated screening tools such as the Beers’ 
Criteria(30) and Screening Tool of Older Persons’ potentially inappropriate 
Prescriptions (STOPP)(31), are therefore frequently used to identify potentially 
inappropriate medicines (PIMs) in observational studies. These tools define PIMs 
based on the assumption that on the balance of probabilities, a medicine is more 
likely to be inappropriate than appropriate, usually in the older people 
population(32). However, these decisions are based on evidence of medicines 
interacting with each other or a disease state, which frequently do not represent all 
patients. Moreover, these tools are based on the assumption that the medicine is 
being used for a licensed indication, which is frequently not the case. Accordingly, 
the tools apply black and white criteria to a population of complex patients, and may 
under or over emphasise the scale of inappropriate prescribing. PIMs therefore 
need to be reviewed in the context of the individual patient to determine whether or 
not the medication is ‘actually’ inappropriate(33).  
A prospective analysis of the admission medication for patients 65 years across six 
European hospitals using the STOPP tool reported an overall PIM prevalence of 
53.3%, ranging from 34.7% to 77.3%(34). The odds of being prescribed a PIM were 
more than doubled for those prescribed six to ten medicines relative to those 
prescribed less (p<0.001). For those prescribed more than 10 medications, the odds 
of being prescribed a PIM were more than seven times greater (p<0.001). Being 
prescribed a larger number of medications was found to independently predict being 
prescribed a PIM (odds ratio (OR) for 6–10 medications: 2.31, 95% confidence 
interval (95% CI); 1.68–3.18, p<0.001; OR for>10 medications: 7.22, 95% CI 4.30–
12.12, p<0.001). Older people, as the population receiving the largest number of 
prescribed medication, are most likely to be prescribed a PIM(25,35,36). The 
aforementioned study did not measure PIM prevalence at discharge, therefore it is 
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unclear whether PIMs are reviewed for appropriate discontinuation during hospital 
admissions. A longitudinal study in an Irish primary care setting included 38,229 
patients 65 years and reported a PIM prevalence of 51.0%(37). A sub-group 
analysis revealed that an admission to hospital was associated with a 72% increase 
in the risk of being prescribed a PIM. Accordingly, older patients in hospital are at 
greater risk of being prescribed a PIM relative to non-hospitalised older patients, 
which has led to renewed calls for hospitals to prioritise addressing PIMs(38). 
 
1.2.2.2 Factors contributing to inappropriate medication use and 
resultant harms 
Several factors may contribute to a medication being inappropriate for a given 
patient; these are often age associated and progressive, and are discussed 
hereafter. 
 
1.2.2.2.1 Physiological changes with age 
Ageing is associated with reduced physiological reserve, leading to a reduction in 
the body’s pharmacokinetic and pharmacodynamic medication processing capacity 
and, through the subsequent accumulation of active compounds, a predisposition to 
ADEs(39). The main physiological changes that impact medication processing are 
summarised in table 1. 
 
Table 1 Summary of age associated physiological changes that impact medication 
processing (reproduced from ElDesoky(40)) 
Body system affected Age associated changes 
Liver Reduced organ mass, blood flow, 
albumin synthesis 
Kidney Reduced glomerular filtration rate, 
tubular function 
Gastrointestinal tract Decreased gastric acid production, 
gastric emptying rate, gut transit time, 
intestinal blood flow, absorption surface 
area, intestinal metabolism 
Circulatory Decreased cardiac output, altered 
tissue perfusion, decreased plasma 
protein binding 
General Reduced total body mass, basal 
metabolic rate, lower water 
composition, increased body fat 
7 
 
 
Two of the body systems outlined in table 1 relate to the body’s main methods for 
processing medication; the liver and kidneys. The liver is the predominant site for 
drug metabolism, which may involve activation of therapeutic metabolites, 
detoxification of harmful intermediates and production of species for elimination 
from the body(40,41). Age associated changes resulting in a decline in the liver’s 
metabolic capacity lead to incomplete activation of metabolites, limiting the potential 
benefits afforded by medication. Additionally, a reduction in capacity to produce 
eliminable metabolites increases the risks of retaining harmful intermediates, 
leading to ADEs. 
The kidneys are the predominant site for drug elimination. The number of glomeruli, 
which are the kidney’s filtration units, declines by 60% between the ages of 30 and 
90 years, leading to a substantial reduction in the kidneys’ capacity to eliminate 
drugs. Older people are therefore at increased risks of retaining harmful metabolites 
via this mechanism(19,42). 
Other age-associated changes effecting the efficacy of medication include reduced 
drug absorption across the gastrointestinal tract, reduced tissue blood perfusion and 
a change in the distribution and regulation of target receptors(41). Non-organ 
specific changes associated with age such as reduced body mass and basal 
metabolic rate render older people more sensitive to the effects of medication 
relative to younger people, and are a predisposition to ADEs such as side 
effects(40). 
Physiological changes with age lead to a net reduction in older people’s capacity to 
process medication, obtain intended benefits and avoid harms. Accordingly, as the 
trajectory of physiological decline progresses with age, a medication previously 
appropriate may become inappropriate several years later.  
 
1.2.2.2.2 Exclusion of older people from clinical trials 
Variation in medication processing between older and younger people is also an 
important consideration when interpreting data derived from clinical trials. 
Historically, upper age limits have been applied to trial participant recruitment, which 
has led to underrepresentation of older people. A retrospective analysis of oncology 
trial demographics revealed that people 65 years accounted for only 32% of study 
populations, however this demographic represents 61% of patients treated with anti-
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cancer medication(43). Similarly, a health technology assessment reporting on the 
socio-demographic exclusions from clinical trials found that people 65 years 
represented only one-fifth of statin trial participants, but form two-thirds of the 
treatment population(44). Consequently, medications approved and frequently 
prescribed for older people may not have been adequately tested for safety and 
efficacy in this population. This practice has been challenged by clinicians and there 
has been a call for trial participant populations to better reflect treatment 
populations(45). 
 
1.2.2.2.3 The prescribing cascade 
A retrospective cohort study of patients in the ambulatory care setting in the USA 
reported an ADE incidence of 50.1 per 1000 person-years(46). Distinguishing 
between ADEs and manifestations of organic disease can be challenging to both 
patients and practitioner, and there is a risk of the former being mistaken for the 
latter. ADEs that are incorrectly diagnosed as a symptom of organic disease may 
result in prescribing a new medication, leading to the ‘prescribing cascade’(47). For 
example, hyperuricaemia is a side effect of thiazide diuretics, which can lead to 
developing the painful inflammatory arthritis condition gout(48). Failure to associate 
developing gout with the prescribing of a thiazide diuretic may lead to inappropriate 
prescribing of anti-gout therapy, rather than substituting for an alternative 
diuretic(49). 
The prescribing cascade has been identified as a significant driver for inappropriate 
medication use(47). Whilst in certain circumstances prescribers may intentionally 
prescribe a medication to manage the side effect of another where no alternative 
exists, it is widely accepted that this should be done so as a last resort(47). 
 
1.2.2.2.4 Treatment guidelines 
Prescribing is frequently informed by treatment guidelines, which are designed to 
ensure that prescribing is underpinned by quality scientific evidence(50). Treatment 
guidelines are clearly beneficial in facilitating evidence-based prescribing within 
therapeutic areas, however their utility in prescribing for older people with multi-
morbidity has been questioned(50). Treatment guidelines are largely disease 
specific and offer little direction for practitioners regarding prescribing in the 
presence of multi-morbidity(51). A recent review applied treatment guidelines by the 
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national body which publishes health and social care guidance in England to a 
hypothetical older patient with multi-morbidity(52). The review found that the 
majority of guidelines recommended initiating several medications, increasing 
medication regimen complexity. None of the guidelines discussed when dose 
reduction or medication discontinuation was likely to be necessary, nor the 
approaches to safely implement them. A study examining nine of the most 
frequently utilised treatment guidelines in the USA reported similar findings(50). 
Whilst four treatment guidelines did consider prescribing in the presence of multi-
morbidity, two of these were morbidities very closely related to the treatment 
guideline’s therapeutic area, such as diabetes and cardiovascular disease(50). 
 
1.3 Medicines optimisation 
Rising financial pressures and limited health system resources have led to calls to 
maximise resource utilisation through minimising avoidable expenditure such as 
inappropriate medication use and resultant harms(53). ‘Medicines optimisation’ 
guidance was developed by the Royal Pharmaceutical Society in 2013 in 
collaboration with NHS England, the Royal College of General Practitioners, the 
Royal College of Nursing, the Association of British Pharmaceutical Industry and the 
Academy of Medical Royal Colleges(7). Medicines optimisation was defined as 
“ensuring that the right patients get the right choice of medicine, at the right time” to 
“improve their outcomes; take their medicines correctly; avoid taking unnecessary 
medicines; reduce wastage of medicines; and improve medicines safety” (7). 
Medicines optimisation acknowledges the value of the safe use of medication whilst 
indicating a need to develop strategies to identify and minimise unsafe use. 
Emphasis is placed on evaluating the appropriateness of prescribed medication 
over time to identify circumstances indicating that discontinuation is necessary. The 
four principles of patient-centred medicines optimisation are provided in figure 1(7). 
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Figure 1 Summary of the four principles of medicines optimisation (adapted from the 
Royal Pharmaceutical Society’s Medicines Optimisation guidance(7)) 
 
The need to address inappropriate medication use aligns with all four principles. 
The use of a medication may be unjustified if a patient experiences side effects that 
have a serious impact on their quality of life (principle 1), information regarding the 
efficacy and safety of a medication may be unavailable for the given patient 
population (principles 2 and 3). As the risks and potential benefits of medication 
change with time, healthcare practitioners should routinely review the 
appropriateness of medication regimens (principle 4). Moreover, principle 4 
recognises that medicines optimisation is not yet embedded into routine practices, 
and that strategies for successful and sustained implementation are required. 
Strategies to support adoption of medicines optimisation have been developed, 
which promote individualised and patient-centred prescribing of medication. 
Practitioners are encouraged to explore patients’ health goals and priorities to 
inform decision making(11,54,55). In 2016, the national body which publishes health 
and social care guidance in England produced guidance for treating patients with 
co-morbidities. This guidance encourages practitioners to consider multi-morbidity 
when tailoring care, including prescribing and reviewing medication(56). 
In the context of high PIM prevalence for older people and the resultant harms and 
financial implications, the medicines optimisation initiative endeavours to ensure 
that medication use is safe, provides benefits that outweigh risks and is aligned with 
1. Understand the patient's 
experience
2. Evidence based choice 
of medicines
4. Make medicines 
optimisation routine 
practice
3. Ensure medicines use is 
as safe as possible
Patient-centred 
approach
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patients’ wishes. A key component of medicines optimisation is identifying 
medications that are inappropriate and developing strategies for appropriate 
discontinuation. 
 
1.4 Deprescribing 
The term ‘deprescribing’ refers to the process of discontinuing inappropriate 
medication to prevent harm and improve health outcomes(25). Deprescribing was 
first defined by Woodward in 2003 as “reviewing all current medications, identifying 
medications to be ceased, substituted or reduced, planning a deprescribing regimen 
in partnership with the patient and frequently reviewing and supporting the 
patient”(25). Woodward suggested that deprescribing could prevent ADEs and 
medication related hospitalisations and, improve patients’ adherence to remaining 
medication. Woodward acknowledged that evidence to support these predictions 
was sparse and therefore called for empirical deprescribing research(25). 
Since Woodward first introduced the term, several further deprescribing definitions 
have emerged, which has led to calls for an agreed definition, to facilitate 
transferability and synthesis of research findings(57). A 2015 systematic review by 
Reeve et al. included 89 articles, of which 37 provided a unique definition for 
deprescribing. The following eight characteristics themes were synthesised from the 
37 definitions(57): 
• Use of the term stop/cease/discontinue/withdraw/remove or other 
synonyms. 
• A description of the type of medication to be ceased (e.g. long term, 
inappropriate medications). 
• Uses the term ‘process’ or ‘structured’. 
• Withdrawal is planned/ supervised/judicious. 
• Describes deprescribing as involving multiple steps. 
• Includes dose reduction and/or substitution. 
• Definition includes a goal or desired outcome of deprescribing. 
• Uses the term ‘taper’. 
 
The following definition, which incorporates five of the eight characteristics was 
proposed by Reeve et al.(57): 
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“Deprescribing is the process of withdrawal of an inappropriate medication, 
supervised by a health care professional with the goal of managing polypharmacy 
and improving outcomes.” 
The included characteristics define deprescribing as a multi-step process and the 
primary goal is to reduce the risks of iatrogenic medication harm. The ‘dose 
reduction and/or substitution’ characteristic was excluded as the authors felt this 
was more strongly associated with ‘optimal prescribing’, whilst deprescribing was 
thought to be the complete withdrawal of a medicine. Excluding the ‘taper’ 
characteristic was considered necessary because medication discontinuation does 
not always require gradual withdrawal. It was deemed unnecessary to include the 
‘involving multiple steps’ characteristic, since this concept was already captured by 
including the ‘process’ characteristic(57). Limitations of the study and resultant 
definition were noted, including later publication of further relevant articles and 
inclusion of research published by the authors themselves. Nonetheless, the 
definition proposed by Reeve et al. is the first and only deprescribing definition 
underpinned by the existing literature. 
Subsequent to Reeve et al.’s synthesised definition, Scott et al. later defined 
deprescribing as the “…systematic process of identifying and discontinuing drugs in 
instances in which existing or potential harms outweigh existing or potential benefits 
within the context of an individual patient’s care goals, current level of functioning, 
life expectancy, values, and preferences”(58). The important element of this 
sentence is the separation between ‘existing and potential harms’. Deprescribing 
may therefore be ‘reactive’ in response to an existing harm, or ‘proactive’ where the 
risk of harm may no longer be outweighed by the potential benefits. 
Whilst deprescribing is a relatively novel term, advocating identification and 
discontinuation of inappropriate medication has long been a component of good 
prescribing practice. The principles of prescribing and discontinuing medication are 
analogous and both are underpinned by an assessment of risks and potential 
benefits(59). The professional body for medical practitioners in the UK mandates 
doctors to monitor and review medication and consider the needs of individual 
patients and the risks posed by their medication. Regular review should be 
undertaken to establish whether a medication is required, effective and 
tolerated(20). Accordingly, whilst there is an expectation that deprescribing should 
form part of current prescribing practice, the aforementioned high PIM prevalence 
suggest that there may be scope to increase this activity in the hospital setting(34). 
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1.4.1 A model for deprescribing 
Reeve et al. sought to develop a model for deprescribing, underpinned by the 
existing literature, which would break the process down into individual stages. A 
literature search identified 10 articles characterising deprescribing processes, which 
informed the development of a model comprising of five sequential deprescribing 
activities (figure 2). 
 
 
Figure 2 Deprescribing model (adapted from Reeve et al.(60)) 
 
Given that inappropriate medication use is prevalent across the primary care, care 
home and hospital settings, deprescribing opportunities should be acted on when 
they present across all healthcare settings. The challenges and potential solutions 
to routine deprescribing across these settings will vary according to contextual 
factors, such as resource availability and practitioners’ knowledge and skills. 
 
1.4.2 Deprescribing priorities 
Determining which medications require deprescribing depends on individual patient 
circumstances. A ‘one size fits all’ list of medications to deprescribe is therefore 
1. Comprehensive 
medication history
2. Identify potentially 
inappropriate medicines
3. Determine if 
medicines can be 
ceased and 
prioritisation
4. Plan and initiate 
withdrawal
5. Monitoring, support 
and documentation
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neither feasible nor helpful. However, clear therapeutic areas have been identified 
as appropriate foci for deprescribing because they are thought to be associated with 
most medication-related harms, and are not routinely deprescribed. In 2015, an 
expert panel of pharmacists, medical practitioners, nurses and social scientists 
participated in a modified Delphi process to specify which medication classes 
should be prioritised for deprescribing in older people(61). The group prioritised and 
ranked 14 commonly prescribed medicines and medication classes for 
deprescribing (table 2). Medication to treat mental health, cardiovascular, 
gastrointestinal and neurological conditions were most strongly represented in the 
ranking, however the 14 medicines/medication classes span the majority of 
therapeutic areas, suggesting generalist knowledge and skills may be required to 
provide holistic deprescribing for older people. 
 
Table 2 Ranked medication classes prioritised for deprescribing for older people 
(reproduced from Farrell et al.(61)) 
Rank Medication class 
1 Benzodiazepines 
2 Atypical antipsychotics 
3 Statins 
4 Tricyclic antidepressants 
5 Proton-pump inhibitors 
6 Urinary anticholinergics 
7 Typical antipsychotics 
8 Cholinesterase inhibitors 
9 Opioids 
10 Selective serotonin reuptake inhibitors 
11 Bisphosphonates 
12 Anticonvulsants 
13 Beta-blockers 
14 Antiplatelets 
 
1.4.3 Resources developed to support deprescribing 
Given the relative novelty of deprescribing as a research and practice priority and 
the complex nature of evaluating the risks and benefits of medication in older 
people, it is unsurprising that several resources to support practitioners to 
deprescribe have emerged. 
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1.4.3.1 Deprescribing tools 
Tools to support practitioners to identify PIMs and thus potential deprescribing 
opportunities were briefly discussed earlier in this chapter. These tools therefore 
support point two of Reeve et al.’s deprescribing model(60): identify potentially 
inappropriate medicines. 
A 2018 systematic review identified 15 tools to support identification of 
deprescribing opportunities in frail older people(62). Reporting of how tools were 
developed was found to be inconsistent and generally poor. However, the majority 
of tools were lists of medication which were thought to be PIMs based on the expert 
opinion of doctors, pharmacists and researchers. Only four tools had been tested in 
the trial environment in prospective studies and none had been tested in definitive 
high-quality trials such as a randomised controlled trial (RCT). The majority of tools 
(n=9) list medicines which are considered PIMs if patients fall into certain categories 
such as confounding morbidity. Examples of these tools include the Screening Tool 
of Older Persons Prescriptions in Frail adults with limited life expectancy 
(STOPPFrail)(63) and, the List of Evidence-Based Deprescribing for Chronic 
Patients (LESS-CHRON)(64). Four medication specific tools were identified which 
provide practitioners with criteria and guidance on how to deprescribe certain 
classes of medicines such as antihyperglycemic agents(65) and proton pump 
inhibitors(66). A further two tools were identified which provide guiding principles for 
practitioners to follow when reviewing medication for opportunities to deprescribe. 
One model developed by Holmes et al. proposes four considerations when 
determining whether to deprescribe; remaining life expectancy; likely duration until 
intended benefits; goals of care; and treatment targets(67). 
The systematic review focussed on deprescribing for frail older people and therefore 
did not capture tools that may be available for deprescribing for older people who 
are not frail. Several other medication lists are available that have been extensively 
utilised in high quality RCTs(68), which were not captured including the Fit fOR The 
Aged (FORTA)(69) criteria and the aforementioned Beers criteria(30) and STOPP 
tool(31). A narrative review published in 2015 identified a further seven 
deprescribing models(70); ‘Geriatric medication evaluation algorithm’, ‘The good 
palliative-geriatric algorithm’, ‘Prescribing optimisation method’, ‘Assess, review, 
minimise, optimise, reassess’, ‘Geriatric Risk Assessment MedGuide’, ‘Medication 
algorithms for reducing polypharmacy in mental health’, and ‘Confirm, estimate, 
assess, sort, eliminate’. These tools are similar in format and content to the 
aforementioned for frail older people(62). 
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Similar to deprescribing guidelines, these tools focus on providing information 
regarding what practitioners should do, such as deprescribe a certain medication for 
a certain group of patients. However, they do not support routine implementation in 
practice by addressing the range of likely barriers and enablers to deprescribing. 
 
1.4.3.2 Deprescribing guidelines 
Several evidence-based guidelines have been developed targeting some of the 
medication classes prioritised for deprescribing in older people(61). The guidelines 
provide practitioners with useful information and decision support regarding when 
and how to deprescribe these medicines. Initial work has focussed on the 
medication classes which were deemed of highest priority, including 
benzodiazepines(71), antipsychotics(72) and proton pump inhibitors(66). These 
guidelines support point four of Reeve et al.’s deprescribing model(60): plan and 
initiate withdrawal. 
An evaluation of the impact of the three deprescribing guidelines on practitioners’ 
deprescribing behaviour was undertaken using a self-efficacy survey. Overall self-
efficacy scores significantly increased for antipsychotic deprescribing (p=0.04) but 
not for proton pump inhibitors and benzodiazepines, suggesting guidelines providing 
knowledge regarding when and how to deprescribe do not address all challenges 
faced by practitioners. This is an important consideration given that the 
deprescribing guidelines take eight months and a year to develop at a cost of 
C$80,000 and C$100,000(73). 
 
1.4.4 Risks of deprescribing 
There is potential for deprescribing to lead to significant improvements in health 
outcomes by preventing harms associated with inappropriate medication. However, 
deprescribing itself is not free from theoretical potential harm, and it is important to 
consider the potential adverse outcomes(74). Both practitioners and patients will 
need to consider the risks and potential benefits of deprescribing within the wider 
clinical context at points three and five of Reeve et al.’s deprescribing model(60): 
determine if medicines can be ceased and prioritisation and monitor, support and 
documentation respectively. 
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1.4.4.1 Adverse drug withdrawal events 
A harmful physiological response to medication withdrawal is termed an adverse 
drug withdrawal event (ADWE) and may present as a return of disease, symptom or 
both. Deprescribing may precipitate ADWEs and this can be difficult to predict and 
mitigate. A retrospective analysis of medication withdrawal in domiciliary older 
people in the USA reported a 26% incidence of ADWEs, and the majority were 
exacerbation of an underlying condition(75). Approximately a third of ADWEs 
resulted in increased healthcare utilisation such as hospitalisation. Similar ADWE 
incidences have been reported from retrospective analyses of medication 
withdrawals in care homes(75). 
Whilst it appears that in most instances medication withdrawal is safe, vigilance is 
required to manage the risks of ADWE precipitation. The aforementioned analyses 
of medication withdrawal and associated ADWEs did not actively seek to include 
medication withdrawal resulting from structured, patient-centred deprescribing as 
has been characterised in this thesis(60). Accordingly, analyses of deprescribing 
trials may produce different findings and are discussed later in this chapter. 
 
1.4.4.2 Pharmacokinetic and pharmacodynamic changes 
Medication withdrawal may alter the pharmacokinetic and pharmacodynamic 
processing of remaining medication in a patient’s regimen. A prospective analysis of 
hospitalised patients concomitantly prescribed potassium sparing and potassium 
decreasing medications evaluated the effect of discontinuing of one of these 
medicines(76). Withdrawal of potassium sparing medication resulted in a decrease 
in serum potassium in 70% of patients, and withdrawal of potassium decreasing 
medication resulted in an increase in serum potassium for 59% of patients. Only a 
small minority of cases represented a change in serum potassium that was deemed 
clinically significant, with 17% of patients developing hypokalaemia and 3.2% 
hyperkalaemia respectively. 
Akin to managing ADWEs, careful planning of deprescribing to manage the risks of 
adverse pharmacokinetic and pharmacodynamic changes is necessary. Hospital 
provides a conducive environment to managing these risks, given that physiological 
and biochemical monitoring is routine practice in this setting. 
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1.4.4.3 Medical condition relapse 
The absence of symptoms indicates that either a medication is working as intended 
or the condition may have resolved. Therefore, a trial of medication withdrawal in a 
controlled and monitored environment is necessary to monitor for symptom relapse. 
A systematic review of medication-specific withdrawal trials included people 65 
years and found variation in incidences of condition relapse(39). Only a small 
number of medication classes were represented, primarily anti-hypertensives, 
benzodiazepines and psychotropic medicines. Up to 85% of patients who had anti-
hypertensive medication withdrawn were normotensive for between six months and 
five years with no increase in mortality. Whilst there is some evidence to suggest 
that certain classes of medication can be withdrawn in the majority of older people 
without condition relapse, evidence is lacking for the majority of medicine classes. 
Accordingly, there is a need to monitor closely for a return of the medical condition 
and agree a strategy for represcribing where necessary. 
Deprescribing of preventative medication may be more challenging than for 
medication prescribed to treat a condition because there are no short-term 
symptoms for which to monitor after medication withdrawal, however a long-term 
increase in mortality post-deprescribing is a possibility. It is therefore important for 
practitioners, patients and carers to work together to identify medication offering 
greater risks than potential benefits and, agree whether or not to agree to 
deprescribe(74). A preventative medication may on the balance of probabilities 
prolong life, however if it adversely affects quality of life, a collaborative decision to 
deprescribe may be taken. 
 
1.4.5 Safety and efficacy of deprescribing 
Prior to implementing any new practice, there is a need to ensure that the potential 
benefits outweigh the risks of iatrogenic harm(77). The primary potential benefit of 
deprescribing is avoidance of harm associated with inappropriate medication, such 
as a reduction in ADEs and thus improvement in quality of life(25,58,78,79). 
Deprescribing may also reduce medication burden, which is more than simply the 
number of medicines in a patient’s regimen, and in addition to ADEs, also 
encompasses other medication-related factors burdening patients such as(80): 
• Practical challenges of taking medication (e.g. opening packaging). 
• Social burden associated with stigmatisation of being prescribed medication. 
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• Medication taking activities interfering with day-to-day life (e.g. multiple daily 
dosing). 
• Receipt of conflicting information and information overload regarding 
medication. 
• Medication being a constant reminder of a patient’s ill health. 
 
Validated tools are available to measure medication burden such as the Living with 
Medicines Questionnaire (LMQ), which may be useful in the trial setting to evaluate 
the effect of deprescribing on medication burden(81). 
The potential benefits of deprescribing must however be weighed up against the 
risks. There is a need to review the existing literature to evaluate the likely safety of 
deprescribing, and identify any evidence supporting the potential benefits that have 
been widely proposed(82). 
A 2016 systematic review and meta-analysis evaluated the effects of interventions 
to deprescribe long-term medications for older people on mortality across 
healthcare settings(83). One hundred and sixteen studies including 17,428 
participants were identified, across 56 RCTs, 22 non-randomised controlled trials 
and 37 uncontrolled trials. The mean participant age was 74 years and 51.8% were 
male. One hundred and three studies were undertaken in primary care setting and 
14 were based in hospitals. Deprescribing interventions had no effect on mortality 
across all RCTs. However, a subgroup analysis showed that patient-specific 
interventions, which were those where investigators identified target medications to 
deprescribe and presented these to the healthcare team, resulted in a significant 
decrease in mortality (p=0.007) compared practitioner education interventions. In 
the non-randomised studies, a significant decrease in mortality was identified. 
Reassuringly, deprescribing did not produce a significant increase in ADWE 
incidence across all study types. No difference in quality of life or risk of falling was 
identified between the intervention and control groups, however people who did fall 
experienced significantly fewer falls in total. Unsurprisingly, the largest outcome 
effect observed was on the medication regime, with both a significant reduction in 
both the number of prescribed medicines (mean difference: -0.99, 95% CI: -0.183--
0.14) and the number of PIMs (mean difference -0.49, 95% CI: -0.70—0.28). 
A more recent 2018 systematic review of RCTs of interventions to deprescribe PIMs 
for older people, specifically in the hospital setting, reported variation in the 
20 
 
magnitude of deprescribing achieved(84). Study samples were relatively small, 
varying from 114 to 409 participants. Of the nine studies included, seven favoured 
the deprescribing intervention and the remainder found no significant difference 
between the intervention and usual care. Of the seven studies favouring the 
intervention, six reported an average PIM reduction of ≤1 between admission and 
discharge. 
Given that over half of older patients admitted to hospital are prescribed at least one 
PIM and over a quarter are prescribed several PIMs(34,85), deprescribing on 
average less than 1 PIM is unlikely to be of clinical relevance(84). The remaining 
study was an 11 month RCT (n=172 patients) testing the effects of a pharmacist-led 
medication review intervention using an adapted version of the STOPP(31) criteria 
on geriatric wards at a large teaching hospital in Belgium. Pharmacists then 
provided deprescribing opportunities to doctors, who used their discretion to accept 
or reject the recommendations. A median additional discontinuation of one PIM was 
reported in the intervention arm between admission and discharge compared with 
the control(86). However, limitations included over half of patients refusing 
participation or being ineligible, limited follow-up of patients after discharge to 
explore whether deprescribing was sustained and other important outcomes such 
as readmission rates were not measured. 
Secondary clinical outcomes were also captured in the systematic review(84). For 
all clinical outcomes, the deprescribing intervention was either comparable to or 
more favourable than the control. Two studies compared the incidence of ADEs 
between the intervention and control group, with one reporting no difference(87) and 
one reporting a significant reduction in ADEs in the intervention group(88). Health-
related quality of life was assessed in two studies, with one reporting no difference 
between groups at six months(89) and one reporting a statistically significant 
improvement in the intervention group(86). Deprescribing interventions were not 
associated with a difference in mortality in the three studies reporting this 
outcome(86,90,91). Similarly, all four studies comparing readmission rates between 
intervention and control groups reported no difference(86,90–92). Of the four 
studies reporting the incidence of falls(86,91,93,94), deprescribing was associated 
with a statistically significant reduction in falls in one study(93). Functional status 
captured using the Barthel index, a validated measure of disability(95), was 
assessed in two studies(93,94), with a significant improvement in function reported 
at discharge in the deprescribing intervention group(94). 
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There is some evidence to suggest that the process of deprescribing in hospital may 
be feasible and that it has not been associated with negative clinical outcomes, and 
in certain circumstances an association with positive clinical outcomes has been 
reported(84). Caution should be applied when interpreting these results given the 
small sample sizes concerned, and studies were not powered to evaluate the 
impact of deprescribing interventions on secondary clinical outcomes. Moreover, the 
trials and participation within them provided the incentive to deprescribe, it is 
therefore not known whether any increase in deprescribing behaviour by 
practitioners was maintained post trial discontinuation or what the long-term effects 
were. 
Designing interventions that sustainably change behaviour requires an 
understanding of the barriers and enablers to the behaviour within the usual, non-
trial environment(96,97). There has been no comprehensive consideration of the 
barriers and enablers to deprescribing in hospital reported for the development of 
interventions(84). Failure to design interventions to overcome the barriers and 
enablers to deprescribing from the perspective of key stakeholders may provide 
some explanation for the limited efficacy reported within evidence syntheses(83,84). 
 
1.4.6 Patient and carers views on deprescribing 
Analogous to prescribing, deprescribing is a patient-centred process(60). A 2013 
systematic review by Reeve et al. synthesised patients’ barriers and enablers to 
deprescribing(98). Of the 21 studies identified, 13 were qualitative, seven mixed-
methods and one study was a quantitative survey. All but one study focused on 
patients’ views regarding the withdrawal of single medications or medication 
classes, such as hypnotics or antidepressants. However, a more recent qualitative 
study explored patients’ views towards deprescribing of non-medication specific 
polypharmacy and reported views indicative of those captured in Reeve et al.’s 
systematic review (table 3)(99). Accordingly, the barriers and enablers from the 
patient perspective are similar regardless of the medication that is being 
deprescribed. Further research on this topic is not therefore a priority as there is 
already a large body of literature with findings transferable to the context of 
deprescribing in polypharmacy. 
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Table 3 Summary of patient barriers and enablers to deprescribing (adapted from 
Reeve et al.(98)) 
Barriers Enablers 
Beliefs regarding future benefits 
associated with continuation of a 
medicine 
Lack of perceived ongoing need for the 
medicines 
Scepticism about the reasons for 
deprescribing 
Lack of perceived effectiveness of the 
medicines 
Lack of confidence in the prescriber’s 
knowledge of how to deprescribe 
Experience of side effects 
Concerns about insufficient guidance 
on how to discontinue medicines 
Practitioner initiated the discussion 
Fear of withdrawal reactions Fear of addiction 
Fear of relapse Discontinuation trial to test the 
medicine’s ongoing effectiveness 
 Provision to enable return to the original 
medicine if the discontinuation trial is 
unsuccessful 
 Dislike of taking medicines 
 Inconvenience associated with taking 
medicines 
 
1.4.6.1 Patient barriers to deprescribing 
Disagreement with the appropriateness of deprescribing may relate to patients 
perceiving that the medication concerned is necessary and will provide future 
benefits(98). Interestingly, fear of missing out on future benefits has been expressed 
by patients despite acknowledging no tangible benefits. Similar reports from carers 
such as family members have also been captured. For example, in one qualitative 
study carers expressed resistance to deprescribing of medication intended to treat 
the symptoms of dementia, despite acknowledging that the medication had not 
yielded benefits for several years(100). Furthermore, some patients report feeling 
psychological benefits from the act of taking several medication, perceiving this as a 
health promoting behaviour(101,102). Patients have also provided their 
perspectives on the appropriateness of different healthcare practitioners’ roles in 
deprescribing. A qualitative study reported patients’ lack of confidence in GPs to 
deprescribe certain specialist medication such as antiepileptic agents(103). This is 
supported by another qualitative study which found patients’ prefer specialists to 
deprescribe medication if the initial prescribing was by a specialist(104). 
Patient barriers to the process of deprescribing related primarily to the perception 
that practitioners have limited time available to support them(98). Several studies 
report patients describing the time allocated in consultations to review medication as 
23 
 
insufficient and, there being anxiety regarding inadequate time invested in ongoing 
monitoring and support. 
A further barrier expressed by patients is feeling compelled to adhere to medication 
taking by carers and practitioners, which negatively influenced any attempts to 
proactively propose deprescribing of suspected inappropriate mediation(98). This 
has been confounded by practitioners’ continued issuing of repeat medication 
prescription endorsing these expectations. 
Unsurprisingly, a previous negative experience following medication withdrawal has 
been associated with discontent to consider future deprescribing propositions. A 
qualitative study exploring patient experiences of discontinuing antidepressant 
medication cited experiences of withdrawal events are likely to heavily influence 
future decisions(105). Similarly, an awareness of the potentially negative 
consequences of deprescribing is reported in most studies and principally relates to 
a fear of worsening or return of symptoms(98,105). 
 
1.4.6.2 Patient enablers to deprescribing 
A key patient reported enabler to deprescribing is that they agree with a healthcare 
practitioner decide that a medicine is no longer appropriate by recognising that the 
risks of continuing to prescribe outweigh the intended benefits(98). For example, a 
patient may arrive at this conclusion if they recognise that the symptoms for which a 
medicine was initially prescribed have now resolved, and the medicine is therefore 
no longer necessary. Paradoxically, the presence of symptoms whilst taking a 
medicine may also lead patients to consider deprescribing, due to a perceived lack 
of efficacy. 
Experiencing ADEs such as a side effect and fear of becoming dependent are 
widely reported triggers for patients to consider deprescribing(98). Patient have 
reported that a formal trial of deprescribing which maintains the option of 
represcribing provides an opportunity to review the appropriateness of deprescribing 
and is therefore an enabler. Interestingly, fear of dependence has been reported by 
patients prescribed medicines that are not routinely considered addictive, such as 
selective-serotonin reuptake inhibitor antidepressants(106). This may suggest that 
patients perceive medicines prescribed to treat certain conditions to be associated 
with addiction, and therefore is an unanticipated enabler for deprescribing which 
could be capitalised upon(98). 
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1.4.6.3 Patient willingness to consider deprescribing 
A questionnaire designed to measure patients’ attitudes towards deprescribing was 
informed by Reeve et al.’s systematic review of patient barriers and enablers to 
deprescribing(98). The Patients’ Attitudes Towards Deprescribing (PATD) 
questionnaire was developed and validated in Australia(107) and first administered 
to a sample of 100 older patients (median age 72 years) attending an outpatient 
clinic. Ninety-two percent of respondents reported willingness to consider 
deprescribing, which was found to be significantly associated with age and the 
number of prescribed medicines. The PATD has been subsequently administered in 
studies in a care homes(108) and hospitals(109,110), with similar reports of high 
willingness to consider deprescribing. 
Incongruously, over half of older people approached in deprescribing trials decline 
participation. Exploration of predictors for this lack of motivation to participate in a 
trial of deprescribing has focussed on external characteristics such as age, gender 
and number of medications. A retrospective analysis of medical records found that 
all variables analysed, including PIM prevalence, number of medicines at admission 
and comorbidities, had no effect on motivation to participate in a trial of 
deprescribing(111). This is unsurprising given that there is a substantial body of 
evidence in the field of behavioural science confirming that a key predictor of 
behaviour is attitude towards the behaviour, which is poorly predicted by external 
characteristics(112–114). Furthermore, external demographic characteristics cannot 
be changed and therefore provide limited benefit to practitioners when attempting to 
identify appropriate patients to approach. 
 
1.4.7 Healthcare practitioner views on deprescribing 
There is no research measuring existing deprescribing practice, however high 
prevalence of PIMs prescribed across healthcare settings suggests practice is not 
routine(36). Qualitative reports from primary care practitioners suggested current 
practice is likely to be limited and dominated by reactive deprescribing, in response 
to an existing harm(115). Accordingly, there remains a need to understand the 
challenges and potential solutions to deprescribing from the perspective of 
practitioners. 
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A 2014 systematic review by Anderson et al. synthesised healthcare practitioner 
views towards deprescribing and included 21 qualitative articles capturing the views 
medical practitioners exclusively, of which the majority were based in the primary 
care setting and all had prescribing privileges(116). A summary of the barriers and 
enablers from the perspective of healthcare practitioners is provided in table 4. 
Table 4 Summary of healthcare practitioner barriers and enablers to deprescribing 
(adapted from Anderson et al.(98)) 
Barriers Enablers 
Inertia because of a fear of negative 
consequences, for example litigation 
Patient receptivity to deprescribing 
Fear of a negative effect on the 
professional relationship with the 
patient 
Capacity to change prescribing 
Fear of the unknown, for example 
potential consequences of withdrawal 
Guidance on how to deprescribe 
Perceived patient ambivalence or 
resistance to change 
Quantification of the benefits and 
harms of medicines 
Lack of time to discuss and implement 
deprescribing with patients 
Confidence to deviate from prescribing 
guidelines 
Concern about undermining inter-
professional relationships 
Greater dialogue with patients to 
increase understanding and shared 
decision-making 
Lack of awareness of inappropriate 
prescribing 
Previous experience of deprescribing 
 
1.4.7.1 Healthcare practitioner barriers to deprescribing 
Practitioners require appropriate knowledge and skills in order to identify 
deprescribing opportunities and plan withdrawal and monitoring strategies, in 
partnership with patients and carers. Moreover, practitioners then need to be 
confident in their ability to apply their knowledge and skills, and a lack of confidence 
has been identified as an important barrier to deprescribing(116). 
Practitioners need to be cognisant of their prescribing practice in order to consider 
deprescribing. Barriers related to self-awareness have been reported in instances 
when the process of weighing up the risks and benefits, or the appropriateness of a 
medication, is considered difficult and/or not routine. The absence of immediate 
observable harms, uncertainty regarding whether a medication is still providing 
benefits and incomplete medication histories (e.g. indication, duration of prescribing) 
contribute to the ambiguity regarding confirming whether a PIM is an ‘actually 
inappropriate medicine’. Unsurprisingly, preventative medication such as statins to 
reduce the risk of cardiovascular events have been identified by practitioners as 
particularly challenging to deprescribe, because of the limited evidence of both 
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harms and benefits regarding their use in the older people population. The 
importance of this barrier is further supported by practitioner reports that 
deprescribing becomes easier when patients receive a poor prognosis, because 
there is no longer a need to consider long-term benefits. However, given that a 
substantial proportion of older people without a poor prognosis could benefit from 
deprescribing, there is a clear need to address this barrier(34). 
Despite high incidence of ADEs in older people(117), prescribers in some studies 
expressed that medicines are generally free of side effects(118). Interestingly, this 
was reported with reference to psychotropic medicines(119), a therapeutic group 
carrying amongst the highest risk of ADEs(46). Underestimating medication risks 
may lead prescribers to fail to recognise opportunities to deprescribe. Interestingly, 
there is some evidence to suggest that clinicians prescribing higher volumes are 
more likely to underestimate the risks of medicines relative to lower volume 
prescribers(116). 
Prescribers that identify inappropriate medicines may not necessarily proceed to 
deprescribe. This was emulated in a qualitative study of general practitioners’ (GPs) 
benzodiazepine prescribing behaviours, which reported that whilst there was 
agreement that there was frequently an identified need to deprescribe this class of 
medication, however practitioners rarely actioned the deprescribing 
opportunity(120). A potential explanation for this is that prescribers assign greater 
uncertainty to deprescribing versus continuing to prescribe for fear of unknown 
adverse outcomes(104,116). For their patients, this may be anticipation of ADWEs 
and for the prescriber, this may be increased workload and for potential litigation. 
GPs have also reported fear of conflict with peers, particularly specialists such as 
those working in the hospital setting, being a barrier to deprescribing the relevant 
medication. 
Anticipated resistance to deprescribing by key stakeholders, primarily the patient 
and carers is a consistently reported barrier to deprescribing. Practitioners report 
being fearful of harming the practitioner-patient relationship by deprescribing being 
incongruously perceived by patients as withdrawal of healthcare(116). This 
perception does not align with the aforementioned evidence-base which suggests 
that the majority of patients are willing to consider deprescribing 
propositions(108)(108–110). Some prescribers have suggested that patients 
actively expressing an interest in deprescribing and being involved in decision-
making enables deprescribing. The extent to which patients are likely to 
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demonstrate these behaviours is unknown, however there is evidence to suggest 
that older people vary significantly in their desire to be involved in decision-making, 
with some favouring a paternalistic approach(121–125). Accordingly, practitioners 
should not rely on patients actively seeking deprescribing opportunities and the 
barrier of anticipated patient and carer resistance to deprescribing requires 
addressing. 
Some practitioners may feel confident in their ability to deprescribe, however other 
factors related to the environment may prevent them from doing so. Limited 
resources to support planning, initiation and monitoring of deprescribing activities is 
frequently reported, with insufficient time being an important factor. For example, in 
the UK setting, standard GP consultations are 10 minutes, which practitioners report 
is insufficient time for decision-making with patients. This may be exacerbated by 
patients attending GP consultations with an agenda of their own, and may not wish 
to spend time within the short consultation on deprescribing(98). 
 
1.4.7.2 Healthcare practitioner enablers to deprescribing 
The enablers to deprescribing from the perspective of healthcare practitioners 
identified by Anderson et al.(98) are largely antonyms of the barriers. For example, 
practitioners who recognise that inappropriate prescribing for older people is an 
important issue are more likely to actively seek deprescribing opportunities. This is 
supported by studies testing interventions designed to raise prescriber awareness of 
PIMs using screening tools, which have demonstrated some increases in 
deprescribing activity in the hospital setting(126–128). 
Practitioners report that a key enabler is having confidence in their ability to identify 
inappropriate medication and work with patients and carers to initiate and monitor 
deprescribing. This confidence is underpinned by provision of relevant training, with 
experience in geriatric medicine being a key enabler(116). GPs without this 
experience have reported that access to a geriatric specialist and a pharmacist for 
advice improves confidence in their ability to safely deprescribe(129,130). 
Fear of the unknown and potentially adverse consequences of failing to deprescribe 
an inappropriate medication for older people are reported motivators to practitioners 
deprescribing. In turn, deprescribing is a perceived opportunity to improve patient 
outcomes and efficient health resource utilisation. 
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1.4.8 Comparison of practitioner and patient views towards 
deprescribing 
The views of practitioners (table 4) and patients (table 3) share commonality in 
terms of the barriers to deprescribing, which are largely a fear of the potential 
consequence of ADWEs. However, practitioners additionally fear the potential 
consequence of harming the practitioner-patient relationship, which has not been 
expressed by patients. 
The practitioner enabler of patient receptivity to deprescribing is complemented by 
the patient enabler of a desire for practitioners to initiate the deprescribing 
discussion. ADEs are a reported patient enabler to deprescribing which aligns with 
practitioners recognising that greater dialogue with patients enables shared-decision 
making to enable deprescribing. 
 
1.4.9 A gap in the literature regarding the barriers and enablers from 
the hospital practitioner perspective 
The Anderson et al. systematic review of practitioner barriers and enablers to 
deprescribing provides an insight into the challenges and potential solutions from 
the primary care perspective(98). However, the hospital perspective is 
underrepresented in the existing literature(98). Anderson et al. identified a single 
qualitative hospital setting study, however noted that it focused on doctors’ 
perceptions of the factors that lead to inappropriate prescribing, and not the barriers 
and enablers to deprescribing in hospital(131). Additionally, despite over half of 
existing deprescribing intervention studies undertaken in the hospital setting either 
involving or being led by pharmacists(84), no literature capturing the views of this 
professional group have been reported(116). In the UK, a core role of the hospital 
pharmacist is to generate an accurate medication history on admission, reconcile 
discrepancies and seek opportunities to optimise pharmaceutical therapy to avoid 
medication-related harms(132). The existing remit of hospital pharmacist therefore 
aligns with steps 1 (comprehensive medication history), 2 (identify potentially 
inappropriate medicines) and 3 (determine if medicines can be ceased and 
prioritised) of Reeve et al.’s deprescribing model(60). Accordingly, this professional 
group is already undertaking activities which could support deprescribing is 
therefore likely to be a key stakeholder for a hospital deprescribing intervention.  
Given that the hospital setting has been identified as a strong candidate for 
developing a deprescribing intervention, there remains a need to explore the 
29 
 
challenges to deprescribing and potential solutions that are specific to this context 
and it’s key stakeholders. Anecdotal recognition by consultant geriatricians and the 
chief pharmacist at the Norfolk and Norwich University Hospitals NHS Foundation 
Trust (NNUH) that deprescribing by hospital practitioners was insufficient, combined 
with the poverty of medical ageing research, led to the NNUH and the University of 
East Anglia jointly funding this PhD.  
 
1.5 Summary 
Population ageing and people living with multi-morbidity has led to an increase in 
prescribing polypharmacy. As people continue to age, physiological changes result 
in altered medication processing, leading to increased susceptibility to ADEs such a 
side effects and diminished benefits. Medications, which on the balance of 
probabilities offer more risks than benefits, are termed PIMs and, older people are 
at highest risk of being exposed to them. Whilst PIMs are not necessarily ‘actually 
inappropriate’ when prescribed for all patients, studies quantifying PIM prescribing 
provide an indication of the scale of inappropriate prescribing. 
Approximately half of older people admitted to hospital are prescribed at least one 
PIM and thus are potentially exposed to unnecessary risk of iatrogenic harm(34), 
leading to calls for these to be addressed through reviewing medicines to determine 
suitability for discontinuation and actually discontinuing them, a process termed 
‘deprescribing’(25,38,133). The hospital setting is a potentially conducive 
environment for deprescribing because some of the activities in Reeve et al.’s 
model (figure 1) are routine practice in hospital(60). In the UK, pharmacist-led 
medicines reconciliations (activity 1) should be completed within 24 hours of 
hospital admission(134). Physiological and biochemical monitoring (activity 5), 
which may include observing patient response to medication withdrawal, is also 
characteristic of hospital practice(132). Activities 2 to 4 require practitioners to 
collaboratively identify inappropriate medication with patients and carers and 
determine whether deprescribing is appropriate. 
The barriers and enablers to deprescribing in the hospital setting have not been 
comprehensively explored and characterised(116). Whilst some of the barriers and 
enablers reported by GPs may overlap with those of practitioners in the hospital 
setting, others may be unique to the hospital setting. GPs have stated that training 
in geriatric medicine and access to a pharmacist are both enablers. Accordingly, 
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geriatricians and pharmacists in hospital may be the appropriate practitioners to 
lead deprescribing in hospital and thus the targets of a novel intervention. 
Deprescribing has been proposed to lead to benefits including a reduction in ADEs 
and improvement in medication adherence and quality of life(25). The potential risks 
associated with deprescribing are precipitation of ADWEs such as symptom or 
condition relapse. While high quality studies investigating clinically significant 
outcomes are limited, deprescribing in hospital appears feasible, safe and has been 
associated with positive clinical outcomes in certain circumstances including a 
reduction in ADRs, improvements health-related quality of life and decreased 
incidents of falls(84). 
Patients responding to surveys have indicated that they are amenable to 
deprescribing proposed by a doctor, however qualitative data also suggests there 
are significant barriers from the patient and carer perspective; this is supported by 
reports of high numbers of patients declining participation in deprescribing trials. 
Practitioners’ views towards deprescribing have been characterised, however the 
existing literature focusses on the primary care perspective and, the challenges and 
potential solutions to deprescribing in the hospital setting are poorly understood. 
This is an important consideration given that the hospital setting is a strong 
candidate for developing a novel deprescribing intervention for older people. 
Several tools and guidelines have been developed to support practitioners to 
identify opportunities to deprescribe. The main barrier addressed by these 
resources is practitioners’ lack of confidence to deprescribe due to knowledge 
deficits. However, their implementation in isolation is likely to have limited or no 
impact unless Whilst knowledge has been reported as a barrier by primary care 
practitioners, others that are not addressed by these resources are also reported 
and likely require consideration when developing a novel intervention. Accordingly, 
implementation of the existing resources to support deprescribing in isolation is 
likely to have limited or no impact unless other barriers are overcome and enablers 
utilised effectively. 
The development of a novel hospital deprescribing intervention for older people 
targeting the behaviours of geriatricians and pharmacists will require empirical 
research to address identified gaps in the existing evidence base. There is 
conclusive evidence that PIM prescribing is prevalent in hospital. Existing 
interventions have yielded little success, and this may be attributed to little or no 
consideration of the barriers and enablers to deprescribing from the perspective of 
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healthcare practitioners. There remains a need to understand existing deprescribing 
practice in hospital in order to establish whether there is sufficient scope to justify 
developing a novel intervention. Patient and carer motivation to participate in 
deprescribing in hospital also needs to be quantified, and any predictors that may 
inform intervention development explored. The barriers and enablers of geriatricians 
and pharmacists to deprescribing in hospital require exploration to identify the 
challenges and potential solutions which an intervention to change behaviour should 
aim to address.
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Chapter 2 Development of theory based 
behaviour change interventions
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2.1 Introduction 
Chapter 1 characterised the nature, magnitude and implications of inappropriate 
medication use in the older people population and introduced the concept of 
deprescribing. An admission to hospital may provide an opportunity to identify and 
safely deprescribe inappropriate medication for older people. This could be 
achieved through the development of a novel intervention that targets the behaviour 
of healthcare practitioners and patients. 
Emphasis is placed on underpinning the early intervention development phases with 
health psychology and behaviour change theory. This methodological approach is 
adopted in order to understand what needs to change to facilitate a change in the 
desired behaviour, and to guide selection of components to include in an 
intervention that may bring about this change. Evidence syntheses have 
demonstrated that existing hospital based interventions have led to limited or no 
clinically significant and sustained implementation of deprescribing. The majority of 
these studies do not provide details of the intervention development process and, 
for those which do, it is not apparent that these have been underpinned by theory 
and/or an evidence base. The absence of robust theory informed development 
processes within the current literature may provide some explanation for the limited 
effects observed from trials of existing deprescribing interventions. 
This chapter provides an overview of historic approaches to intervention 
development and considers this in light of current guidance. Furthermore, 
theoretical approaches are considered within the context of developing a novel 
deprescribing intervention for the hospital setting. Finally, a theoretical approach to 
underpin the development of a novel hospital deprescribing intervention is selected. 
 
2.2 Behaviour change is complex 
Developing new models of care which are both effective and cost-effective are the 
intended outcomes of health services research. Translation of these new models of 
care into routine healthcare practice requires practitioners, patients and carers to 
change established patterns of behaviour(135). Problems can arise if adoption of a 
new practice is counter to established patterns of behavioural and/or 
professional/personal norms, which can lead to disparity between recognised best 
practice and the care received by patients. Failure to implement new models of care 
is a long standing and well established problem, which has led to a ‘translational 
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gap’ between the evidence base and realities of healthcare practice(136). Results 
from studies conducted in the United States of America (USA) and the Netherlands 
suggest that between 30% to 40% of patients do not receive evidence-based 
healthcare and 20% to 25% receive unnecessary or harmful care(137). 
Interventions to promote adoption of new models of care frequently only focus on 
either the healthcare practitioner or the patient, and do not consider all elements 
which may affect the behaviours of those involved. Why and how humans behave is 
a result of several influencing and interacting factors, all of which require 
consideration when developing an intervention to change behaviour(138). 
To date there is limited evidence for the effectiveness of interventions targeting 
deprescribing of inappropriate medication for older people in the hospital 
setting(84). The focus is frequently on pharmacists performing the initial medication 
review to identify inappropriate medication, there are often implicit assumptions that 
they have the required knowledge and skills to perform this and, that they are 
adequately incentivised to spend sufficient time undertaking the review and 
implementing their recommendations. The behaviour of the doctor in response to 
the pharmacist’s recommendation to deprescribe is often not considered, similarly 
neither is that of the patient or carer. The reviews are frequently performed 
assuming that the patient is adherent to their medicines and that requisite 
monitoring will be undertaken after discharge. 
A 2018 systematic review sought to deconstruct existing deprescribing interventions 
and identify the individual components that were included to bring about the desired 
behaviour change(139). In accordance with previous evidence syntheses(84), 
effectiveness of hospital based deprescribing interventions was negligible. The 
authors reported poor descriptions of intervention content across all included 
studies, which presented significant challenges to understanding intervention 
content. For the five hospital based interventions which were deconstructed, nine 
components were identified. Providing practitioners with feedback on their 
behaviour, social support, providing instructions on how to deprescribe and 
communication from a credible source were the components most frequently 
included. The majority of interventions contained only two components and 
focussed on a single practitioner group such as the doctor. Given the complexity of 
deprescribing and the plethora of barriers and facilitators from the practitioner, 
patient and carer perspectives(98,116), it is unsurprising that these interventions are 
not effective. This reflects limited consideration of the factors necessary to bring 
about change in the development of existing hospital deprescribing interventions. 
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Unfortunately, due to the small sample sizes and heterogeneity between studies, 
definitive associations between the nine components with either intervention 
success or failure could not be explored(139,140). This limits the utility of the 
existing deprescribing literature in informing the development of novel hospital 
interventions because it is not possible to learn from the successes and failures of 
the past. 
There is a need for the development of a novel hospital deprescribing intervention 
which seeks to change behaviour through overcoming the barriers and enablers 
from the perspectives of practitioner, patients and carers. Prior to embarking on this 
task, an understanding of how interventions to change behaviour are developed and 
operationalised and, identification of a suitable methodological approach for 
application to the present context, is necessary. 
 
2.2.1 Behaviour change interventions 
Behaviour change interventions (BCIs) are widely used to promote adoption of 
desired behaviours by individuals and organisations, including changing practice in 
the healthcare context(141). The National Institute for Health and Care Excellence 
(NICE) describe BCIs as having “enormous potential to alter current patterns of 
disease”(141), because they target the key barriers and facilitators, or determinants, 
of behaviour(142). BCIs were described by Collins et al.(143) as an “aggregation of 
a set of components, which may include behaviours, behaviour parameters (‘dose’ 
and ‘frequency’) and the specified mode of delivery”(144). The granular components 
of BCIs are the ‘active ingredients’ and whilst these are key to intervention success, 
they can be challenging to define and are traditionally poorly reported in BCI 
evaluations(144). Akin to the behaviours which BCIs aim to change, they are 
themselves regarded as ‘complex interventions’ owing to multiple interacting 
components, number and difficulty of behaviours involved, number of target groups 
or organisation levels, number and variability of outcomes and the degree of 
flexibility or tailoring permitted in practice(96). 
 
2.2.2 Historic approaches to behaviour change 
Historic approaches to implementing new practices have followed a ‘trial and error’ 
approach which was empirically driven and researcher-led(141,145). There was 
also the absence of clear rationale for the methodological approaches used during 
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the design process, including selection of intervention components(145). This has 
led to limited understanding of the anticipated mechanisms of behaviour change 
and, is a proposed source of intervention failure(146). Moreover, ambiguity 
surrounding how interventions are theorised to bring about behaviour change 
renders negative results unhelpful, as there is limited scope to explore, learn and 
progress from an ineffective intervention. This restricts opportunities to identify 
factors predictive of successful implementation of a new practice and improve 
strategies to change behaviour(146) 
A 2004 Health Technology Assessment systematic review assessed the 
effectiveness and efficiency of approaches to changing healthcare practitioners’ 
behaviour(147). The majority of included studies involved the provision of education 
only and yielded modest to moderate changes in practice. Responses to an 
associated survey administered to policy makers revealed that respondents felt 
interventions comprising of the provision of education only to address knowledge 
gaps were feasible(147). Accordingly, the limited reported effectiveness of early 
BCIs is unsurprising given that in the majority of cases, only one of the likely several 
determinants of behaviour, such as knowledge, were being targeted(147). Similarly, 
a more recent overview of systematic reviews by O’Brien et al. identified and 
appraised BCIs targeting healthcare practitioners(138). A plethora of interventions 
and behaviours were identified alongside varying degrees of effectiveness. In 
accordance with previous reports, evidence was weak for behaviour change 
resulting from passive dissemination of education and recommendations(147), while 
educational outreach and reminders demonstrated greater success(138). BCIs 
targeting multiple determinants of behaviour were more effective than single-
determinant interventions(138). O’Brien et al. also stressed the importance of 
considering the influence of environments in which interventions are implemented, 
because interventions appear to work in some settings and not in others(138). 
Accordingly, the context to which the planned implementation of an intervention 
relates, requires careful consideration when developing BCIs. 
The aforementioned Health Technology Assessment called for the development of a 
“…coherent theoretical framework of health professional and organisational 
behaviour and behaviour change to inform better choice of interventions…”(147). 
Notwithstanding, the challenges associated with changing behaviour are not to be 
underestimated and as aptly put by Haynes et al., there are “no magic bullets” to 
developing interventions to improve healthcare practitioners’ practice(148). 
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2.3 Using theory to underpin Behaviour Change Interventions 
The Medical Research Council (MRC) published guidance on the development and 
evaluation of complex interventions to improve health in 2000(144), later updated in 
2008(96) to reflect accumulation of knowledge and experience. The 2008 update 
sought to address limitations identified in its predecessor, including divergence from 
a linear model of intervention development mirroring the phases of drug 
development and evaluation. The updated guidance places increased emphasis on 
early phase development, particularly the application of theory and recognition that 
complex interventions require tailoring to individual contexts. The resultant 
framework provides guidance for the development and evaluation of healthcare 
interventions for use by researchers and policymakers, surmised in figure 3. 
 
Figure 3 Key steps of the Medical Research Council guidance on developing and 
evaluating complex interventions (adapted from (96)) 
 
The rationale for identifying and developing theory is to understand the change 
process by drawing on the existing evidence, and health psychology and behaviour 
change theory. This approach seeks to identify the variables underpinning decisions 
to perform or not to perform a behaviour(149), providing a schematic of the 
mechanisms that may propel the behaviour into routine practice. This emphasis on 
theory contrasts the methodological approach to early BCI development discussed 
Feasibility/piloting
1. Testing procedures
2. Estimating recruitment/retention
Determining sample size
Evaluation
1. Assessing effectiveness
2. Understanding change process
3. Assessing cost-effectiveness
Implementation
1. Dissemination
2. Surveillance and monitoring
3. Long term follow-up
Development
1. Identifying the evidence base
2. Identifying/developing theory
3. Modelling process and outcomes
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earlier in this chapter. There is some evidence to suggest BCIs underpinned by 
theory are more likely to be effective than those which are empirically driven(150). 
However, despite advocating for its use, the MRC guidance does not advise 
researchers on how to select and apply appropriate theory. Accordingly, there is a 
need to navigate the plethora of available health psychology and behaviour change 
theories in order to determine which are appropriate for the behaviour and context 
of interest. 
 
2.3.1 Classic theories used to develop behaviour change interventions 
Nilsen defines a theory as “a set of analytical principles or statements designed to 
structure our observation, understanding and explanation of the word”(146). 
Theories are made up of relationships between dependent and independent 
variables existing in a domain where the theory applies, which together can predict 
an outcome, such as a behaviour(146). 
Initially, theories applied to the development of BCIs were ‘borrowed’ from the fields 
of psychology, sociology and organisational theory and, are often referred to as the 
‘classic theories’(146). These theories were developed to explain how behaviour 
change occurs through describing the underlying mechanisms. Determinants of 
practitioners’ behaviours are believed to be similar to those of people generally, 
therefore many classic theories have been applied to the study of practitioners’ 
behaviour change(151). A systematic review of studies based on social cognitive 
theories identified 72 articles describing the application of theory to understand the 
determinants of practitioners’ behaviour(152). The Theory of Planned Behaviour, 
which proposes that the constructs of attitude toward the behaviour, subjective norm 
and perceived behavioural control predict intention and behaviour, was the most 
frequently adopted theory. However, other, often overlapping theories, such as 
Triandis’ Theory of Interpersonal Behaviour, whilst also considering attitudes and 
norms, consider other determinants such as emotions and habits(153). 
Michie et al. suggest intervention developers are faced with three key challenges 
when attempting to select the most appropriate theory or theories to apply to their 
behaviour of interest(112). Firstly, no one theory comprehensively explains human 
behaviour and therefore with behavioural problems with multiple barriers and 
facilitators to address, several individual theories may be relevant. Incongruously, 
several of the classic theories overlap to some degree, incorporating redundancy 
when attempting to apply more than one potentially applicable theory to 
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comprehensively explore a behavioural problem. Secondly, there is no systematic 
basis on which to select the most relevant theories to apply to a given behavioural 
problem and, there is a risk of missing critical theories in doing this. Finally, theories 
in general only describe the underlying mechanisms of behaviour change and 
therefore they do not guide selection of intervention components which act on these 
mechanisms to bring about change(146). Accordingly, whilst expert health and 
behavioural psychologists developing interventions may be able to identify 
intervention components based on the mechanisms explained by classic theories, 
those without such knowledge and skills are unlikely to be successful(112). It is 
therefore unsurprising that researchers face significant challenges when attempting 
to underpin BCI development with theory(146,154). 
Whilst the application of the classic theories represents a significant advancement 
towards developing theory-informed BCIs, they were not devised for this purpose 
and do not offer a systematic approach to comprehensively explaining behaviour 
and selecting appropriate intervention components. The field of implementation 
science has since emerged and is “the scientific study of methods to promote the 
systematic uptake of research findings and other evidence-based practices into 
routine practice, and, hence, to improve the quality and effectiveness of health 
services”(155). This is a broad field which considers the behaviour of patients, 
practitioners, organisations and policy makers and represents a paradigm shift from 
historic atheoretical and classic theory approaches to BCI development. 
Implementation science is rapidly developing, however in terms of facilitating theory-
informed intervention development, a novel set of frameworks and theories have 
emerged from within the field which offer simplified and clarified access to 
psychology and behaviour change theory. These are considered herein for 
application to the development of a novel hospital deprescribing intervention. 
 
2.3.2 Determinant frameworks 
Rather than working with one theory, Michie et al. argue that researchers 
developing BCIs require access to a complete set of theoretical explanations for 
behaviour change in order to understand the underlying mechanisms. Determinant 
frameworks are a synthesis of several behaviour change theories and provide a 
structure of descriptive categories, and may describe the relationship between these 
categories, that are theorised to produce a phenomenon(146). Determinant 
frameworks describe the general categories of barriers and enablers that are 
40 
 
thought to influence an outcome such as practitioners’ behaviour. These are 
particularly useful for designing interventions where a change in the determinants, 
such as overcoming barriers and/or utilisation of facilitators, is required to enact the 
desired change in behaviour(146). 
 
2.3.2.1 The Fishbein et al. Theoretical Integration of Key Behavioural 
Determinants 
The first attempt to combine several behaviour change theories into one 
determinant framework was led by Fishbein. Through a three day consensus 
conference, a group of theorists and health psychologists drew on theories to 
identify the key determinants of behaviour which could be applied universally to any 
behavioural analysis(149,156). This work was undertaken in the context of Human 
Immunodeficiency Virus prevention behaviours, with a focus on health promotion 
such as condom use during intercourse. Fishbein et al. concluded that there were 
eight key determinants of human behaviour (figure 4). 
The determinants of behaviour were hypothesised to explain why some individuals 
or groups performed a behaviour whilst others do not. Three of the determinants, 
‘Intentions’, ‘Environmental constraints’ and ‘Skills’ are regarded as essential to 
performing any behaviour. The remaining five determinants influence the strength 
and direction of ‘Intentions’ and, are not necessarily important determinants of all 
behaviours(149,156). 
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Figure 4 The Fishbein et al. Theoretical Integration of Key Behavioural 
Determinants (adapted from 19,34) 
 
The Fishbein et al. conceptualisation of the determinant framework represented a 
significant advance in the field of behavioural science and has paved the way for 
further progress in applying theory to the development of BCIs. For the first time, 
developers of BCIs need not attempt to select from the plethora of potentially 
relevant theories. Instead, the Fishbein et al. work provided a vehicle for the 
application of several theoretical constructs simultaneously, with intervention 
developers able to identify the key determinants relevant to the behaviour, context 
and population of interest. However, as with all determinant frameworks, the causal 
model linking the eight determinants to behaviour have not been characterised. 
Whilst this framework provides a useful foundation on which to establish 
determinant frameworks, there are several limitations. Firstly, the development work 
was undertaken in the context of patient’s health behaviours and not that of people 
delivering health services, such as practitioners. Although overlapping behavioural 
determinants between these populations may exist, practitioners’ behaviour may be 
determined by additional contributory factors not present in the Fishbein et al. 
framework, such as knowledge of a disease or medication. Subsequent frameworks 
have included several additional domains, suggesting the Fishbein et al. framework 
may not be comprehensive and therefore limits its utility to developing BCIs(157). 
Additionally, there exists no direct link between identifying the determinants of 
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behaviour using the framework and understanding how to bring about behaviour 
change. 
 
2.3.2.2 Theoretical Domains Framework 
The Theoretical Domains Framework (TDF) is an in an integrative framework of 
behaviour change theories developed through a collaboration between 
psychologists and health service researchers to allow non-behaviour scientists to 
select from a comprehensive theoretical framework(157). Developed by Michie et al. 
in 2005, the TDF is a synthesis of 33 behaviour change theories and 128 theoretical 
constructs judged to be most relevant to changing behaviour, which are organised 
into 14(157) (originally 12(158)) theoretical domains. Each theoretical domain 
represents a determinant of behaviour (table 5). It can be seen that eight of the 
domains overlap with the Fishbein et al. framework(156), indicated in parenthesis in 
table 5. However, Michie et al. identified an additional six determinants which are 
not included in the Fishbein et al. framework(156): ‘Knowledge’; ‘Memory, attention 
and decision processes’; ‘Behavioural regulation’; ‘Intentions’; ‘Goals’; ‘Optimism’. 
The TDF does not explain relationships between determinants, however it is 
described as “…theoretical lens through which to view the cognitive, affective, social 
and environmental influences on behaviour…”(159). The TDF is therefore a 
framework for understanding a behaviour and provides a foundation for changing 
the behaviour through identifying areas to change in designing interventions. 
The 14 domains are used to structure methods of gathering evidence to understand 
the behaviour within a context. This ‘behavioural diagnosis’ identifies what needs to 
change and within which theoretical domains. The TDF has been applied widely to 
the study of healthcare practitioners’ behaviour and more recently to patients’ and 
members of the public. A 2012 evidence synthesis of literature applying the TDF 
identified 133 articles spanning qualitative research, surveys, systematic reviews, 
randomised studies and a process evaluation(160). Uses of the TDF have included 
identifying influencers of behaviour, systematic intervention design, process 
evaluation of randomised trials and identification of intervention components(159).  
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Table 5 Domains of the Theoretical Domains Framework 
* Domains in parenthesis provide the corresponding domains of the Fishbein et al. 
Theoretical Integration of Key Behavioural Determinants (149,156) 
The TDF’s strengths are in its comprehensive set of underpinning theories and 
constructs that facilitate an accessible and systematic approach to understanding 
behaviour and developing BCIs. Whilst the TDF was developed independently to 
the Fishbein et al. framework, the significant overlap between eight of the TDF’s 
domains and the eight behavioural determinants included in the Fishbein et al. 
framework affords some confidence in the importance of these domains in 
determining behaviour. 
Theoretical domain Definition 
1. Knowledge An awareness of the existence of something 
2. Skills (Skills) An ability or proficiency acquired through practice 
3. Social/ Professional 
Role and Identity (Self-
standards/sanctions) 
A coherent set of behaviours and displayed personal 
qualities of an individual in a social or work setting 
4. Beliefs about 
Capabilities (Self-
efficacy) 
Acceptance of the truth, reality or validity about an 
ability, talent or facility that a person can put to 
constructive use 
5. Optimism The confidence that things will happen for the best 
or that desired goals will be attained 
6. Beliefs about 
Consequences 
(Anticipated 
outcomes) 
Acceptance of the truth, reality, or validity about 
outcomes of a behaviour in a given situation 
7. Reinforcement Increasing the probability of a response by arranging 
a dependent relationship, or contingency, between 
the response and a given stimulus 
8. Intentions (Intentions) A conscious decision to perform a behaviour or a 
resolve to act in a certain way 
9. Goals Mental representations of outcomes or end states 
that an individual wants to achieve 
10. Memory, Attention and 
Decision Processes 
The ability to retain information, focus selectively on 
aspects of the environment and choose between two 
or more alternatives 
11. Environmental Context 
and Resources 
(Environmental 
constraints) 
Any circumstance of a person’s situation or 
environment that discourages or encourages the 
development of skills and abilities, independence, 
social competence and adaptive behaviour 
12. Social Influence 
(Perceived normative 
pressure) 
Those interpersonal processes that can cause 
individuals to change their thoughts, feelings, or 
behaviours 
13. Emotion (Emotional 
sanctions) 
A complex reaction pattern, involving experiential, 
behavioural, and physiological elements, by which 
the individual attempts to deal with a personally 
significant matter or event 
14. Behavioural 
Regulation 
Anything aimed at managing or changing objectively 
observed or measured actions 
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The array of methodological approaches, behaviours and contexts to which the TDF 
has been applied demonstrates that it is a broad and flexible tool. The wide 
coverage of potential behavioural determinants offered by the 14 theoretical 
domains facilitates isolation of important beliefs that may not be elicited through 
atheoretical or single theory approaches. Moreover, the TDF considers the influence 
of other groups of people on the individual whose behaviour is being targeted. 
However, critics of the TDF argue that empirical exploratory work confined to the 
rigid theoretical domains may restrict expression of views regarding a behaviour to 
align with the TDF domains only. For example, a qualitative topic guide informed by 
the TDF may produce results different to a traditionally inductive methodological 
approach. Accordingly, there is a potential risk of failing to identify barriers or 
facilitators that are instrumental to enacting behaviour change. This potential 
problem was explored in a mixed-methods study comparing application of the TDF 
with a parallel atheoretical approach to explore hand hygiene behaviour(161). There 
was considerable convergence in the barriers and facilitators identified by both 
approaches, however use of the TDF appeared to identify barriers which had an 
important influence on the behaviour which were not ordinarily reported, such as 
emotions. Accordingly, owing to a comprehensive coverage of behavioural 
determinants, application of the TDF appears to prompt identification of novel 
concepts not captured through purely inductive approaches(160). 
 
2.3.3 Implementation theories 
These theories focus on understanding and explaining the processes of 
implementing a new behaviour, often through a BCI, into a new context. Through 
the application of implementation theory, researchers prioritise critical aspects 
related to the ‘how’ and ‘why’ of implementation, which are often a derivation of the 
barriers and facilitators to the behaviour(146). Some implementation theories are 
completely novel whilst others, in addition to the determinant frameworks, were 
developed by adapting existing theories. 
 
2.3.3.1 Normalization Process Theory 
Normalization process theory (NPT) is a novel development from the field of 
implementation science that focuses on understanding and explaining what people 
do, rather than what they believe or intend, within a healthcare context. NPT was 
originally developed for use within the context of implementation of electronic health 
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applications, however more recently the theory has been applied widely, including 
for chronic disease management, maternity care and language interpretation 
services(162). A systematic review of studies employing NPT in BCIs identified 130 
manuscripts spanning controlled and non-controlled trials, qualitative studies, 
survey studies and a prospective cohort study(163). Seven categories of studies 
were included: service organisation and delivery, implementation of diagnostic and 
therapeutic interventions, implementation of e-Health and telemedicine, 
implementation of screening and surveillance tools, decision support and shared 
decision making, implementing change in professional roles and guideline 
implementation. 
NPT explains the conscious and deliberate processes by which complex 
interventions become routinely embedded into practice by focusing on the factors 
that promote or inhibit routine embedding of complex interventions(164,165). NPT 
proposes that “material practices become routinely embedded in social contexts as 
the result of people working, individually and collectively, to implement them”(165). 
The observable work required of people to implement practice is proposed to be 
operationalised through four ‘generative mechanisms’ or constructs: coherence, 
cognitive participation, collective action and reflexive monitoring, explained below: 
• Coherence: the process and work of sense-making and understanding that 
individuals and organisations have to go through in order to promote or 
inhibit the routine embedding of a practice. 
• Cognitive participation: the work that individuals and organisations have to 
do to enact the new practice. 
• Collective action: is how people make the practice or behaviour work in 
reality, considering what they require to make it happen. 
• Reflective monitoring: the work inherent in the informal and formal appraisal 
of a new practice once it is in use, in order to assess its advantages and 
disadvantages, and which develops users’ comprehension of the effects of a 
practice. 
 
The barriers and facilitators that promote or inhibit embedding of a practice or 
behaviour are theorised to act on one or more of these four generative mechanisms. 
Accordingly, people, both individuals and as a collective, need to exert work on 
these mechanisms to change their behaviour to embed a new practice. Figure 5 
provides an overview of how the four generative mechanisms interact with each 
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other and with affective factors within NPT. The theory proposes that in order to 
achieve sustained embedding of practice or behaviour, people are required to 
continuously invest in actions that sustain change within the social context(165). 
NPT also considers that the environments in which healthcare practitioners’ practice 
are dynamic, therefore people’s investments in embedding a practice or behaviour 
are themselves affected by changes in the environment. For example, failure to refill 
alcohol gel dispensers in hospitals leading to a deterioration in practitioners’ hand 
hygiene practice. Through an understanding of the generative mechanisms and 
affecters within a given social context, NPT was developed to involve stakeholders 
in the implementation process to understand the work required of them to embed a 
new practice or behaviour. 
 
Figure 5 Model of the components of Normalization Process Theory (taken from 
May et al.(165)) 
 
NPT is an explanatory, theoretically-underpinned framework that informs 
identification of factors that promote or inhibit implementation of BCIs, such as those 
used to change healthcare practice. Underpinning implementation of BCIs with NPT 
facilitates formulation of clear implementation strategies and, informs analysis and 
large scale implementation and trial design(162). NPT is therefore particularly useful 
when an understanding of how a pre-developed intervention or a new technology 
can be implemented into the intended context. 
Whilst NPT has been successfully applied to implement several BCIs, some 
criticisms of the theory have been reported, including an overemphasis on agents; 
47 
 
the people who are targeted by BCIs, at the expense of the social and 
environmental contexts in which a new practice or behaviour must embed. This is 
an important limitation given the wealth of literature suggesting contextual factors 
are important to changing behaviour and are themselves modifiable(138). This is of 
particular relevance to deprescribing in hospital, given that factors such as resource 
availability in healthcare environments have been identified as influencers on 
deprescribing behaviour in primary care(116). Whether this is also an important 
influencer on deprescribing behaviour in the hospital setting remains unknown, 
however given it is relevant in other healthcare settings, the theory selected for the 
present programme of work should consider this potentially important determinant. 
NPT has also been criticised for a reported overemphasis on the target group’s 
behaviour, such as healthcare practitioners, at the expense of groups who 
experience the effects of the change in behaviour, such as patients. This limitation 
may be of particular importance in cases where the consequences of behaviour 
change is perceived by practitioners to be negatively received by patients. This is 
also an important limitation in the context of deprescribing in hospital, given that 
primary care practitioners report the influence of other people, such as patients, 
carers and other practitioners as important influencers on deprescribing(116). It is 
conceivable that practitioners in the hospital setting’s deprescribing behaviour may 
similarly be influenced by social factors and thus a theory selected for the present 
programme of should equally consider social influences. 
 
2.3.3.2 Other implementation theories 
Other theories developed within the field of implementation science that focus on 
embedding a new practice or behaviour include Organisational Readiness and 
Implementation Climate. Similar to NPT, Organisational Readiness and 
Implementation Climate focus on the individuals whose behaviour is being targeted. 
Organisational Readiness emphasises the importance of the psychological state in 
which organisational members feel committed to implementing a change and 
confidence in their abilities to do so(166). Implementation Climate on the other hand 
focuses on the strength of an organisation’s climate for the implementation of an 
innovation and how well the innovation aligns with the user’s values(158). For the 
purposes of this theory, an organisation’s climate is defined as “employees' shared 
summary perceptions of the extent to which their use of a specific innovation is 
rewarded, supported, and expected within their organization”(158). Similar to NPT, 
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these theories allow researchers to prioritise mechanisms that are most critical to 
behaviour change, providing an understand the how and why of 
implementation(146). 
As with all theories, implementation theories do not attempt to be all encompassing 
and thus the application of a single implementation theory risks omitting 
consideration of a mechanism which may be crucial to behaviour change when 
developing a BCI. Moreover, these theories are applied to the study of implementing 
an established BCI and do not facilitate initial development, including selection of 
intervention components. Accordingly, they are most useful after a BCI has been 
developed and researchers are looking to develop strategies for effective 
implementation. 
 
2.3.4 From explaining behaviour to changing behaviour 
A theoretical understanding of behaviour recognises the determinants that require 
change to be targeted in a BCI. However, there remains a need to identify how to 
change behaviour through acting on these determinants(167). Hardeman et al. 
noted in 2005 that there was a missing link between understanding behaviour with 
theory and choosing appropriate, corresponding intervention components(168).  
A Behaviour Change Technique (BCT) is characterised in the Encyclopaedia of 
Behavioural Medicine as(169): 
“…a systematic procedure included as an active component of an intervention 
designed to change behaviour… A BCT is thus the smallest component compatible 
with retaining the postulated active ingredients, that is, the proposed mechanisms of 
change, and can be used alone or in combination with other BCTs.” 
According to Michie et al.(170), the defining characteristics of a BCT are that they 
are: 
• Observable 
• Replicable 
• Irreducible 
• A component of an intervention designed to change behaviour 
• A postulated active ingredient within the intervention 
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Clear and consistent reporting of BCTs is particularly important and should follow 
the standard scientific principles of transparency to allow others to learn, reproduce 
and build on the existing literature. BCT reporting in early interventions underpinned 
by health psychology theory was poor and inconsistent. Challenges arose with 
defining individual BCTs in a meaningful and replicable manner, complicated by 
language and formatting differences across research groups. Accordingly, several 
subjective author-defined labels for identical BCTs emerged alongside variation in 
practice in terms of label specificity(150,171). 
In an attempt to establish a ‘common language’ of BCTs, in 2008 Abraham and 
Michie identified and assigned labels to 26 BCTs from published intervention 
descriptions and manuals using consistent terminology and standard definitions 
(172). For example, the BCT ‘Provide information on consequences’ was assigned 
the label ‘Information about the benefits and costs of action or inaction, focusing on 
what will happen if the person does/ does not perform the behaviour’. The 
development of this early taxonomy of BCTs was described as a significant step 
forward in the field of implementation science and was poised to facilitate specificity 
in the reporting of BCI content. Moreover, common reporting of BCTs was proposed 
to enable meta-analytic review of BCI effectiveness, yielding a further advancement 
in the field. 
Whilst consistent reporting of BCTs provided a basis for identifying those which are 
effective for certain behaviours and in certain contexts, the need remained to 
address the gap between explaining behaviour using theory and changing that 
behaviour. In 2008, group of expert health psychologists and health services 
researchers, led by Michie, sought to bridge this gap by linking standardised 
definitions for BCTs to the domains of the TDF that they were likely to effectively 
enact behaviour change(167). The original 26 BCTs defined in the taxonomy were 
added to through a brainstorming exercised and a total of 35 BCTs were linked to 
the TDF. 
Further advancing the reporting of intervention contents, in 2013 Michie et al. 
developed the first extensive taxonomy of BCTs, expanding the original taxonomy of 
26 BCTs(172) to 93 BCTs hierarchically clustered into 16 groups, yielding the 
‘Behaviour Change Technique Taxonomy version 1’ (BCTTv1)(173). Building on this 
and the existing 2008 TDF work(167), Cane et al. subsequently mapped the 
BCTTv1 to the TDF(167). Fifty-nine BCTs were reliably mapped onto 12 of the 14 
TDF domains. For the domains of ‘Social/professional role and identity’ and 
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‘Memory, attention and decision processes’, no BCTs have yet been linked. For the 
remaining 12 domains, there is variation in the number of BCTs linked, for example 
the domain of ‘Reinforcement’ is linked to 17 BCTs whilst only one BCT is linked to 
the ‘Optimism’ domain. 
Mapping of the BCTTv1 onto the TDF provides a structured and systematic 
approach to applying health psychology theory and evidence-based intervention 
components to the understanding of behaviour and subsequent development of 
BCIs. This methodological approach has been widely adopted internationally to the 
development of healthcare BCIs, including encouraging timely cancer symptom 
presentation among people living in deprived communities(174), enhancing nurses’ 
use of electronic medication management and improving appropriate polypharmacy 
for older people in primary care(175). 
 
2.3.5 Selecting a theoretical approach for developing a hospital 
deprescribing intervention for older people 
The programme of worked described in this thesis involves the development of a 
hospital deprescribing intervention for older people targeting geriatricians’ and 
pharmacists’ behaviour, underpinned by health psychology theory. The 
impracticalities and drawbacks associated with applying classic theories, as 
described earlier in this chapter, to the development of BCIs renders this 
methodological approach unsuitable to the present programme of work(146). 
Accordingly, there is a need to select from underpinning the development of this 
intervention with either a determinant framework, such as the TDF, or an 
implementation theory, such as NPT. 
Chapter 1 discussed the available literature concerning primary care practitioners’ 
views towards deprescribing and characterised the barriers and facilitators from the 
perspective of this group of practitioners(116). Whilst a number of the reported 
barriers and facilitators may also apply to the hospital, there are likely to be others 
such as those relating to the hospital environmental context, which remain 
unknown. Accordingly, there is a knowledge gap in terms of an understanding of the 
determinants of hospital practitioners’ deprescribing behaviour. In order to develop 
and implement a deprescribing intervention in hospital, there remains a need to 
understand the barriers to this behaviour in order to select appropriate intervention 
components in order for circumvention. Similarly, the factors that hospital 
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practitioners feel may facilitate deprescribing is also of interest in order to guide the 
selection of intervention components. 
There is insufficient existing evidence on which to predicate and implement a 
deprescribing intervention in the hospital setting. Consequently, application of an 
implementation theory such as NPT, where the focus is on implementing a defined 
existing intervention or technology, is not an appropriate methodological approach 
to the development of a theory informed deprescribing intervention for the hospital 
setting. 
There is therefore a need to conduct empirical research exploring hospital 
practitioners’ barriers and enablers to deprescribing, and through underpinning this 
work with health psychology theory, identify and understand the behavioural 
determinants requiring targeting in a BCI. The use of a determinant framework to 
guide understanding of the behaviour therefore provides a vehicle for developing a 
deprescribing intervention for the hospital setting. The TDF’s 14 domains provide 
comprehensive theoretical coverage of behavioural determinants, which is of 
particular relevance to the present research given the limited existing understanding 
of the behaviour. Moreover, there is precedent for applying the TDF to explore 
poorly understood behaviours, frequently through qualitative methodological 
approaches such as focus groups and interviews to inform both the discussions and 
analysis(159). Moreover, a unique advantage to the TDF over other determinant 
frameworks is the linking of theoretical domains to the BCTTv1, enabling 
intervention developers to progress from a theoretical understanding of the 
behaviour to developing an evidence-based intervention. 
Once potential BCTs have been identified using the TDF and BCTTv1, there 
remains a need to select those which are most likely to facilitate adoption of a new 
behaviour. This is particularly relevant as many of the TDF’s theoretical domains 
have each been linked to multiple BCTs thus there is likely to be a need to select 
from a list of potentially effective BCTs, those which are most likely to be 
implementable within the social and environmental context of interest. The APEASE 
criteria (table 6) for designing and evaluating interventions offers a systematic 
approach to selecting from the BCTs identified using the TDF. APEASE facilitates 
selection of BCTs which are most likely to be appropriate by considering six factors 
which are all equally relevant to intervention success(97). Application of APEASE 
facilitates selection from a list of potentially effective BCTs by considering factors 
related to implementation and feasibility. APEASE has been applied to the 
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development of numerous BCIs, and selection of BCTs using the criteria has been 
undertaken by both researchers(176) and the target audience such as healthcare 
professionals(177).  
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Table 6 The APEASE criteria for designing and evaluating interventions 
(reproduced from Michie, Atkins and West(97)) 
Criterion Description 
Affordability Interventions often have an implicit or explicit budget. It 
does not matter how effective, or even cost effective it may 
be if it cannot be afforded. An intervention is affordable if 
within an acceptable budget it can be delivered to, or 
accessed by, all for whom it could be relevant or of benefit. 
Practicability An intervention is practicable to the extent that it can be 
delivered as designed through the means intended to the 
target population. For example, an intervention may be 
effective when delivered by highly trained staff with 
extensive resources but in routine practice this may not be 
achievable. 
Effectiveness and 
cost-effectiveness 
Effectiveness refers to the effect size of the intervention in 
relation to the desired objectives in a real world context. It 
is distinct from efficacy which refers to the effect size of the 
intervention when delivered under optimal conditions in 
comparative evaluations. Cost-effectiveness refers to the 
ratio of effect to cost. If two interventions are equally 
effective then clearly the most cost-effective should be 
chosen. If one is more effective but less cost-effective than 
another, other issues such as affordability come to the 
forefront of the decision-making process. 
Acceptability Acceptability refers to the extent to which an intervention is 
judged to be appropriate by relevant stakeholders (public, 
professional, and political). Acceptability may be different 
for different stakeholders. 
Side effects/safety An intervention may be effective and practicable but have 
unwanted side-effects or unintended consequences. These 
need to be considered when deciding whether or not to 
proceed. 
Equity An important consideration is the extent to which an 
intervention may reduce or increase the disparities in 
standard of living, wellbeing, or health between different 
sectors of society. 
54 
 
Chapter 3 Deprescribing admission medication at 
a UK teaching hospital; a report on 
quantity and nature of activity 
 
This chapter is derived from the publication: 
Scott, S., Twigg, M. J., Farrow, C., May, H., Patel, M., Taylor, J., … Bhattacharya, 
D. (2019). Development of a hospital Deprescribing Implementation Framework: A 
focus group study with geriatricians and pharmacists. Age and Ageing, accepted in 
press.
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3.1 Introduction 
Chapter 1 discussed that the prescribing of a medication is informed by numerous 
factors including the diagnosis, general health and psycho-social circumstances of 
the patient(178). As these factors are not static; monitoring is required to ensure the 
prescribing does not result in a potentially inappropriate medicine (PIM), which are 
believed to afford more risks than benefits and are a pre-disposition to adverse drug 
events (ADEs)(85).  
The term ‘deprescribing’ was introduced, which is “the systematic process of 
identifying and discontinuing drugs in instances where existing or potential harms 
outweigh existing or potential benefits within the context of an individua l patient’s 
care goals, current level of functioning, life expectancy, values and 
preferences”(58). The important element of this sentence is the differentiation of 
‘existing harms’ from ‘potential harms’, suggesting deprescribing may be ‘reactive’ 
or ‘proactive’ respectively(115). Surmised in Chapter 1, evidence and opinion in the 
literature presents a strong case for the development and implementation of a novel 
hospital deprescribing intervention. A multi-centre prospective analysis of older 
people’s admission medication reported PIM prevalence ranging from 34.7% to 
77.3% across six European university teaching hospitals(34), suggesting there are 
opportunities to deprescribe during a hospital admission. However, deprescribing 
practice in hospital is poorly understood and it is unclear to what extent 
deprescribing is routine practice in hospital(116). There is a need to establish the 
scope to increase deprescribing practice in hospital prior to embarking on the 
development of a novel intervention. Older people are most likely to benefit from an 
intervention to deprescribe PIMs, given that this population is most at risk of being 
prescribed a PIM and sustaining resultant iatrogenic harm. However, extending an 
evaluation to all adults in hospital increases the probability of identifying and 
characterising any successful deprescribing activity which may be useful in 
informing the development of a novel intervention. 
 
3.2 Aim 
To describe admission medication deprescribing activity in adults in the hospital 
setting 
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3.3 Objectives 
1. To identify the proportion of admission medications prescribed in the hospital 
setting that are deprescribed 
2. To develop definitions for ‘reactive’ and ‘proactive’ deprescribing 
3. Quantify the proportion of admission medication deprescribing activity that is 
‘proactive’ and ‘reactive’ according to the definitions developed 
 
3.4 Ethics approval 
The study was confirmed as a service evaluation by the University of East Anglia 
Faculty of Medicine and Health Sciences Research Ethics Committee (Reference: 
2016/2017 - 52 SE) and the Audit and Improvement department at the Norfolk and 
Norwich University Hospitals NHS Foundation Trust (Reference: SW/ms). The study 
protocol and ethical and governance approval letters are provided in appendices 1 
and 2 respectively. 
 
3.5 Methods 
A project management group was convened comprising academic supervisors 
representing the disciplines of behavioural science, trial design, statistics, qualitative 
research, geriatric medicine and hospital pharmacy practice. The patient and carer 
voice were represented by NN and JG respectively. NN was a National Institute for 
Health Research patient research ambassador and patient prescribed 
polypharmacy. JG was a research administrator and carer to a patient prescribed 
polypharmacy. The role of the project management group was to review all key 
methodologic and analytical decisions plus monitor project progress. 
 
3.5.1 Methodological approach 
The aim of this study requires a methodological approach that measures existing 
deprescribing practice and provides sufficient data to enable categorisation of any 
observed deprescribing activity into ‘reactive’ and ‘proactive’ deprescribing. A 
retrospective study design may be appropriate given that the required data are 
collected routinely using electronic prescribing (e-prescribing) systems and 
documented in patients’ medical records, and could therefore be retrospectively 
analysed. Whilst this approach can provide the required data quickly and efficiently, 
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some limitations have been reported. Notably, retrospective studies use existing 
data that have been recorded for reasons other than research, therefore the 
availability and accuracy of data, particularly when handwritten medical records are 
concerned, are uncertain(179). 
An alternative approach may be a prospective design, such as asking practitioners 
to record their own deprescribing activity. This method permits researchers to 
specify the data to be collected, thus overcoming some of the challenges associated 
with a retrospective design. However, a prospective study could prompt a change in 
practitioners deprescribing practice and is an important consideration with reference 
to the aim of this study. This potential for subjects to alter their behaviour due to an 
awareness of being studied is a widely recognised phenomenon termed the 
‘Hawthorne effect’. First coined by French in 1953, the Hawthorne effect is 
described as “…a marked increase in production related only to special social 
position and social treatment”(180). Practitioners may therefore increase 
deprescribing activity for the study duration due to the Hawthorne effect and revert 
to usual practice upon completion. Additionally, given that addressing PIMs is a 
widely recognised priority, practitioners cognisant of a study measuring 
deprescribing activity may also exhibit social desirability bias, which is “the 
pervasive tendency of individuals to present themselves in the most favourable 
manner relative to prevailing social norms…”(181). Any study which prompted a 
change in deprescribing practice would constitute an intervention, which is a 
deviation from the aim of this study. The need to evaluate existing hospital 
deprescribing activity in the present study has led to adoption of a retrospective 
methodological approach. Limitations associated with accuracy or availability of 
data will be mitigated by extracting some data from a hospital’s comprehensive e-
prescribing database. 
 
3.5.2 Data collection 
A retrospective analysis of all admission medications prescribed and discontinued at 
a large United Kingdom (UK) teaching hospital was undertaken over four weeks in 
February 2017. Data were extracted from the hospital’s electronic prescribing 
system for all wards and specialities except the Emergency Department and 
Intensive Care Unit as e-prescribing was not implemented in these areas. The 
hospital’s policy was to complete medicines reconciliation for 90% of patients within 
24 hours of admission, and data collection for all patients occurred at least 48 hours 
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after admission. Prescriptions newly initiated during the admission and medication 
recorded as temporarily suspended were excluded because the study was designed 
to capture the extent to which admission medicines are deprescribed. There were 
no patient exclusion criteria. 
Patient sex and age, medication name and the e-prescribing reason for medication 
discontinuation (selected by the prescriber from a list of 20 pre-defined reasons on 
the e-prescribing system, provided in figure 6) were recorded and extracted for 
analyses. 
Not all medications recorded as discontinued on the e-prescribing system are 
‘deprescribed’, such as those assigned the e-prescribing reason ‘Incorrect 
prescription’ or ‘Changed to when required’. Accordingly, a team of hospital 
pharmacists (n=3) and consultant geriatricians (n=2) classified the e-prescribing 
reasons into ‘not considered deprescribing’ (excluded from analysis) and ‘potentially 
deprescribing’ as described in figure 6. 
A sample of 200 medication discontinuations assigned a ‘potentially deprescribing’ 
e-prescribing reason were further analysed by reviewing medical records to confirm 
or refute deprescribing activity and categorise the activity into proactive or reactive. 
This sample size was chosen because it was the maximum number of medication 
discontinuations for which the research team and hospital research site agreed was 
feasible to review, taking into consideration the need to recall archived medical 
records and the capacity for two members of the research team to independently 
review and categorise the discontinuation. As there are no estimates of 
deprescribing prevalence in usual hospital care, an estimate based on a UK 
deprescribing intervention trial reporting 8.5% of admission medicines deprescribed 
was used to inform the present study(182). Accepting this will be lower in the 
absence of an intervention, a maximum of 5.0% admission medicines likely to be 
deprescribed was estimated. This sample size (n=200) provides a 95% confidence 
interval of 3.0% around the estimate of the quantity of admission medications that 
are confirmed deprescribing activities. Hence, the sample size is both practical and 
provides a precise estimate of the deprescribing rate. 
The majority of e-prescribing reasons are unambiguous such as ‘Acute kidney 
injury’. However, the reason ‘No longer clinically necessary’ was deemed 
ambiguous by the hospital site based research team of hospital pharmacists (n=3) 
and consultant geriatricians (n=2), as in their experience, this was often selected by 
prescribers when a suitable reason could not be identified. Medication 
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discontinuations not assigned an e-prescribing reason were also considered 
ambiguous. Accordingly, sampling of 200 medication discontinuations was stratified 
on e-prescribing reasons assigned to medication discontinuations, with a smaller 
number of discontinuations assigned unambiguous reasons (one-sixth of the total or 
100% if three or less occurrences) sampled. Stratification was necessary as the 
hospital site based research team felt that the rates of reactive and proactive 
deprescribing varied between e-prescribing reason statements and, there was 
substantial uncertainty regarding the likely nature of deprescribing activity deemed 
ambiguous, hence stratification ensured that each reason was fairly represented in 
the overall sample. 
Medication discontinuations assigned the ambiguous reason and where no reason 
was given were evenly sampled for the remaining reviews. Within each strata, 
medication discontinuations were randomly sampled using a random number 
generator. Figure 6 provides the numbers sampled across the e-prescribing reason 
strata. 
Informed by the existing literature(115), academics pharmacists (n=4), senior 
hospital pharmacists (n=26), senior geriatricians (n=28), and a patient and carer 
representative, the definitions for reactive and proactive deprescribing were 
developed and used to categorise deprescribing behaviour. The process for 
definition development was initially to present the Scott et al.(58) definition for 
deprescribing introduced in Chapter 1 to the project management group at a 
meeting. Group brainstorming occurred and initial definitions were generated. The 
definitions were then refined through email communication between the project 
management group and presented to the wider audience of senior hospital 
pharmacists and senior geriatricians for comment and validation. The definitions 
were accepted without further refinement and are provided below: 
• Reactive deprescribing: discontinuing a medicine in response to an adverse 
clinical trigger. 
• Proactive deprescribing: discontinuing a medicine if future gains are unlikely 
to outweigh future harms. 
 
One hospital pharmacist extracted the prescriber’s rationale for medication 
discontinuation verbatim from medical records. Each discontinuation was 
independently categorised by a hospital pharmacist and consultant geriatrician into 
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proactive, reactive or not deprescribing. Inter-rater reliability was assessed using 
Cohen’s Kappa, with ĸ=0.6-0.8 considered good and ĸ>0.8 excellent(183). 
Disagreements were resolved through reviewer discussion and referral to a third 
reviewer (hospital pharmacists or consultant geriatrician) if necessary.  
Data from the stratified sample of 200 reviews were extrapolated to the total 
‘potentially deprescribing’ discontinuations through multiplying sample deprescribing 
prevalence within each reason statement by the total number of discontinuations 
within each reason statement. These were summed to estimate the total proportion 
and 95% confidence interval (95% CI) of admission medicines deprescribed in 
hospital and the proportion (95% CI) which were reactive and proactive. 
 
3.6 Results 
From 24,552 admission medicines prescribed for 2,309 patients, 977 
discontinuations were recorded across 415 patients, of which 682 (69.8%) were 
‘potentially deprescribing’ according to the e-prescribing reason assigned by the 
prescriber discontinuing the medication. Of patients who had a medication 
discontinued, females constituted 228 (54.9%) patients and the median interquartile 
(IQ) age was 79.0 (66.0, 86.0) years. Figure 6 provides the e-prescribing reasons 
for discontinuation retained and excluded from the analysis according to whether 
they were potentially consistent with deprescribing as defined in the introduction.  
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Figure 6 e-prescribing recorded medication discontinuations excluded and retained 
from analysis according to the e-prescribing reason selected by the prescriber 
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Stratified sampling and, proactive and reactive categorisation of the 200 medication 
discontinuations further analysed by reviewing the medical records are described in 
figure 7. Unambiguous e-prescribing reasons accounted for 21.0% of the sample. 
The remaining 158 (79.0%) records were evenly sampled from the ambiguous e-
prescribing reason ‘No longer clinically necessary’ and from no e-prescribing reason 
recorded. 
One-hundred and forty-three (71.5%) discontinuations reviewed were not consistent 
with the definitions for proactive or reactive deprescribing for the reasons; end of life 
care, treatment escalation or the medication being stopped in error. For a further 13 
(6.5%), insufficient information was available for categorisation. The remaining 44 
(22.0%) confirmed deprescribing activities were categorised into 7 (15.9%) 
proactive and 37 (84.1%) reactive. Agreement between reviewers categorising 
deprescribing activity was excellent (κ=0.872, p<0.01)(183). 
Reasons provided in the medical records for medication deprescribed reactively 
were; side effect (21 (56.8%)), acute kidney injury (8 (21.6%)), treatment failure (5 
(13.5%)), swallowing difficulty (1 (2.7%)), allergic reaction (1 (2.7%)) and interaction 
with other treatment (1 (2.7%)). All proactive deprescribing was in response to 
resolution of the indication for which the medication was first prescribed as reported 
by the patient or physiological parameters. 
Data extrapolation calculations and formulae are provided in appendices 3 and 4 
respectively. Extrapolation of the 200 stratified sample data to the 682 total 
discontinuations yielded 22.01% (95% CI 19.0%-25.2%) consistent with 
deprescribing, of which 19.3% (95% CI 13.0%-25.6%) are proactive and 80.7% 
(95% CI 74.4%-87.0%) are reactive. This corresponds to 0.6% (95% CI 0.5%-0.7%) 
of all admission medications prescribed being deprescribed
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Figure 7 Categorisation of a stratified sample of 200 recorded medication 
discontinuations and extrapolation to the total 682 recorded medication 
discontinuations potentially considered deprescribing (according to the e-prescribing 
reason provided) 
*Medication discontinued however rationale provided in the medical records was not 
consistent with proactive or reactive deprescribing e.g. medication discontinued due 
to end of life diagnosis. **Medication re-prescribed at the point of medical records 
review. Medication discontinuation recorded for an erroneous reason such as 
discontinued in error and immediately re-prescribed.
Unambiguous e-prescribing reasons sampled 
(n=42 (21.0%)) 
• Acute kidney injury. Not to be restarted (n=2) 
• Biochemistry deranged (n=2) 
• Blood dyscrasia (n=3) 
• Drowsy (n=2) 
• Formulation no longer appropriate (n=11) 
• Haemodynamically unstable (n=1) 
• Interaction with other treatment (n=3) 
• Patient refusing to take (n=1) 
• Renal impairment (n=1) 
• Route no longer appropriate (n=15) 
• Suspected toxicity/high levels (n=1) 
Ambiguous e-prescribing reasons or no reason 
given sampled (n=158.0, 79.0%)) 
• No longer clinically necessary (n=79) 
• No reason documented (n=79) 
Confirmed 
deprescribing (n=11, 
(26.2%)) 
• Reactive (n=11, 
(100%)) 
Not deprescribing 
(n=31, (73.8%)) 
• Neither* (n=9, 
(29.0%)) 
• Not discontinued** 
(n=21, (67.7%)) 
• Insufficient 
information to 
categorise (n=1, 
(3.2%)) 
Not deprescribing 
(n=125, (79.1%)) 
• Neither* (n=41, 
(32.8%)) 
• Not discontinued** 
(n=72, (57.6%)) 
• Insufficient 
information to 
categorise (n=12, 
(9.6%)) 
Confirmed 
deprescribing (n=33, 
(20.9%)) 
• Reactive (n=26, 
(78.8%)) 
• Proactive (n=7, 
(21.2%)) 
Not deprescribing (n=531) 
• Neither* (n=155, (29.2%)) 
• Not discontinued* (n=331, 
(62.3%)) 
• Insufficient information 
available to categorise (n=45, 
(8.5%)) 
Deprescribing (n=151) 
• Proactive (n=29, 
(19.2%)) 
• Reactive (n=122, 
(80.8%)) 
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3.7 Discussion 
This study addresses a key gap in the existing evidence base for deprescribing in 
hospital through quantifying the extent to which deprescribing occurs in the absence 
of an intervention. Moreover, the study is strengthened by its conceptualisation of 
reactive and proactive deprescribing and, subsequent multidisciplinary 
categorisation of identified activity according to these behaviours. Together with 
existing literature describing the extent of PIMs prescribed for hospitalised 
patients(34), an indication of the need for and scope of a novel hospital 
deprescribing intervention is provided. 
Despite not excluding any deprescribing activity based on patients’ age and with the 
exception of the emergency department and intensive care unit clinical specialities, 
the average age of patients who had an admission medication discontinued was 
almost 80 years. This is unsurprising given that older people are at highest of risk of 
being prescribed a PIM and experiencing resultant harms(34), and are therefore 
likely to require medication discontinuation. Very limited deprescribing activity was 
identified at the one UK teaching hospital under analysis in this study. Moreover, 
this activity was dominated by reactive deprescribing, suggesting that practitioners 
in hospital require the presence of a clinical trigger such as an adverse drug event 
to prompt deprescribing. The less than one fifth of deprescribing activity categorised 
as proactive accords with a qualitative primary care study, which reported that 
practitioners find it challenging to evaluate potential risks and harms associated with 
medication to inform deprescribing(115). It is conceivable that hospital practitioners 
may also find this challenging. Findings from the present study support this 
hypothesis, as the observed proactive deprescribing was only in cases with 
documented evidence of no clinical benefit thus only potential for harm. There was 
therefore no proactive deprescribing identified as a result from a complex evaluation 
of risks and benefits, underscoring the need for empirical research to explore 
practitioners’ barrier and facilitators to proactive deprescribing in hospital. 
Owing to the four week data collection window, a relatively large number of patients’ 
admission medications were screened for subsequent discontinuation, affording 
some confidence in the trends reported. However, the restriction of data collection 
to a single UK hospital restricts generalisability of these findings and is an important 
limitation. Whilst there is no reason to suspect that practice between hospitals 
differs significantly, more widespread, international analysis of deprescribing in 
hospital is warranted. A further limitation is the large proportion of sampled 
medication discontinuations that were either categorised as not deprescribing or 
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where there was insufficient information to categorise, which incorporates a degree 
of ambiguity around the final proportions. Random, stratified sampling and 
extrapolation of almost a third of the total medication discontinuations was 
employed to mitigate this limitation. Moreover, the data accord with primary care 
reports of practitioners expressing difficulty with deprescribing, particularly activity 
which is characteristic of proactive deprescribing(115,116). Accordingly, whilst the 
aforementioned uncertainty may have resulted in deprescribing proportions 
deviating somewhat from the true values, the reported trends are in agreement with 
the existing literature. Given that the present study aimed to understand whether 
there was likely to be any scope to increase deprescribing in hospital, this limitation 
does not impact the recommendations derived from these data. 
The sampling strategy for ‘unambiguous’ e-prescribing reasons (one-sixth of the 
total or 100% if three or less occurrences) resulted in five of the reasons being 
sampled for less than three occurrences. This limitation may have resulted in 
deprescribing proportions deviating somewhat from the true values within the 
affected reasons. This could have been mitigated by modifying the sampling 
strategy to be ‘one-sixth of the total but a minimum of three’ applied to the affected 
reasons. 
This study could have been further strengthened by independently assessing the 
prevalence of PIMs within the prescribed admission medication using a validated 
tool such as the Screening Tool of Older Persons’ potentially inappropriate 
Prescriptions (STOPP)(31). Using these data to contextualise the observed 
deprescribing activity, rather than relying on a comparison with literature data, may 
have been preferable. The prevalence of PIMs in the study population could have 
been lower than that reported in the literature, which may have provided some 
explanation for the limited deprescribing activity observed. However, PIM 
prevalence in hospital has been extensively studied, and a significant deviation from 
the literature in the one hospital is unlikely(34,37,85,184–189). 
The PIM prevalence within the confirmed deprescribing activity was also not 
assessed because the prescribers’ medical records documented rationale was used 
to confirm whether medicines were ‘actually’ inappropriate, according to the 
definitions for reactive and proactive deprescribing. Accordingly, additional 
screening for medicines that were ‘potentially’ inappropriate was not relevant to the 
study aim. 
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Accepting the limitations of not assessing admission medication PIM prevalence in 
the present study, from the deprescribing prevalence of 0.6% reported in this study 
and the literature reported PIM prevalence of approximately 50%(34,37,85,184–
189), it can be concluded that the vast majority of PIMs prescribed as part of 
patients’ admission medication are unlikely being deprescribed in hospital. This 
finding contributes to the evidence base for deprescribing in hospital and indicates 
that there may be significant scope for increasing proactive deprescribing through 
the development and implementation of a novel intervention. 
In Chapter 1, geriatricians’ and pharmacists’ deprescribing behaviours were 
identified as potential intervention targets. However, the extent to which an 
intervention to promote deprescribing is acceptable to these professional groups 
and feasible within existing resource constraints remains unknown(116). Moreover, 
given that addressing inappropriate prescribing is a widely recognised priority, the 
low activity reported in this study suggests there are significant barriers to effective 
deprescribing in hospital. Accordingly, there remains a need to explain the low 
proactive deprescribing activity in hospital and explore the support required for 
geriatricians and pharmacists to deprescribe. 
It is unclear whether increasing deprescribing in the hospital setting is acceptable to 
both patients and their carers. For example, practitioners are reported to influence 
patients’ willingness to deprescribe, and this influence may vary between a patients’ 
regular general practitioner and hospital practitioners(98). Accordingly, establishing 
the extent to which deprescribing is acceptable to patients and their carers prior to 
the development of a novel intervention is necessary. 
The low proactive deprescribing activity identified in this study suggests there is 
scope to develop a novel deprescribing intervention to identification and 
discontinuation of inappropriate medication in hospital. Identification of barriers and 
facilitators from both the practitioner, and patient and carer perspectives is 
necessary to understand the targets for such an intervention.
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Chapter 4 Attitudinal predictors of older peoples’ 
and carers’ desire to deprescribe in 
hospital 
 
This chapter is derived from the publication: 
Scott S, Clark A, Farrow C, May H, Patel M, Twigg MJ, Wright DJ, Bhattacharya D. 
Attitudinal predictors of older peoples’ and carers’ desire to deprescribe in hospital. 
BMC geriatrics. 2019 Dec;19(1):108.
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4.1 Introduction 
The prevalence of potentially inappropriate medicines (PIMs) on hospital admission 
is estimated to be 51.3%(34), however the empirical work undertaken in Chapter 3 
identified that deprescribing practice in hospitals is limited in number and largely 
reactive in response to iatrogenic harm rather than proactive to prevent future 
harm(190). Accordingly, there is likely to be scope to increase proactive 
deprescribing activity in hospital through the development of a novel intervention. 
Prescribing should be based on a partnership as the prescriber is the disease 
expert and the patient is the expert on their illness(191). It is therefore unsurprising 
that patient engagement in decision-making is a proposed essential component of 
successful deprescribing(60). Consultations between practitioners and patients are 
an opportunity to determine whether deprescribing is appropriate, agree strategies 
for ongoing monitoring and establish the patient’s desire to try deprescribing(60). 
Trials across multiple settings report up to half of older patients decline 
deprescribing interventions(111,192–194). Exploration of predictors for this lack of 
desire to deprescribe has focussed on external characteristics such as age, gender 
and number of prescribed medications. A recent retrospective analysis of hospital 
electronic medical records reported that all external patient characteristics analysed, 
including PIM prevalence, number of medicines at admission and comorbidities had 
no effect on patients’ willingness to accept deprescribing(111). It is unsurprising that 
these characteristics do not predict desire to deprescribe as there is a substantial 
body of evidence in the field of behavioural science confirming that a key predictor 
of behaviour is attitude towards the behaviour, which is poorly predicted by external 
characteristics(112–114). Furthermore, external demographic characteristics cannot 
be changed thus contribute little to guiding physicians or those developing 
deprescribing interventions. Identification of attitudinal predictors of desire to 
deprescribe may therefore provide modifiable targets for an intervention targeting 
patients’ and carer’ behaviour. Such attitudinal predictors are likely to be related to 
the patient reported barriers and enablers characterised in chapter 1 of this 
thesis(116), however the extent to which these may predict desire to deprescribe 
remains unknown. 
Informal carers such as family members are increasingly involved in medication 
decision-making. For patients that are unable to participate in these decisions, such 
as those living with cognitive impairment, carers frequently assume sole 
responsibility(195,196). Furthermore, carers influence engagement with 
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deprescribing by physicians and patients who are able to participate in decision-
making(98,116). Despite the wide ranging influence exerted by carers on the 
deprescribing processes, their level of engagement with and attitudinal factors 
influencing desire to deprescribe are unknown. 
The Patients’ Attitudes Towards Deprescribing (PATD) questionnaire was 
introduced in Chapter 1 of this thesis. Older people completing the PATD across the 
care homes, outpatient and acute hospital settings report being satisfied with 
existing medication whilst incongruously, over 90% also indicate willingness to 
accept deprescribing proposed by a doctor(107,109,110,197). This high level of 
willingness contrasts the significant proportion of participants in deprescribing trials 
declining deprescribing propositions(111,192–194). This gap between reported 
willingness and observed behaviour requires further exploration. Given that 
willingness to accept deprescribing proposed by a doctor has demonstrated limited 
variation in responses, this may not provide the best data for explaining this gap 
The Australian-validated revised Patients’ Attitudes Towards Deprescribing 
questionnaire (rPATD) explores factors that influence desire to deprescribe not 
captured by the PATD. The rPATD items are grouped into the four factors of burden 
of taking medication, appropriateness of medication (perceived harms and benefits), 
concerns about stopping the medication and level of involvement in making 
decisions about medicines. The appropriateness factor provides the new item “I 
would like to try stopping one of my medicines to see how I feel without it”. This item 
provides an indication of the patient’s attitude towards their prescribed medication 
by indicating their desire to try stopping a medicine. Furthermore, given that a 
significant proportion of previously reported deprescribing trials have been 
pharmacist-led(84), this item may provide better data for explaining the gap 
between reported willingness to accept deprescribing proposed by a doctor and 
observed declining of deprescribing propositions. 
Given the similarities between the two English speaking nations, the Australian-
validated rPATD is likely to be an appropriate survey to capture attitudes towards 
deprescribing in the United Kingdom (UK) hospital setting. However, contextual 
differences between the two nations such as prescription medicines being free of 
charge to all older people in the UK, may require minor adaptations to be made to 
the rPATD prior to use in the UK setting. 
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4.2 Aim 
To describe the desire and attitudes of older people and carers in hospital to be 
involved in deprescribing 
 
4.3 Objectives 
1. Adapt the revised Patients’ Attitudes Towards Deprescribing (rPATD) 
questionnaire for the UK older people and carer population. 
2. Describe the attitudes of older people and carers in hospital towards 
deprescribing. 
3. Estimate older people and carers in hospitals’ desire to be involved in 
medicine decision-making. 
4. Estimate older people and carers in hospital’ desire to try deprescribing. 
5. Identify any attitudinal predictors of older people and carers in hospitals’ 
desire to try deprescribing. 
 
4.4 Ethics approval 
Ethical and governance approval were obtained from the Greater Manchester West 
Research Ethics Committee (REC reference: 17/NW/0582) and the UK Health 
Research Authority respectively. The study protocol and ethical and governance 
approval letters are provided in appendices 5 and 6 respectively. 
 
4.5 Justification for and critique of the revised Patients’ 
Attitudes Towards Deprescribing questionnaire (rPATD) 
The rPATD was developed through retention of the original 10 items from the 
original validated PATD and additional items generated from a systematic review of 
patient barriers and enablers to deprescribing(198) a qualitative focus groups with 
older people and carers(199). The comprehensive review of the literature and 
additional exploratory work informing the rPATD items affords confidence that it is 
an appropriate tool to measure patients’ and carers’ desire to deprescribe and 
identify the attitudinal predictors of this desire. It is unsurprising that the rPATD 
explores additional potential barriers and enablers to deprescribing relative to the 
PATD given the methodological approach use to generate items, and some of these 
differences are described earlier in the chapter introduction. 
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The rPATD was initially piloted in the Australian setting with 12 older people (mean 
age 83.1 years) and 11 carers (mean age 70.3 years) of such people. Participants 
self-administered the questionnaire, which was iteratively refined to improve 
wording between participants. Concurrent cognitive interviews with a think-aloud 
(see section 1 below for more information on this methodological approach) was 
also employed with the first five participants from each group to facilitate rPATD 
refinement. Participants were also asked whether there were any additional barriers 
or enablers to deprescribing not capture by the rPATD which should be included. 
The piloting was concluded when no further refinements were deemed necessary, 
resulting in a 45-item and 40-item rPATD for patients and carers respectively, with 
face validity established. 
Investigation of the rPATD’s psychometric properties and validation followed the 
piloting and was undertaken through widespread dissemination of the questionnaire, 
with 583 valid responses (383 patients and 200 carers). Internal consistency, which 
is an assessment of how reliably items within a factor (e.g. Burden of taking 
medication) measure the same construct as intended, was evaluated using 
Cronbach’s alpha(200). The Cronbach’s alpha for both the patient and carer 
versions were 0.648 and 0.670 respectively, indicating moderate internal 
consistency(200). 
Content validity, which is the degree to which an item is relevant to, and measures, 
the target construct  barrier or enabler)(201), was evaluated by an expert panel of 
geriatricians, nurses, clinical pharmacologists, pharmacists and researchers. The 
panel scored each item according to whether or not it was an accurate measure of 
the construct. All items were deemed both relevant and to accurately measure the 
construct(201). 
Construct validity is the extent to which items organise into a structure that is 
explanatory of the factors under investigation(202). Exploratory Factor Analysis was 
used to select the items that best represented each rPATD factor. The final four 
factors retained, explained 55.8% and 62% of the variance for the patient and carer 
rPATD versions respectively. 
Finally, test-retest reliability was evaluated, which assesses the within-participant 
consistency of questionnaire items. This is undertaken through administration of the 
questionnaire to the same participants twice, and comparing the responses. The 
rPATD was administered to 22 and 19 patient and carer respondents respectively 
twice, three weeks apart. Test-retest reliability was evaluated using weighted 
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Cohen’s Kappa; no rPATD items performed poorly, 11 items performed ‘fair’, 18 
items performed ‘moderately’, 11 items performed ‘good’ and one item performed 
‘very good’(183). 
The rPATD provides comprehensive coverage of potential barriers and enablers to 
deprescribing and has been validated in a context very similar to the UK setting. 
Whilst the rPATD performed less favourably in some psychometric tests, it was 
deemed an appropriate tool to address the aim of the study which was to capture 
likely desire of patients and carers to deprescribe in the hospital setting. 
 
The remainder of this chapter is divided into two sections: 
Section 1 
Refinement and testing of the Australian-validated rPATD questionnaire for the UK 
setting 
 
Section 2 
Administration of the rPATD, adapted for the UK setting, to older people and carers 
in hospital 
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4.6 Section 1: Refinement and testing of the Australian-
validated rPATD questionnaire for the UK setting 
With the author’s consent, minor adaptations were made to the rPATD(203) prior to 
UK use. People aged ≥65 years in the UK are exempt from prescription charges 
thus an item in the rPATD burden factor exploring views towards paying for 
medication was rephrased to explore perceptions of the National Health Service’s 
(NHS) medication expenditure. The item was phrased “I feel my medicines are 
value for money for the NHS” and appropriate variation for carers. The burden factor 
captures the burden, such as financial, on the individual patient (or carer), whilst the 
re-rephrased item relating to burden on the NHS represents burden to the state. In 
recognition of this difference, for the purposes of data reporting, the re-phrased 
question was presented separately from the burden factor under the heading 
burden to the National Health Service. 
For survey responses to be valid, respondents must interpret the questions as the 
researcher intended and the response choices must allow participants to answer in 
a way that best reflects their views(204). Failure of a survey item to satisfy these 
criteria may result in response error, which is a discrepancy between the theoretical 
truth and that which is reported by the respondent(205). 
The Australian context in which the rPATD was developed and validated is very 
similar to the UK setting, for example in both countries, English is the predominant 
language and both adopt the principle of universal access to healthcare. It is 
therefore very unlikely that using the rPATD in the UK context will lead to a 
significant change in the questionnaire’s psychometric properties. Accordingly, it 
was deemed unnecessary to re-evaluate all rPATD psychometric properties, such 
as internal consistency using Cronbach’s alpha. This is supported by recent use of 
the rPATD in contexts which deviate greater from the Australian setting relative to 
the UK including Ethiopia(206), Malaysia(207), United States of America(208), 
without revalidation. 
However, it was felt that the face and content validity of the re-phrased question 
relating to burden to the National Health Service required assessment by the target 
population prior to a definitive study. Additionally, whilst there are no reasons to 
anticipate that this rephrasing would lead to UK participants experiencing difficulties 
completing the remainder of the Australian-validated rPATD, it was felt that 
assessment of the entire questionnaire in the UK population was warranted to 
determine face and content validity. Minor re-phrasing of one question is very 
74 
 
unlikely to lead to a change in other psychometric properties therefore additional 
assessments of the refined rPATD’s psychometric properties were not deemed 
necessary. 
 
4.6.1 Methodological approach 
The stages of information processing by questionnaire respondents required to 
select a response are provided in figure 8. A respondent must be able to undertake 
each of these stages in order to select a response that accurately reflects their 
opinion. 
 
Figure 8 Stages of information processing undertake to answer questionnaire 
items(204,209) 
 
Question interpretation requires respondents to understand the meaning of the 
words and phrases contained within a question. Including complex jargon resulting 
from an overestimation of the target population’s ability is a common course of 
confusion. Retrieving information from memory involves participants recalling a 
familiar event or situation relevant to forming a response to the question. If the 
question topic is insignificant or unfamiliar, respondents may select an answering by 
‘guessing’ at random or fail to provide an answer all together. When deciding how to 
respond, participants order their initial thoughts in order to form an internal answer, 
which a perceived socially desirable response. Self-censoring is more prominent 
when questions request information perceived as private or confidential such as 
those related to income or lifestyle behaviours(209). Finally, respondents select 
from the available options a response that is an adequately reflection of the 
internally formulated answer. If an option corresponding with the internal answer is 
not available, respondents may become confused or frustrated. Participants may 
select an option that is not representative of their answer to the question or fail to 
provide an answer(204). 
Responses provided following a breakdown in one or more of the information 
processing stages cannot be reliably considered a participant’s views. It is therefore 
Interpret 
question
Retrieve 
information 
from memory
Decide how to 
respond
Select answer 
from available 
responses
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necessary to understand how the target population perceive a questionnaire and 
identify and correct flaws prior to dissemination in a future study. 
 
4.6.1.1 Cognitive interviewing 
Verbal reporting techniques are increasingly used in the testing of health services 
surveys(210). Cognitive interviewing is a form of verbal reporting that allows 
evaluation of how the target audience perceives survey instruments and their 
constructs. How a participant interprets a question, processes the information, 
applies information stored in memory and prepares a response are captured as 
verbal data during the cognitive interview process. Data gathered may be used to 
identify survey flaws and improve questions prior to administration in a study(205). 
Guiding participants to ‘think aloud’ as a direct method of understanding cognitive 
processes was a technique largely developed by Ericsson and Simon in the 
1980s(211). Participants are instructed to perform a task, such as completion of a 
survey, and concurrently verbalise their thought processes allowing the researcher 
to experience how a participant arrives at a given response(212,213). Verbal 
probing is a technique that can be used by researchers in cognitive interviews to 
gain a rich understanding of how a participant has interpreted a question and 
processed specific constructs of a task such as questions in a survey(205,211). 
Testing questionnaire through cognitive interviews has high face validity, as the data 
generated are respondent’s thought processes verbalised as they complete the 
questionnaire, rather than a formed judgement(214). 
A questionnaire designed to capture patients’ experiences of living with end stage 
renal failure was developed and refined using the hybrid think-aloud-verbal probing 
approach(213). Post questionnaire development, participants representative of the 
population of interest underwent cognitive interviewing and were asked to complete 
the questionnaire while ‘reading aloud’ and ‘thinking aloud’ as they responded. The 
addition of verbal probing allowed the interviewer to explore unanticipated 
verbal/non-verbal behaviours such as hesitation. The authors delineated between 
cognitive interviewing and standard piloting, declaring the former allowed for 
refinement in the study population and “clarifying the precise nature and cause of 
[these] issues”(213). 
There is no specific strategy to determine the number of cognitive interviews 
required to test and refine questionnaires. Researchers must therefore apply their 
own judgement. The number of participants required will depend on the how easily 
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interpretable and answerable the questions contained are. The questionnaire may 
proceed through a handful of cognitive interviews without encountering problems. 
On the other hand, new problems may arise with each successive interview and any 
adaptations by the researcher must be tested and may present new problems. 
Sufficient interviews have been conducted when participants express little or no 
difficulty in interpreting and responding to the questionnaire. 
Modest samples sizes of between 5 and 15 individuals are generally used(205) 
based on the following three assumptions(215): 
• Observing four or five participants will identify 80% of problems. 
• Observing additional participants will reveal fewer and fewer new problems. 
• Severe problems are easier to identify with the first few participants. 
 
Assuring the validity of cognitive interviewing as a method of questionnaire testing 
and refinement is challenging and Willis proposes several limitations to this 
methodological approach(205). Participants are generally self-selecting and are 
unlikely to be fully representative of the target population. As such, recruitment 
gravitates towards participants of higher educational levels than average 
questionnaire respondents, unless the recruitment strategy is been developed to 
limit this occurrence. 
The physical and social environments between a cognitive interview study and a 
definitive study will likely differ which may impact on the results. The extent to which 
this is of relevance depends on how likely these factors are to impact on the 
process of question interpretation and answer forming. Additionally, cognitive 
interviews are unlikely to explore motivational barriers as these participants are 
generally patient and forgiving. As a result, cognitive interviews may underestimate 
problems encountered in the field. 
Cognitive interviews tend to focus exclusively on the respondent and do not 
consider problems arising from a researcher who is administering a questionnaire in 
the field. Accordingly, cognitive interviews are not appropriate tools for detecting 
measurement errors arising from the researcher. However, developers can be 
mindful of this and anticipate and address such problems if necessary. 
The aim of cognitive interview data analysis is to review verbalisations on a question 
by question basis and identify and describe problems mapped to modifiable 
question features. There are a range of methods available and two overarching 
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analyses are described by Willis(205); informal analysis and formal coding. In its 
simplest form, informal analysis consists of the researcher hand documenting 
summaries of participants’ verbalisations. This method requires the researcher to 
continuously listen, identify what is relevant and record. While this is the fastest 
method, the cognitive demands on the researcher are significant and non-detection 
of important problems is a risk. Audio recording the sessions is a significant 
improvement(205) and may lend to greater sensitivity as the data can be reviewed 
several times and by additional researchers if necessary. 
Analysis by formal coding involves transcription of verbalisations and examining 
sections of text by assigning coding categories such as “Respondent changes 
question to fit their knowledge”(205). While formal coding may appear rigorous, 
Willis argues that codes do not necessarily reflect the problems. Instead, codes 
represent the behaviours and strategies enacted in response to a problem. Owing to 
this, formal coding may not be the most appropriate method of analysis for 
pretesting questionnaires. 
Willis suggests it is unnecessary and in fact undesirable to pursue formal coding for 
cognitive interviews where the aim is diagnosing problems and making question 
modifications(210). Coding ultimately results in data reduction and removing the 
‘problem’ from its context, the original comment, provides less information to 
facilitate adaptation. As a result, the researcher is required to return to the original 
text for context, rendering the code useless. Accordingly, Willis advocates 
qualitative written comments derived from informal analysis, which are “wholly 
suitable-and even preferable-for this purpose”(210). 
 
4.6.2 Methods 
This project was overseen by the project management group described in Chapter 
3. 
 
Face and content validity of the UK adapted rPATD were assessed using cognitive 
interviews with older people and carers. 
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4.6.2.1 Participant identification and recruitment 
Members of the public with demographic characteristics similar to the older people 
and carers populations in which the UK adapted rPATD is intended to be used in a 
future hospital study were recruited. 
 
4.6.2.1.1 Study sample 
Older people aged ≥65 years prescribed ≥5 medicines (polypharmacy(216)) were 
eligible. Anyone self-reporting an unpaid role in managing the medication of 
somebody satisfying the inclusion criteria for the study’s older people participant 
arm were eligible as carers. People unable to speak or read English and carers 
aged <18 years old were excluded. 
 
4.6.2.1.2 Recruitment 
Participants were recruited from the large pool of students and employees at the 
University of East Anglia (UEA). 
Due to the rPATD having been validated in a context similar to the UK and only the 
one minor adaptation made, it was envisaged the number of interviews necessary 
would be on the lower end of the five to 15 guide cited in the literature(205). Given 
that the patient and carer rPATD versions are very similar except for the item 
perspectives, the combined number of patients and carers required to test the 
adapted rPATD versions required was estimated to be five. 
Posters inviting eligible people to participate in the study were placed across the 
university campus in permitted locations such as coffee shops, advertising boards 
and social spaces. Additionally, an advertisement was placed in the university-wide 
weekly email bulletin 
A summary of the participant recruitment process is provided in figure 9. People 
contacting the researcher expressing an interest in the study were offered a 
participant information leaflet (PIL) relevant to the participant group relevant to them 
(older person or carer) including details of the study and how to enrol sent via email, 
UEA internal mail (if UEA staff or student) or by post. 
Eligible potential participants expressing a desire to participate were invited by a 
researcher to a mutually convenient 30-40 minute appointment at the UEA. 
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4.6.2.1.3 The cognitive interview appointment 
Written, informed consent was obtained prior to any data collection. Participants 
were also asked to provide the following demographic information using a data 
collection form: 
• Type of participant (older person or carer) 
• Gender 
• Age 
• Number of prescribed medicines (taken by care recipient if carer) 
 
During the cognitive interviews, the researcher directed the participants through the 
think-aloud procedure. The interviews were audio recorded and the researcher 
observed the participant completing the questionnaire and concomitant think-aloud 
process, taking notes where appropriate. The researcher used verbal probing where 
necessary during the think-aloud process and/or at the end of the interview. 
The procedure was as follows: 
1. The think-aloud procedure requires the participant to be taught how to 
undertake the task. This involves a brief practice exercise at the 
beginning of the interview to prepare the participant for the process. The 
training task employed is provided below: 
2. “Try to visualize the place where you live, and think about how many 
windows there are in that place. As you count up the windows, tell me 
what you are seeing and thinking about it”(205). 
3. After the practice exercise, the researcher invited questions and provided 
clarification where necessary. 
4. Once satisfied the participants is familiar with the think-aloud process, 
the researcher read out the following instructions verbatim: 
5. “Think-aloud as you complete the questionnaire. Please pretend as if I 
am not here and do not ask for my assistance during the task. If you fall 
silent for a while, I will remind you to continue to think aloud and I may 
ask some questions during the process. If you feel uncomfortable at any 
stage, please let me know that you’d like to stop. Finally, please 
remember I am testing the questionnaire and not you during this 
process. Do you have any questions before we start?” 
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6. The researcher minimised their influence on the participants think-aloud 
process by sitting out of line of sight. Participants were not interrupted 
during the think-aloud, however prompt to continue thinking-aloud during 
period of silence and asked probing questions where appropriate. 
7. Upon completion of the questionnaire, the researcher undertook verbal 
probing to further explore participant interpretation and processing of 
questionnaire construct where necessary. 
8. Once the interview is complete, participants were thanked for their 
participation and provided an opportunity to submit additional feedback 
on any part of the research process. 
 
Figure 9 characterises how the questionnaire adaptation and cognitive interviewing 
process continued until no further refinements were necessary.
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Figure 9 Process of questionnaire adaptation and refinement using the cognitive 
interview method
Cognitive 
interview
Questionnaire 
adapted by 
healthcare 
practitioners and 
researchers
Individual 1:1 cognitive 
interview conducted
Participant completes 
questionnaire and verbalises 
thoughts
Verbalisations documented 
by researcher
Results suggest 
questionnaire 
requires 
refinement?
Yes
Additional cognitive 
interview necessary 
to test new 
adaptation
No
Adapted 
questionnaire 
refnement complete
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4.6.2.1.4 Data analysis 
No analysis of participant questionnaire responses was undertaken as the aim was 
to determine face and content validity of the rPATD adapted for the UK context. 
The research team applied judgement in determining the implications of cognitive 
interview findings. The required number of interviews was determined by the 
research team was dictated by the number of interviews required for questionnaire 
refinement. 
Informal analysis of cognitive interviews as described earlier in this chapter was 
undertaken. Handwritten notes made by the researcher during the cognitive 
interviews and subsequent review of audio recordings with the wider research team 
were analysed to inform problem identification and questionnaire refinement. 
After completing each cognitive interview, a report was prepared comprising: 
1. A summary of any problems identified for each question. 
2. An overall summary including general observations of how participants 
described their experience of completing the questionnaire. 
 
The report was presented to the wider research team for comment and a decision 
made to either make adaptations and re-enter cognitive interviewing for further 
testing or terminate the adaptation process as detailed in figure 9. 
 
4.6.3 Results 
After three cognitive interviews with older people and carers (six in total), no further 
recommendations for improving the rPATD items were suggested. Patient 
participant’s ages ranged between 69 and 73 years and two were male. Patients 
were taking between five and 15 medicines. All three carer participants were female 
aged between 28 and 54 years and, two of their care recipients were female. 
Carers’ care recipients were taking between five and 11 medicines. 
A summary of the problems identified and changes made to patient and carer 
questionnaire versions are provided in tables 7 and 8 respectively. No 
recommendations for improving the original rPATD items were identified. However, 
the first participant, a carer, expressed difficulty with responding to the adapted item 
regarding NHS spending on medication, citing insufficient knowledge of the cost-
effectiveness of medicines. This in turn led to difficulties with expressing a view on 
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whether they felt medicines were providing value for money to the NHS. The 
participant acknowledged the relevance of exploring views towards medication 
expenditure and suggested rephrasing the item as follows: “I feel the NHS spends a 
lot of money on my care recipient’s medicines”. The proposed revision was 
accepted by the research team and presented to subsequent participants, with 
appropriate adaptation for the patient rPATD version. The adapted item was 
acceptable to the remaining two carers and three patients, thus no further 
refinements were necessary. No additional factors potentially influencing attitudes 
towards deprescribing not already present in the rPATD were proposed. As face 
and content validity were demonstrated, no further adaptations to the rPATD were 
necessary.
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Table 7 Report for patient questionnaire cognitive interviews 
1. Participant and cognitive interview characteristics 
 Patient 1 (participant 2) Patient 2 (participant 4) Patient 3 (participant 6) 
Age 69 87 73 
Gender Male Male Female 
Number of medicines 6 5 15 
Time taken to complete questionnaire 
(mm:ss) 
12:52 14:49 06:57 
2. Questionnaire review 
Burden to the National Health Service 
I feel my medicines are value for 
money for the NHS* 
Question not present in the 
questionnaire version 
completed by this participant 
Question not present in the 
questionnaire version completed 
by this participant 
Question not present in the 
questionnaire version 
completed by this participant 
I feel the National Health Service 
(NHS) spends a lot of money on my 
medicines** 
No issues No issues No issues 
Burden 
Taking my medicines every day is 
very inconvenient 
No issues No issues No issues 
I feel that I am taking a large number 
of medicines 
No issues No issues No issues 
I feel that my medicines are a burden 
to me 
No issues No issues No issues 
Sometimes I think I take too many 
medicines 
No issues No issues No issues 
Appropriateness 
I feel that I may be taking one or more 
medicines that I no longer need 
No issues No issues No issues 
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Table 7 (continued) 
I would like to try stopping one of my 
medicines to see how I feel without it 
No issues No issues No issues 
I would like my doctor to reduce the 
dose of one or more of my medicines 
No issues No issues No issues 
I think one or more of my medicines 
may not be working 
No issues No issues No issues 
I believe one or more of my medicines 
may be currently giving me side 
effects 
No issues No issues No issues 
Concerns about stopping 
I would be reluctant to stop a 
medicine that I had been taking for a 
long time 
No issues No issues No issues 
If one of my medicines was stopped, I 
would be worried about missing out 
on future benefits 
No issues No issues No issues 
I get stressed whenever changes are 
made to my medicines 
No issues No issues No issues 
If my doctor recommended stopping a 
medicine, I would feel that he/she was 
giving up on me 
No issues No issues No issues 
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Table 7 (continued) 
I have had a bad experience when 
stopping a medicine before 
No issues No issues No issues 
Involvement 
I have a good understanding of the 
reasons I was prescribed each of my 
medicines 
No issues No issues No issues 
I know exactly what medicines I am 
currently taking, and/or I keep an up-
to-date list of my medicines 
No issues No issues No issues 
I like to know as much as possible 
about my medicines 
No issues No issues No issues 
I like to be involved in making 
decisions about my medicines with my 
doctors 
No issues No issues No issues 
I always ask my doctor, pharmacist or 
other healthcare professional if there 
is something I don’t understand about 
my medicines 
No issues No issues No issues 
Global 
If my doctor said it was possible I 
would be willing to stop one or more 
of my regular medicines 
No issues No issues No issues 
Overall, I am satisfied with my current 
medicines 
No issues No issues No issues 
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Table 7 (continued) 
Additional comments Questionnaire was 
aesthetically appropriate and 
easy to complete in an 
acceptable amount of time. 
Questionnaire was aesthetically 
appropriate and easy to 
complete in an acceptable 
amount of time. 
Questionnaire was aesthetically 
appropriate and easy to 
complete in an acceptable 
amount of time. 
3. Conclusion 
Additional researcher comments Nil Nil Participant wanted the 
researcher to be aware that 
they had dyslexia and were 
able to complete the 
questionnaire with no 
problems. 
 
 
 
   
4. Research team refinement decisions 
 No refinements necessary No refinements necessary No refinements necessary 
*Question removed and replaced by a re-phrased version (see below) based on feedback from carer 1 (table 8) 
**Question re-phrased from “I feel my medicines are value for money for the NHS” as originally proposed by the research team based on 
feedback from carer 1 (table 8)
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Table 8 Report for carer questionnaire cognitive interviews 
1. Participant and cognitive interview characteristics 
 Carer 1 (participant 1) Carer 2 (participant 3) Carer 3 (participant 5) 
Age 54 28 49 
Gender Female Female Female 
Number of medicines taken by care 
recipient 
11 8 5 
Time taken to complete 
questionnaire (mm:ss) 
16:30 23:16 14:00 
2. Questionnaire review 
Burden to the National Health Service 
I feel my care recipients’ medicines 
are value for money for the NHS 
Issue: 
The participant felt this question 
was difficult to answer as their 
care recipient was exempt from 
paying for medicines and thus it 
was difficult to determine whether 
the medicines were value for 
money. The participant conveyed 
an appreciation for the rationale 
behind the question however felt 
it requested them to ‘calculate’ 
the value of medicines. The 
participant suggested the revised 
question following probing. 
Question not present in the 
questionnaire version completed 
by this participant 
Question not present in the 
questionnaire version 
completed by this participant 
I feel the National Health Service 
(NHS) spends a lot of money on my 
care recipient’s medicines 
Question added after this 
participant completed the 
questionnaire 
No issues No issues 
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Table 8 (continued) 
Burden 
I feel that the person I care for is 
taking a large number of medicines 
No issues No issues No issues 
I feel that my care recipient’s 
medicines are a burden to them 
No issues No issues No issues 
Sometimes I think the person I care 
for takes too many medicines 
 
 
 
No issues No issues No issues 
Appropriateness 
I feel that the person that I care for 
may be taking one or more 
medicines that they no longer need 
No issues No issues No issues 
I would like the doctor to try stopping 
one of my care recipient’s medicines 
to see how they feel without it 
No issues No issues No issues 
I would like the doctor to reduce the 
dose of one or more of my care 
recipient’s medicines 
No issues No issues No issues 
I think one or more of my care 
recipient’s medicines may not be 
working 
No issues No issues No issues 
I believe one or more of my care 
recipient’s medicines may be 
currently giving them side effects 
No issues No issues No issues 
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Table 8 (continued) 
Concerns about stopping 
I would be reluctant to stop one of 
my care recipient’s medicines that 
they had been taking for a long time 
No issues No issues No issues 
I get stressed whenever changes 
are made to my care recipient’s 
medicines 
No issues No issues No issues 
I feel that if I agreed to stopping one 
of my care recipient’s medicines 
then this is giving up on them 
No issues No issues No issues 
The person that I care for has had a 
bad experience when stopping a 
medicine before 
No issues No issues No issues 
Involvement 
I know exactly what medicines the 
person that I care for is currently 
taking and/or I have an up-to-date 
list of their medicines 
No issues No issues No issues 
I like to know as much as possible 
about my care recipient’s medicines 
No issues No issues No issues 
I like to be involved in making 
decisions about my care recipients 
medicines with their doctors 
No issues No issues No issues 
I always ask the doctor, pharmacist 
or other healthcare professional if 
there is something I don’t 
understand about my care 
recipient’s medicines 
No issues No issues No issues 
 
91 
 
Table 8 (continued) 
Global 
If their doctor said it was possible I 
would be willing to stop one or more 
of my care recipient’s medicines 
No issues No issues No issues 
Overall, I am satisfied with my care 
recipient’s current medicines 
No issues No issues No issues 
Additional comments Question: “I feel my care 
recipients’ medicines are value for 
money for the NHS” suggested to 
be re-phrased to capture whether 
participants felt a lot of money 
was spent on medicines. 
 
Questionnaire was aesthetically 
appropriate and easy to complete 
in an acceptable amount of time. 
Questionnaire was aesthetically 
appropriate and easy to 
complete in an acceptable 
amount of time. 
Questionnaire was 
aesthetically appropriate and 
easy to complete in an 
acceptable amount of time. 
3. Conclusion 
Additional researcher comments Nil Nil Nil 
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Table 8 (continued) 
4. Research team refinement decisions 
 Question: “I feel my care 
recipients’ medicines are value for 
money for the NHS” revised 
based on participants’ feedback 
and the carer research team 
representative to “I feel the 
National Health Service (NHS) 
spends a lot of money on my care 
recipient’s medicines”. 
 
The patient version of the 
question was also rephrased to “I 
feel the National Health Service 
(NHS) spends a lot of money on 
my medicines” on the advice of 
the patient research team 
representative. 
No refinements necessary No refinements necessary 
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4.7 Section 2: Administration of the rPATD, adapted for the UK 
setting, to older people and carers in hospital 
 
4.7.1 Methods 
This project was overseen by the project management group described in Chapter 
3. 
 
4.7.1.1 Study sample and setting 
Patients and visiting carers were independently recruited (i.e. they were not paired) 
from seven Older People’s Medicine (OPM) wards at one and two UK hospitals 
respectively. Criteria for patients triaged to an OPM ward were minimum age 
(ranging between 70 to 80 years across sites) and either multiple co-morbidities or 
physical frailty.  
All inpatients from OPM wards prescribed at least five pre-admission medicines 
(polypharmacy(216)) were eligible. The number of pre-admission medicines was 
determined from the hospitals’ pharmacy medicines reconciliation records, which 
use at least two sources of information, such as a community pharmacy record and 
a patient’s own report, to establish an accurate medication history. Patients unable 
to speak or read English, deemed by the healthcare team as unable to provide 
informed consent, inappropriate to approach for recruitment for reasons such as 
being seriously unwell or unable to make informed decisions about medicines were 
excluded. For patients who were unable to provide informed consent or make 
informed decisions about medicines, any of their visitors during the study period 
were screened as carer participants. Accordingly, patients and carers were not 
paired. 
All visitors self-reporting an unpaid role in managing the medication of an inpatient 
satisfying the inclusion criteria for the study’s patient participant arm were eligible as 
carers. Carers unable to speak or read English and aged <18 years old were 
excluded. 
 
4.7.1.2 Recruitment and survey administration 
Patients were screened for eligibility and approached for inclusion by an OPM 
doctor, nurse or pharmacist. Patients expressing an interest were approached by a 
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researcher who provided an information leaflet and answered questions. Written, 
informed consent was obtained for rPATD administration and collection of 
demographic information. The rPATD was self-completed on an electronic tablet by 
patients at the bedside with a researcher present to assist if necessary. Patient 
demographics and the number of pre-admission medicines were recorded. 
Visitors of OPM wards were screened by a research nurse for eligibility to determine 
whether they were carers self-reporting an unpaid role in managing the medication 
of an OPM patient. Only one carer per OPM patient was approached for recruitment 
as it was deemed unethical by the study team’s patient and carer members to 
approach several carers for one patient. As no identifiable personal information was 
collected from carers, consent was implied through self-completion of the 
questionnaire. Carers who agreed to participante were provided with a 
questionnaire pack including an anonymous demographic information collection 
form and the rPATD. Carers were invited to self-complete the questionnaire and 
provide demographic information for themselves and their care recipient in addition 
to indicating their relationship with the care recipient and the number of pre-
admission medications. Carers were instructed to return the pack to a member of 
ward staff. 
Participants were asked to respond to the rPATD reflecting on medication as 
prescribed prior to admission (pre-admission medicines) but in the context of 
deprescribing in the hospital setting. 
 
4.7.1.3 Sample size justification 
No participant data are reported for the rPATD to inform sample size estimation. 
Participant data from the original PATD indicate the largest difference in the 
proportion of respondents agreeing with a dichotomised outcome was 65% to 35%, 
representing the ‘worst case scenario’ in terms of precision(109). This was reported 
for the item “I feel that I am taking a large number of medications”. Accordingly, 
responses for all items are estimated to a reasonable degree of precision. 
Based on the 65% to 35% PATD response distribution, assuming a similar 
distribution for the rPATD and anticipated minimal adaptations required for UK use, 
a sample of 75 participants per population provides a 95% confidence interval (CI) 
of ±11.0% or smaller around the estimates of agreement with each rPATD item. 
This sample size is therefore appropriate for estimating the percentage ‘agreement’ 
with dichotomised rPATD items. 
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4.7.1.4 Statistical analysis 
Analyses were performed using IBM SPSS Statistics version 23.0 for Windows. 
Descriptive statistics were used to characterise the participants and rPATD 
responses. Items are reported grouped under the four rPATD factors; burden, 
appropriateness, concerns about stopping and involvement and new heading 
burden to the National Health Service. Global item 1 captures willingness to accept 
deprescribing proposed by a doctor and global item 2 captures satisfaction with 
current medications. 
The primary outcome of desire to try stopping a medicine was the appropriateness 
question “I would like to try stopping one of my medicines to see how I feel without 
it” (patients) and “I would like the doctor to try stopping one of my care recipient’s 
medicines to see how they feel without it” (carers). 
In order to identify respondents with a desire to try stopping a medicine, responses 
to the primary outcome, involvement item relating to likely desire to be involved in 
medicine decision-making and the and two global rPATD questions were 
dichotomised into those in agreement (agree and strongly agree) and those 
ambivalent or in disagreement (strongly disagree, disagree and neither agree nor 
disagree). 
 
4.7.1.4.1 Logistic regression 
Logistic regression analysis is a statistical modelling approach used to describe the 
relationship between several predictor variables to a dichotomous dependent 
variable, where the latter is typically coded as 1 or 0 for its possible two 
categories(217). The logistic model is defined as a probability of the occurrence of 
one of two possible outcomes. The resultant logistic model is useful in situations 
where the response variable takes only one of two possible values. The first step of 
a logistic regression analysis is to postulate a statistical model describing the 
relationship between the dependent and independent variables. The model is then 
fitted to the data and the adequacy of fit is verified. Appropriate statistical inferences 
are then made and the relationship between predictors and the dependent variable 
is quantified by a parameter termed the odds ratio. 
Backward binary logistic regression was performed between statements in the four 
factors and the primary outcome. To identify perceived barriers predicting desire to 
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try stopping a medicine, responses to each statement were dichotomised into those 
who disagreed that it was a barrier (strongly disagree and disagree) and those who 
were ambivalent or in agreement (neither agree nor disagree, agree and strongly 
agree) that it was a barrier. Variables with less than 5.0% distribution in responses 
cross-tabulated with the primary outcome were excluded as it was felt that these 
had insufficient variability to be reliably modelled. 
 
4.7.2 Results 
Figure 10 summarises recruitment of patients and carers; the primary reason for 
patient ineligibility was being unable to provide informed consent. For carers, non-
involvement with medicines was the primary reason for exclusion.
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Figure 10 Participant recruitment flow
Patients Carers 
Screened for eligibility 
n=215 
Eligible 
n=107 
Excluded (n=108) 
• 71 Unable to 
provide 
informed 
consent 
• 15 Seriously 
unwell 
• 12 Unable to 
make 
decisions 
about 
medicines 
• 10 Other 
Recruited 
n=75 
Not recruited (n=32) 
• 8 Discharged 
• 1 Deceased 
• 22 Declined 
• 1 Other 
Screened for eligibility 
n=215 
Eligible 
n=113 
Excluded (n=102) 
• 45 non-
involvement 
with medicines 
• 29 care 
recipient not 
cared for by 
the OPM 
speciality 
• 15 care 
recipient 
prescribed <5 
medicines 
• 7 carer <18 
• 5 care recipient 
seriously 
unwell 
• 1 carer 
unavailable 
Recruited 
n=76 
Not recruited (n=41) 
• 18 declined 
• 11 carer 
departed without 
completing 
questionnaire 
• 11 care recipient 
deteriorated 
• 1 care recipient 
objected 
Provided complete questionnaire data 
n=72 
Provided 
incomplete 
questionnaire data 
n=4 
Provided complete questionnaire data 
n=75 
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4.7.2.1 Patients 
Recruitment of the target 75 patients from those eligible produced a recruitment rate 
of 70.1% (95% CI: 52.7, 87.5). The median (IQ) age was 87.0 (83.0, 90.0) years 
and 34 (45.3%) were female. The median (IQ) number of medications prescribed 
prior to admission was 8.0 (6.0, 10.0). 
 
4.7.2.1.1 Responses to the rPATD questionnaire 
Table 9 illustrates patients’ rPATD responses. Agreement with deprescribing 
proposed by a doctor was high, with 97.4% (95% confidence interval (CI) (93.8-
100.0)) agreeing with global item 1 (If my doctor said it was possible I would be 
willing to stop one or more of my regular medicines). Conversely, only 29.3% (95% 
CI 19.0-39.6) agreed with the primary outcome item (I would like to try stopping one 
of my medicines to see how I feel without it). A further 92.0% (95% CI 85.9-98.1) 
agreed with global item 2 (Overall, I am satisfied with my current medicines), 
indicating high satisfaction with current medications. Just over half (58.7% (95% CI 
47.6-69.8)) of patients expressed a desire to be involved in medication-decision 
making in response to the relevant involvement item (I like to be involved in making 
decisions about my medicines with my doctors).
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Table 9 Patients’ responses to the rPATD 
Item 
 
Strongly 
disagree 
Number 
(%) 
Disagree 
Number 
(%) 
Neither 
agree 
nor 
disagree 
Number 
(%) 
Agree 
Number 
(%) 
Strongly 
agree 
Number 
(%) 
% 
(95% 
CI) 
agree* 
Burden to the National Health Service 
I feel the 
National Health 
Service (NHS) 
spends a lot of 
money on my 
medicines 
1 (1.3) 4 (5.3) 7 (9.3) 
44 
(58.7) 
19 (25.3) 
84.0 
(75.7-
92.2 
Burden 
Taking my 
medicines 
every day is 
very 
inconvenient 
22 (29.3) 37 (49.3) 4 (5.3) 
11 
(14.7) 
1 (1.3) 
16.0 
(7.7-
24.3) 
I feel that I am 
taking a large 
number of 
medicines 
6 (8.0) 26 (34.7) 7 (9.3) 
27 
(36.0) 
9 (12.0) 
48.0 
(37.0-
59.3) 
I feel that my 
medicines are 
a burden to me 
21 (28.0) 38 (50.7) 5 (6.7) 7 (9.3) 4 (5.3) 
14.6 
(6.6-
22.6) 
Sometimes I 
think I take too 
many 
medicines 
11 (14.7) 26 (34.7) 7 (9.3) 
23 
(30.7) 
8 (10.7) 
41.4 
(30.3-
52.5) 
Appropriateness 
I feel that I may 
be taking one 
or more 
medicines that 
I no longer 
need 
13 (17.3) 29 (38.7) 8 (10.7) 
17 
(22.7) 
8 (10.7) 
33.4 
(22.7-
44.1) 
I would like to 
try stopping 
one of my 
medicines to 
see how I feel 
without it* 
14 (18.7) 30 (40.0) 9 (12.0) 
16 
(21.3) 
6 (8.0) 
29.3 
(19.0-
39.6) 
I would like my 
doctor to 
reduce the 
dose of one or 
more of my 
medicines 
13 (17.3) 32 (42.7) 15 (20.0) 
11 
(14.7) 
4 (5.3) 
20.0 
(10.9-
29.1) 
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Table 9 (continued) 
Item 
 
Strongly 
disagree 
Number 
(%) 
Disagree 
Number 
(%) 
Neither 
agree 
nor 
disagree 
Number 
(%) 
Agree 
Number 
(%) 
Strongly 
agree 
Number 
(%) 
% 
(95% 
CI) 
agree* 
I think one or 
more of my 
medicines may 
not be working 
12 (16.0) 26 (34.7) 22 (29.3) 
13 
(17.3) 
2 (2.7) 
20.0 
(10.9-
29.1) 
I believe one or 
more of my 
medicines may 
be currently 
giving me side 
effects 
21 (28.0) 29 (38.7) 4 (5.3) 
15 
(20.0) 
6 (8.0) 
28.0 
(17.8-
38.1) 
Concerns about stopping 
I would be 
reluctant to 
stop a 
medicine that I 
had been 
taking for a 
long time 
7 (9.3) 35 (46.7) 5 (6.7) 
21 
(28.0) 
7 (9.3) 
37.3 
(26.4-
48.4) 
If one of my 
medicines was 
stopped, I 
would be 
worried about 
missing out on 
future benefits 
14 (18.7) 28 (37.3) 5 (6.7) 
25 
(33.3) 
3 (4.0) 
37.3 
(26.4-
48.4) 
I get stressed 
whenever 
changes are 
made to my 
medicines 
17 (22.7) 39 (52.0) 7 (9.3) 
10 
(13.3) 
2 (2.7) 
16.0 
(7.7-
24.3) 
If my doctor 
recommended 
stopping a 
medicine, I 
would feel that 
he/she was 
giving up on 
me 
30 (40.0) 31 (41.3) 2 (2.7) 8 (10.7) 4 (5.3) 
16.0 
(7.7-
24.3) 
I have had a 
bad experience 
when stopping 
a medicine 
before 
53 (70.7) 11 (14.6) 5 (6.7) 4 (5.3) 2 (2.7) 
20.7 
(11.5-
29.9) 
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Table 9 (continued) 
Item 
 
Strongly 
disagree 
Number 
(%) 
Disagree 
Number 
(%) 
Neither 
agree 
nor 
disagree 
Number 
(%) 
Agree 
Number 
(%) 
Strongly 
agree 
Number 
(%) 
% 
(95% 
CI) 
agree* 
Involvement 
I have a good 
understanding 
of the reasons 
I was 
prescribed 
each of my 
medicines 
6 (8.0) 3 (4.0) 6 (8.0) 
38 
(50.7) 
22 (29.3) 
80.0 
(70.9-
89.1) 
I know exactly 
what 
medicines I 
am currently 
taking, and/or 
I keep an up-
to-date list of 
my medicines 
5 (6.7) 10 (13.3) 3 (4.0) 
28 
(37.3) 
29 (38.7) 
76.0 
(66.3-
85.7) 
I like to know 
as much as 
possible 
about my 
medicines 
3 (4.0) 10 (13.3) 5 (6.7) 
35 
(46.7) 
22 (29.3) 
76.0 
(66.3-
85.7) 
I like to be 
involved in 
making 
decisions 
about my 
medicines 
with my 
doctors 
6 (8.0) 19 (25.3) 6 (8.0) 
23 
(30.7) 
21 (28.0) 
58.7 
(47.6-
69.8 
I always ask 
my doctor, 
pharmacist or 
other 
healthcare 
professional if 
there is 
something I 
don’t 
understand 
about my 
medicines 
1 (1.3) 13 (17.3) 2 (2.7) 
33 
(44.0) 
26 (34.7) 
78.7 
(69.4-
88.0 
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Table 9 (continued) 
Item 
 
Strongly 
disagree 
Number 
(%) 
Disagree 
Number 
(%) 
Neither 
agree 
nor 
disagree 
Number 
(%) 
Agree 
Number 
(%) 
Strongly 
agree 
Number 
(%) 
% 
(95% 
CI) 
agree* 
Global 
If my doctor 
said it was 
possible I 
would be 
willing to stop 
one or more 
of my regular 
medicines 
1 (1.3) 1 (1.3) 0 
50 
(66.7) 
23 (30.7) 
97.4 
(93.8-
100) 
Overall, I am 
satisfied with 
my current 
medicines 
0 1 (1.3) 5 (6.7) 
49 
(65.3) 
20 (26.7) 
92.0 
(85.9-
98.1) 
*Sum of agree and strongly agree
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4.7.2.1.2 Regression analysis 
All items had at least 5% distribution in responses when cross-tabulated with the 
primary outcome (appendix 8) and were therefore all entered into the regression 
analysis. The resulting model predicted 62.9% (Negelkerke R2) of the variance and 
the Hosmer and Lemeshow goodness-of-fit test implied the model’s estimates fit the 
data to an acceptable level (p=0.238). The full regression analysis is provided in 
table 10. The predictors of a patients’ lack of desire to try stopping a medicine were 
the burden item “Sometimes I think I take too many medicines” and the 
appropriateness items “I feel that I may be taking one or more medicines that I no 
longer need” and “I would like my doctor to reduce the dose of one or more of my 
medicines”.
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Table 10 Regression analysis of rPATD items predicting lack of patients’ desire to try stopping a medicine 
rPATD item 
Number agree with item* (% 
not willing to deprescribe**) 
Unadjusted 
OR 
p-value 
Adjusted 
OR 
p-
value 
Burden to the National Health Service 
I feel the National Health Service (NHS) spends a lot of 
money on my medicines 
70 (58.6) 0.943 0.950   
Burden 
Taking my medicines every day is very inconvenient 16 (43.8) 0.462 0.177   
I feel that I am taking a large number of medicines 43 (46.5) 0.290 0.015*   
I feel that my medicines are a burden to me 16 (31.3) 0.233 0.016*   
Sometimes I think I take too many medicines 38 (31.6) 0.072 <0.001** 0.195 0.045* 
Appropriateness 
I feel that I may be taking one or more medicines that I 
no longer need 
33 (27.3) 0.075 <0.001** 0.179 0.016* 
I would like to try stopping one of my medicines to see 
how I feel without it (entered as the dependent 
variable/primary outcome) 
     
I would like my doctor to reduce the dose of one or more 
of my medicines 
30 (23.3) 0.066 <0.001** 0.199 0.021* 
I think one or more of my medicines may not be working 37 (37.8) 0.162 0.001*   
I believe one or more of my medicines may be currently 
giving me side effects 
25 (44.0) 0.405 0.071   
Concerns about stopping 
I would be reluctant to stop a medicine that I had been 
taking for a long time 
33 (57.6) 1.084 0.865   
If one of my medicines was stopped, I would be worried 
about missing out on future benefits 
33 (60.6) 0.867 0.762   
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Table 10 (continued) 
rPATD item 
Number agree with item* 
(% not willing to 
deprescribe**) 
Unadjusted 
OR 
p-value 
Adjusted 
OR 
p-
value 
I get stressed whenever changes are made to my 
medicines 
19 (47.4) 1.852 0.250   
If my doctor recommended stopping a medicine, I would 
feel that he/she was giving up on me 
14 (57.1) 1.080 0.898   
I have had a bad experience when stopping a medicine 
before 
 
11 (63.6) 0.783 0.718   
Involvement 
I have a good understanding of the reasons I was 
prescribed each of my medicines 
66 (65.2) 14.957 0.013*   
I know exactly what medicines I am currently taking, 
and/or I keep an up-to-date list of my medicines 
60 (63.3) 2.591 0.107   
I like to know as much as possible about my medicines 62 (58.1) 0.865 0.817   
I like to be involved in making decisions about my 
medicines with my doctors 
50 (58.0) 0.921 0.868   
I always ask my doctor, pharmacist or other healthcare 
professional if there is something I don’t understand about 
my medicines 
61 (57.4) 0.748 0.637   
*Number of participants out of total of n=75 who agree (agreed or strongly agree) that the rPATD item was a barrier or enabler 
**Proportion of participants who disagree (disagree or strongly disagree) with the primary outcome question of expressing a desire to try 
stopping a medicine (“I would like to try stopping one of my medicines to see how I feel without it”) 
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4.7.2.2 Carers 
The carer arm over recruited by one participant producing a recruitment rate of 
67.2% (95% CI: 49.9, 84.5) for the 76 carers who completed the questionnaire. 
Thirty-five (46.1%) carers were a spouse or partner and the remaining 41 (53.9%) 
were another relative. The median (IQ) age of carers and care recipients were 70.0 
(57.0, 83.0) and 86 (83.0, 89.0) respectively. Females constituted 47 (61.8%) and 
48 (63.2%) of carers and care recipients respectively. The median (IQ) number of 
medicines prescribed for care recipients prior to admission was 8.0 (6.0, 10.3). 
 
4.7.2.2.1 Responses to the rPATD questionnaire 
Table 11 illustrates carers’ rPATD responses. Agreement with deprescribing 
proposed by a doctor was high, with 76.3% (95% CI 66.7-85.9) of carers agreeing 
with global item 1 (If their doctor said it was possible I would be willing to stop one 
or more of my care recipient’s medicines). Conversely, only 43.5% (95% CI 32.4-
54.6) agreed with the primary outcome (I would like the doctor to try stopping one of 
my care recipient’s medicines to see how they feel without it). A further 80.3% (95% 
CI 71.3-89.3) agreed with global item 2 (Overall, I am satisfied with my care 
recipient’s current medicines), indicating high satisfaction with current medications. 
Approximately two thirds of carers (65.8% (95% CI 55.1-76.5)) expressed a desire 
to be involved in medication-decision making in response to the relevant 
involvement item (I like to be involved in making decisions about my care recipients 
medicines with their doctors).
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Table 11 Carers’ responses to the rPATD 
Item Strongly 
disagree 
Number 
% 
Disagree 
Number 
% 
Neither 
agree 
nor 
disagree 
Number 
% 
Agree 
Number 
% 
Strongly 
agree 
Number 
% 
% 
(95% 
CI) 
agree* 
Burden to the National Health Service 
I feel the 
National Health 
Service (NHS) 
spends a lot of 
money on my 
care recipient’s 
medicines 
0 5 (6.6) 28 (36.8) 
26 
(34.2) 
17 (22.4) 
56.6 
(45.5-
67.7) 
Burden 
I feel that the 
person I care 
for is taking a 
large number 
of medicines 
4 (5.3) 14 (18.4) 18 (23.7) 
31 
(40.8) 
9 (11.8) 
52.6 
(41.4-
63.8) 
I feel that my 
care recipient’s 
medicines are 
a burden to 
them 
8 (10.5) 37 (48.7) 14 (18.4) 
16 
(21.1) 
1 (1.3) 
22.4 
(13.0-
31.8) 
Sometimes I 
think the 
person I care 
for takes too 
many 
medicines 
8 (10.5) 21 (27.6) 23 (30.3) 
21 
(27.6) 
3 (3.9) 
31.5 
(21.1-
41.9) 
Appropriateness 
I feel that the 
person that I 
care for may be 
taking one or 
more 
medicines that 
they no longer 
need 
4 (5.3) 22 (28.9) 22 (28.9) 
25 
(32.9) 
3 (3.9) 
36.8 
(26.0-
47.6) 
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Table 11 (continued) 
Item Strongly 
disagree 
Number 
% 
Disagree 
Number 
% 
Neither 
agree 
nor 
disagree 
Number 
% 
Agree 
Number 
% 
Strongly 
agree 
Number 
% 
% 
(95% 
CI) 
agree* 
I would like the 
doctor to try 
stopping one of 
my care 
recipient’s 
medicines to 
see how they 
feel without it* 
7 (9.2) 22 (28.9) 14 (18.4) 
29 
(38.2) 
4 (5.3) 
43.5 
(32.4-
54.6) 
I would like the 
doctor to 
reduce the 
dose of one or 
more of my 
care recipient’s 
medicines 
7 (9.2) 22 (28.9) 29 (38.2) 
16 
(21.1) 
2 (2.6) 
23.7 
(14.1-
33.3) 
I think one or 
more of my 
care recipient’s 
medicines may 
not be working 
5 (6.6) 22 (28.9) 32 (42.1) 
17 
(22.4) 
0 
22.4 
(13.0-
31.8) 
I believe one or 
more of my 
care recipient’s 
medicines may 
be currently 
giving them 
side effects 
6 (7.9) 25 (32.9) 18 (23.7) 
23 
(30.3) 
4 (5.3) 
35.6 
(24.8-
46.4) 
Concerns about stopping 
I would be 
reluctant to 
stop one of my 
care recipient’s 
medicines that 
they had been 
taking for a 
long time 
2 (2.6) 20 (26.3) 13 (17.1) 
35 
(46.1) 
6 (7.9) 
54.0 
(42.8-
65.2) 
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Table 11 (continued) 
Item Strongly 
disagree 
Number 
% 
Disagree 
Number 
% 
Neither 
agree 
nor 
disagree 
Number 
% 
Agree 
Number 
% 
Strongly 
agree 
Number 
% 
% 
(95% 
CI) 
agree* 
I get stressed 
whenever 
changes are 
made to my 
care recipient’s 
medicines 
16 (21.1) 28 (36.8) 19 (25.0) 
13 
(17.1) 
0 
17.1 
(8.6-
25.6) 
I feel that if I 
agreed to 
stopping one of 
my care 
recipient’s 
medicines then 
this is giving up 
on them 
15 (19.7) 29 (38.2) 16 (21.1) 
13 
(17.1) 
3 (3.9) 
21.0 
(11.8-
30.2) 
The person 
that I care for 
has had a bad 
experience 
when stopping 
a medicine 
before 
43 (56.6) 22 (28.9) 6 (7.9) 5 (6.6) 0 
6.6 
(1.0-
12.2) 
 
 
Involvement 
I know exactly 
what medicines 
the person that 
I care for is 
currently taking 
and/or I have 
an up-to-date 
list of their 
medicines 
0 12 (15.8) 3 (3.9) 
41 
(53.9) 
16 (21.1) 
75.0 
(65.0-
85.0) 
I like to know 
as much as 
possible about 
my care 
recipient’s 
medicines 
0 3 (3.9) 8 (10.5) 
39 
(51.3) 
22 (28.9) 
80.2 
(71.0-
89.4) 
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Table 11 (continued) 
Item Strongly 
disagree 
Number 
% 
Disagree 
Number 
% 
Neither 
agree 
nor 
disagree 
Number 
% 
Agree 
Number 
% 
Strongly 
agree 
Number 
% 
% 
(95% 
CI) 
agree* 
I like to be 
involved in 
making 
decisions about 
my care 
recipients 
medicines with 
their doctors 
2 (2.6) 10 (13.2) 10 (13.2) 
33 
(43.4) 
17 (22.4) 
65.8 
(54.8-
76.8) 
I always ask 
the doctor, 
pharmacist or 
other 
healthcare 
professional if 
there is 
something I 
don’t 
understand 
about my care 
recipient’s 
medicines 
1 (1.3) 10 (13.2) 7 (9.2) 
39 
(51.3) 
15 (19.7) 
41.0 
(29.6-
52.4) 
Global 
If their doctor 
said it was 
possible I 
would be 
willing to stop 
one or more of 
my care 
recipient’s 
medicines 
2 (2.6) 1 (1.3) 14 (18.4) 
50 
(65.8) 
8 (10.5) 
76.3 
(66.7-
85.9) 
Overall, I am 
satisfied with 
my care 
recipient’s 
current 
medicines 
2 (2.6) 2 (2.6) 10 (13.2) 
51 
(67.1) 
10 (13.2) 
80.3 
(71.3-
89.3) 
*Sum of agree and strongly agree
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4.7.2.2.2 Regression analysis 
Item 1 from burden and 2 from involvement were not entered into the regression 
due to them having <5% distribution in responses when cross-tabulated with the 
outcome. All other items had at least 5% distribution in responses when cross-
tabulated with the primary outcome (appendix 9). The resulting model predicted 
70.1% of the variance (Negelkerke R2) and the Hosmer and Lemeshow goodness-
of-fit test implied the model’s estimates fit the data to an acceptable level (p=0.852). 
The full regression analysis is provided in table 12. The predictors of a carers’ lack 
of desire to try stopping a medicine were the appropriateness items “I feel that the 
person that I care for may be taking one or more medicines that they no longer 
need” and “I would like the doctor to reduce the dose of one or more of my care 
recipient’s medicines”.
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Table 12 Regression analysis of rPATD items predicting lack of carers’ desire to try stopping a medicine 
Question 
Number agree with item* 
(% not willing to 
deprescribe**) 
Unadjusted 
OR 
p-value 
Adjusted 
OR 
p-value 
Burden to the National Health Service 
I feel the National Health Service (NHS) spends a lot of 
money on my care recipient’s medicines 
71 (35.2) 0.136 0.081   
Burden 
I feel that the person I care for is taking a large number of 
medicines 
58 (34.5) 0.526 0.240   
I feel that my care recipient’s medicines are a burden to 
them 
31 (22.6) 0.305 0.023*   
Sometimes I think the person I care for takes too many 
medicines 
47 (21.3) 0.142 <0.001***   
Appropriateness 
I feel that the person that I care for may be taking one or 
more medicines that they no longer need 
50 (20.0) 0.092 <0.001*** 0.056 0.005 
I would like the doctor to try stopping one of my care 
recipient’s medicines to see how they feel without it 
(entered as the dependent variable/primary outcome) 
     
I would like the doctor to reduce the dose of one or more 
of my care recipient’s medicines 
47 (10.6) 0.025 <0.001*** 0.022 <0.001*** 
I think one or more of my care recipient’s medicines may 
not be working 
49 (22.4) 0.145 <0.001***   
I believe one or more of my care recipient’s medicines 
may be currently giving them side effects 
45 (24.4) 0.234 0.004**   
 
 
113 
 
Table 12 (continued) 
Question 
Number agree with item* 
(% not willing to 
deprescribe**) 
Unadjusted 
OR 
p-value 
Adjusted 
OR 
p-value 
Concerns about stopping 
I would be reluctant to stop one of my care recipient’s 
medicines that they had been taking for a long time 
54 (44.4) 2.720 0.083   
I get stressed whenever changes are made to my care 
recipient’s medicines 
32 (40.6) 1.197 0.706   
I feel that if I agreed to stopping one of my care recipient’s 
medicines then this is giving up on them 
32 (43.8) 1.504 0.393   
The person that I care for has had a bad experience when 
stopping a medicine before 
11 (18.2) 0.313 0.157   
Involvement 
I know exactly what medicines the person that I care for is 
currently taking and/or I have an up-to-date list of their 
medicines 
60 (41.7) 2.143 0.287   
I like to know as much as possible about my care 
recipient’s medicines 
69 (39.1) 1.286 0.841   
I like to be involved in making decisions about my care 
recipients medicines with their doctors 
60 (40.0) 1.333 0.666 9.799 0.089 
I always ask the doctor, pharmacist or other healthcare 
professional if there is something I don’t understand about 
my care recipient’s medicines 
61 (42.6) 3.343 0.143   
*Number of participants out of total of n=76 who agree (agreed or strongly agree) that the rPATD item was a barrier or enabler 
**Proportion of participants who disagree (disagree or strongly disagree) with the primary outcome question of expressing a desire to try 
stopping a medicine (“I would like the doctor to try stopping one of my care recipient’s medicines to see how they feel without it”)
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4.8 Discussion 
Engagement of patients and carers is a core component of deprescribing, yet a 
substantial proportion indicated limited desire to be involved in medication decision-
making. Furthermore, the low desire to try stopping a medicine is in agreement with 
the substantial proportions of participants declining deprescribing in the trial 
environment(111,192–194). However, patients and carers overwhelmingly report 
agreement with deprescribing proposed by a doctor. Practitioners should not 
therefore dismiss deprescribing opportunities due to patients and carers choosing to 
be less involved in decision-making. The three diagnostic indicators for establishing 
desire to try stopping a medicine are perceptions of the number and necessity of 
medicines and, a desire for dose reduction. These may also assist physicians with 
targeting relevant attitudinal predictors during deprescribing discussions. 
Given similarities between the two English-speaking nations, it is unsurprising that 
minimal adaptations to the Australian rPATD were required before UK use as a 
result of the cognitive interviews. The item exploring burden of paying for medication 
was adapted to reflect the UK context. Recruiting the cognitive interview participants 
from the pool of university staff and students may have resulted in a highly self-
selecting audience, which may not necessarily be representative of the main study 
participants. Efforts were made to mitigate this, for example the participant eligibility 
criteria for both the cognitive interviews and main study being identical except for 
the settings (university versus hospital wards). As discussed in in section 4.6, self-
selecting audiences tend to be from higher educational backgrounds than the 
average questionnaire respondent(205). This could have led to results which 
suggested that the rPATD had face and content validity in a highly educated 
population which may not be generalisable to the main study population. It was not 
practical to conduct the cognitive interviews in the hospital ward environment owing 
to a number of restrictions including prohibition of audio recording in shared ward 
bed bays. However, a potential strategy to mitigate this limitation could have been to 
recruit participants from other sources such as the charity Age UK, who may have 
been able to facilitate recruitment of participants more representative of the main 
study population. 
Whilst the sample size estimation was based on PATD data, the distribution of 
patients’ agreement responses to the rPATD yielded confidence intervals equal to 
or narrower than predicted. For carers however, the distributions of agreement to 
five rPATD items yielded confidence intervals of up to 0.5% wider than predicted. 
This may be a limitation of the carer sample size justification being based on 
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patients’ responses to the original PATD. Based on the present study, whilst trends 
in patient and carer attitudes towards deprescribing appear to accord, there appears 
to be a larger distribution across responses for carers, thus requiring a larger 
sample size. Nonetheless, the deviation in predicted confidence intervals for the five 
aforementioned carer rPATD items is very small, affording some confidence in 
these findings. 
The high consent rates provides some confidence in the generalisability of the 
findings to the populations of the hospitals at which the research was conducted. 
The presence of a researcher to support patients self-completing the rPATD may 
have biased responses. However, similarities with the carer rPATD responses 
indicate that researcher presence is unlikely to have unduly influenced the findings. 
Half of potentially eligible patients were excluded due to inability to participate in 
medication decision-making. Inclusion of carers therefore provides representation of 
this previously under-researched population(108–110,197). The patient participant 
population is comparable to previous PATD studies(108–110,197) and to a pan 
European study evaluating older people’s hospital admissions(34). The carer 
population was comparable with a US study exploring treatment preferences of 
carers involved in medication decision-making(195). These similarities indicate that 
the study findings may be generalisable beyond the two hospital study sites. 
Similar to previous patient PATD responses in the outpatient clinic, acute hospital 
and care home settings, the global rPATD items in the present study demonstrated 
little variation, with the majority of respondents agreeing with deprescribing 
proposed by a doctor whilst also being satisfied with current medicines(108–
110,197). There was, however, greater variation in responses to the items relating 
to patients’ and carers’ desire to be involved in medicine decision-making. This 
agrees with the existing literature in relation to some older people expressing 
preference for a passive role in decision-making(121–125) and may also be true of 
carers, who were similarly older in age(218). 
Medication expenditure was acknowledged as a burden to the NHS by the majority 
of respondents, however this did not predict desire to try stopping a medicine. 
Patients did not consider their medications a burden as evidenced by no items in 
the burden factor attracting general agreement. Carer responses were similar, 
however the majority felt care recipients were taking a large number of medicines. 
The appropriateness factor demonstrated greatest divergence between patients and 
carers. The majority of patients perceived their medicines were appropriate, 
116 
 
whereas carers were ambivalent. This may be due to carers feeling that they lack 
understanding of their care recipient’s treatments(121). 
Whilst there is qualitative literature indicating that deprescribing generates concerns 
for patients(98), the majority of patient respondents indicated that they did not hold 
concerns about stopping medication. This may be due to differences between 
actively inviting people to generate potential concerns versus inviting an opinion on 
specific concerns as in the present study(219). Carer responses were similar to 
patients’, however resistance to deprescribing long-standing medication was 
conveyed but did not predict lack desire to try stopping a medicine. Physicians 
report reluctance to propose deprescribing for fear of patients perceiving this as 
withdrawal of care(116); the present study suggests neither patients nor carers hold 
this view. 
Some caution should be applied to this message, as whilst the majority of 
respondents agreed with deprescribing proposed by a doctor, they also reported 
content with existing medication. This potentially reflects a desire to conform, which 
may lead to agreement with a doctor’s recommendation to deprescribe despite 
concerns(125) and reluctance to report adverse outcomes such as return of 
symptoms(124).  
The reported preference for a passive role in medication decision-making by older 
people in the literature(121) was expressed by some patients and carers in their 
responses to items in the involvement factor. Whilst items relating to the passive 
behaviour of knowledge acquisition regarding prescribed medicines attracted high 
agreement, the item relating to liking to be involved in decisions about medicines 
was lower. 
The attitudinal predictors of desire to try stopping a medicine for both patients and 
carers are perceived necessity and a desire for dose reduction. As both items are 
from the appropriateness factor, this may represent a limitation of using an 
appropriateness item as the primary outcome. However, this could also suggest that 
attitude towards the appropriateness of medication is the most suitable target for a 
behaviour change intervention. Additionally, the predictive ability of the burden item 
regarding taking too many medicines for patients and not for carers suggests that a 
patients’ perceived burden of medicine taking is an important indicator of their 
desire to try stopping a medicine. 
The high agreement with deprescribing proposed by a doctor reported in this study 
endorses the development of a hospital deprescribing intervention for older people 
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which focusses on targeting practitioners’ behaviours to ensure they are routinely 
proposing appropriate deprescribing. However, deprescribing should be a patient 
centred process(60), therefore the views of patients and carers should be 
considered when developing such an intervention. As the target behaviour for both 
patients and carer is wanting to try deprescribing and a key predictor of this 
behaviour is attitude towards deprescribing(112–114), the three attitudinal 
predictors are potential intervention targets. The finding that perceived medication 
necessity and a desire for dose reduction are predictors of both patients’ and carers’ 
desire to try stopping a medicine may offer efficiencies for intervention design. 
Behaviour change techniques offer an evidence-based approach to modifying 
attitudes towards a behaviour. For example, a practitioner may identify that a patient 
is prescribed an inappropriate medicine who is ambivalent to deprescribing. The 
present study indicates that one or more of three attitudinal predictors of desire to 
try stopping a medicine may alter this ambivalence. For example, the patient’s 
perception that they are not taking too many medicines can be targeted with the 
evidence-based behaviour change technique ‘information about emotional 
consequences’(172,220). This theory-based approach to changing patients’ attitude 
towards deprescribing has been reported in the EMPOWER trial, which includes the 
behaviour change technique ‘information about health consequences’(221). 
Patients and carers overwhelmingly report agreement with deprescribing proposed 
by a doctor yet vary in the extent to which they want to be involved in medicine 
decision-making. Practitioners should not therefore dismiss deprescribing 
opportunities due to patients and carers choosing to be less involved in decision-
making. Three attitudinal predictors of reported desire to try stopping a medicine 
provide potentially modifiable targets for developing a hospital deprescribing 
intervention which considers patients’ and carers’ behaviour in addition to that of the 
healthcare practitioner.
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Chapter 5 Geriatricians’ and pharmacists’ 
barriers and enablers to deprescribing 
for older people in hospital: A focus 
group study using the Theoretical 
Domains Framework 
 
This chapter is derived from the publication: 
Scott, S., Twigg, M. J., Clark, A., Farrow, C., May, H., Patel, M., … Bhattacharya, D. 
Development of a deprescribing implementation framework for the hospital setting: 
A focus group study with geriatricians and pharmacists. Age and Ageing. 2019. 
Accepted in press.
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5.1 Introduction 
Chapter 3 identified that deprescribing practice in hospital is limited and dominated 
by reactive deprescribing in response to existing harms. Accordingly, there is likely 
to be significant scope to increase the proactive deprescribing practice in hospital, 
where a medication is discontinued if future gains are unlikely to outweigh future 
harms. Chapter 4 explored older patients’ and carers’ views towards deprescribing 
in hospital and concluded that the vast majority were willing to have one of their 
medicines deprescribed if this is proposed by a doctor. Accordingly, a hospital 
deprescribing intervention should focus on supporting practitioners in hospital to 
work with patients and carers to deprescribe inappropriate medication. 
An overview of the current literature presented in Chapter 1 proposed that 
geriatrician-led deprescribing in hospital may overcome some of the barriers to 
deprescribing from the primary care setting perspective. Pharmacists in National 
Health Service (NHS) hospitals play an important role in medicines management 
and optimisation of pharmacological treatments(132), thus they are also likely to 
play a key role in hospital deprescribing. The barriers and enablers to deprescribing 
from the perspective of geriatricians and pharmacists in hospital remain unknown, 
therefore empirical research is indicated to inform the development of a novel 
deprescribing intervention. The extent to which these might also vary between 
hospital organisations is also unclear. Large teaching hospitals may benefit from 
greater resources relative to smaller district general hospitals; however, the former 
may treat patients with more severe illness, potentially limiting capacity to adopt 
new models of care(222–224). The nature and relative importance of barriers and 
enablers to deprescribing may differ across hospital contexts. There is therefore a 
need to understand the implementation problems and potential solutions to guide 
the development of a scalable deprescribing intervention for the hospital setting. 
Chapter 2 emphasised the importance of applying theory when developing complex 
interventions to understand the processes of change required to adopt a new 
behaviour such as deprescribing(142). The Theoretical Domains Framework (TDF), 
which is an integrative framework of behaviour change theories organised into 14 
theoretical domains(157), was selected as the theoretical approach underpinning 
the development of a hospital deprescribing intervention. Identification of domains 
that are important to the target behaviour provides the theoretical understanding 
required to develop an intervention. 
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5.2 Aim 
To understand geriatricians’ and pharmacists’ perceived barriers and enablers to 
deprescribing in hospital. 
 
5.3 Objectives 
1. Describe the barriers and enablers of geriatricians and pharmacists to 
deprescribing in hospital. 
2. Identify the TDF domains that are relevant to geriatricians and pharmacists 
deprescribing behaviour in hospital. 
3. Prioritise TDF domains within which geriatricians’ and pharmacists’ behaviour 
are required to change to facilitate them to deprescribe in hospital. 
 
5.4 Ethics approval 
Ethical and governance approval were obtained from the University of East Anglia 
Faculty of Medicine and Health Sciences Research Ethics Committee (Reference 
2017/2018 – 59) and UK Health Research Authority respectively. The study protocol 
and ethical and governance approval letters are provided in appendices 10 and 11 
respectively. 
 
5.5 Methods 
This project was overseen by the project management group described in Chapter 
3. 
 
5.5.1 Study design 
Given the need to explore in-depth the thoughts and ideas of geriatricians and 
pharmacists regarding deprescribing and the absence of published literature from 
which to derive a survey(116), an exploratory qualitative approach was selected. 
Qualitative research is described as a “naturalistic, interpretative approach, 
concerned with exploring phenomena ‘from the interior’ and taking the perspectives 
and accounts of research participants as a starting point”(219). The key features of 
qualitative research are a focus on process, flexibility and a concern with ‘what’, 
‘why’ and ‘how’, rather than ‘how many’. Focus groups were chosen to address the 
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study aim as they generate data through interactions between participants thus 
yielding additional material not otherwise captured through other qualitative 
methods such as in-depth interviews(219). This group ‘brainstorming’ and ‘problem 
solving’ mirrors team-based clinical decision-making in hospital(225). Participants 
assume some responsibility for directing the discussion and the researcher’s role is 
less pronounced and thus less influential than in individual interviews. The 
consolidated criteria for reporting qualitative research (COREQ) checklist guided 
reporting (appendix 12). 
 
5.5.1.1 Reflexivity 
The lead researcher (SS) was a practicing hospital pharmacist when the research 
activities described in this chapter were undertaken. Moreover, members of SS’s 
supervisory team and the wider project management group comprised academic 
pharmacists, senior hospital pharmacists, consultant geriatricians, a patient and 
carer. It is therefore inevitable that the research team will have had preconceptions 
around the barriers and enablers to deprescribing in. Moreover, all members of the 
research team had actively sought involvement with the project, therefore they were 
likely to bring a vested interest in the research’s success, which may also have led 
to the introduction of biases. 
There is potential for researchers’ preconceptions to influence and contaminate 
study processes such as data collection and interpretation in all methodological 
approaches, which may lead to findings which are biassed and not an accurate 
reflection of the truth. Qualitative enquiry however is particularly vulnerable to this 
effect owing to researchers’ intimate involvement in both the research process and 
product. This introduces challenges to objectively conducting the research and 
analysing data(226). Accordingly, there is a need for continuous self-critique and 
self-appraisal in order to explain how preconceptions and experiences more broadly 
may or may not influence the research. This attribute is termed ‘reflexivity’, which 
has been defined as “the analytic attention to the researcher’s role in qualitative 
research”(227). 
Reflexive researchers must be aware of and acknowledge the factors which may 
influence their behaviour throughout the research process. This involves exploration 
of the researcher(s) relationship with the subject matter. Whilst the aim of reflexivity 
is to promote and sustain objectivity in qualitative research, it is inevitable that a 
researcher will influence the product. Reflexivity therefore also acknowledges this, 
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and researchers are encouraged to be transparent thorough the research process. 
This is achieved in part by completing agreed quality checklists such as COREQ 
(appendix 12). 
The strategy adopted to promote objectivity in the study described in this chapter is 
termed ‘bracketing’(228), which is defined as “the suspension of all biases and 
beliefs regarding the phenomenon being researched prior to collecting data about 
it”(226). The process described by Wall et al.(229) was adopted for the study in this 
chapter, which encompassed SS keeping a reflexive diary. Initially (before any data 
collection), SS documented his specific beliefs and issues regarding the subject 
matter that he felt required bracketing (pre action bracketing). For example, SS felt 
that a barrier to deprescribing in hospital was likely to be that practitioners lack the 
required knowledge and skills, which was documented in the reflexive diary and 
bracketed. Being actively aware of these preconceptions facilitated SS in 
suspending them during the data collection and analysis process. Subsequently, 
after each focus group SS reflected on and documented learning from the 
discussions and research process (in action bracketing). In accordance with the pre 
action bracketing process, this new knowledge was suspended to ensure continued 
objectivity in subsequent focus groups. 
The reflexive process was shared with the wider research team in order to facilitate 
objectivity at the research team level. 
 
5.5.2 Setting 
Four hospitals across three English counties, two of which were 1000 and 1200 
inpatient bed teaching hospitals with four and six geriatric wards respectively, and 
two were 450 and 550 inpatient bed district general hospitals with 3 geriatric wards 
each. 
The proportion of prescribing pharmacists across the four hospital sites varied from 
approximately one fifth to one quarter of all pharmacists. Whilst the proportions of 
prescribing pharmacists were typical of hospitals across the region (East of 
England), they were lower than other regions. The proportion of prescribing 
pharmacists in hospitals nationally varies significantly, from 2.5% to 71% of 
pharmacists(230). Accordingly, the four hospitals included in this study were in the 
lower 50% of hospitals nationally for the proportion of pharmacist prescribers. 
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Standard care across the four hospitals was for patients to receive a pharmacy-led 
medicines reconciliation within 24 hours of admission. None of the four hospitals 
adopted full clinical pharmacy service seven days a week, however all operated a 
dispensary service on weekends and an emergency on-call service out of hours. 
This sample setting was used to explore influencers of deprescribing for older 
people during a hospital admission and capture any variation arising from differing 
resources and patient populations. 
 
5.5.3 Sample 
Greater specificity in defining whose behaviour needs changing leads to greater 
specificity of the enablers and barriers identified(159). This study therefore focussed 
on geriatricians and pharmacists who were the target professional groups for 
behaviour change. We included senior geriatricians and pharmacists who worked in 
the four hospitals based on practice experience (minimum six and four years 
respectively). Senior geriatricians were defined as those with at least six years of 
practice experience whilst senior pharmacists were defined as those with at least 
four years of practice experience and a post-graduate qualification in clinical 
pharmacy. Senior pharmacists from all clinical specialities were invited in 
recognition of the range of responsibilities often adopted despite speciality. 
Eight focus groups were planned to explore similarities and differences in attitudes 
between geriatricians and pharmacists, and identify hospital characteristics that 
might influence deprescribing. Each hospital site hosted two focus groups: one with 
geriatricians and one with pharmacists, with five to eight participants each (n=40 to 
64 in total). 
The principles for deciding saturation in theory-based qualitative studies outlined by 
Francis et al. were followed to determine whether data saturation had been 
achieved(231). However, as a study objective was to explore any differences in 
views between district general and teaching hospital contexts, an a priori decision 
was made to convene all eight planned focus groups irrespective of whether data 
saturation was achieved prior to conducting all focus groups. 
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5.5.4 Recruitment 
All potentially eligible participants at the hospital sites were invited by email from a 
nominated gatekeeper of their respective specialities. The email comprised a 
participant information leaflet (including details of the study aims) and focus group 
scheduling arrangements. Potential participants were directed to complete an online 
expression of interest survey requesting the following information: professional 
group, gender, hospital seniority grade and prescribing authority status (pharmacists 
only). Potential participants were purposively sampled to maximise variation in 
demographic and seniority grade. A mixture of prescribing and non-prescribing 
pharmacists were sought to explore any differences in attitudes arising from the 
acquisition of additional prescribing competencies. Employing hospitals were 
remunerated for participants’ time commitment to the research. 
All potential participants sampled for recruitment participated in the study. Three 
pharmacists who were not purposively sampled and did not complete the online 
expression of interest survey attempted to attend the focus group at hospital 1 (table 
9). In line with the study protocol and conditions of ethical and governance approval 
(maximum eight participants), the three aforementioned pharmacists were declined 
participation. 
 
5.5.5 Data collection 
Researchers, geriatricians, clinical pharmacists, and patient and carer 
representatives developed a semi-structured topic guide informed by the 
deprescribing literature. Guiding questions were designed to elicit participants’ 
views regarding the following: 
1. Perception of existing deprescribing practice. 
2. Barriers to increasing deprescribing practice. 
3. Enablers for increasing deprescribing practice. 
 
Standard questions were adapted to elicit the barriers and enablers to deprescribing 
within all 14 TDF domains and served as probes where necessary to ensure full 
coverage of the TDF in discussions(97). The topic guide was piloted with clinical 
pharmacists and geriatricians yielding minor rephrasing and ordering of guiding 
questions (available in appendix 10). Piloting of the topic guide and discussions with 
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gatekeepers indicated that a one-hour focus group was feasible for in depth 
discussions. 
Standard questions were adapted to elicit barriers and enablers to deprescribing 
within all 14 TDF domains and used them as probes to ensure full coverage of the 
TDF in discussions. The topic guide was piloted with geriatrician and pharmacist 
collaborators (n=3) who were representative of the target focus group population; 
they did not participate in the study. The purpose of the piloting was to check 
understanding of questions, ascertain the depth of data generated from the guide, 
and assess the feasibility of covering all TDF domains in the allotted time. 
Focus group data were collected between February and May 2018. Written, 
informed consent was obtained from participants at the beginning of each focus 
group, which were convened in meeting rooms at the hospital sites. Two academic 
pharmacist researchers (SS and DB) facilitated the focus groups, made field notes 
during the discussions and audio recorded the events. SS completed training in 
qualitative research methodology and the principles and practice of behaviour 
change research prior to the study. DB has extensive experience of conducting 
qualitative research underpinned by behaviour change theory. 
 
5.5.6 Analysis 
A research administrator transcribed verbatim focus group recordings which were 
then anonymised and checked for accuracy by a researcher (SS). Data were 
imported into NVivo 11 (QSR International, Melbourne, Australia) to facilitate the 
following three phases of analysis: 
1. Thematic analysis to identify determinants of deprescribing for older people 
in hospital. 
2. Mapping of all identified determinants of deprescribing to the TDF. 
3. Prioritising TDF domains for targeting in a deprescribing intervention. 
 
This methodological approach draws on recent theory-based intervention 
development research(161,232,233). All processes of the analysis were shared with 
the study management group which included geriatricians, pharmacists and, patient 
and carer representatives, to enhance transparency and validity of interpretation. 
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5.5.6.1 Phase 1: Thematic analysis 
Data were initially analysed through the five customary steps of thematic analysis as 
described by Braun and Clarke(234) to ensure resultant themes were not restricted 
to the pre-defined TDF domains.  
 
Step 1: Data familiarisation 
SS and DB facilitated all focus groups and therefore had some prior knowledge of 
the data. SS re-read the transcripts several times to facilitate familiarity the breadth 
and depth of content. During this process, SS made informal notes regarding initial 
ideas for coding, which were to be referred to during later phases of the analysis. 
 
Step 2: Generating initial codes 
SS coded inductively by organising the data into the barriers and enablers to 
deprescribing. Data extracts were coded inclusively, i.e. relevant text surrounding 
the phenomena of interest was retained, to ensure no loss of context. Two 
researchers experienced in qualitative (MJT) and behaviour change (DB) research 
then reviewed the codes and associated data extracts, and codes were refined 
through discussions. 
 
Steps 3, 4 and 5: Searching for themes, reviewing themes and defining 
themes 
Three researchers (SS, MJT and DB) sorted the codes by considering how different 
codes could be combined to form an overarching theme and sub-themes. All 
relevant data extracts were collated within the identified themes. Themes were then 
refined to ensure that the data within each theme cohered together meaningfully, 
and there were clear and distinct differences between themes. Finally, themes were 
defined in order to capture the essence of what the themes were about in order to 
present for analysis. 
Inductive coding and thematic analysis were undertaken concurrently after each 
focus group. Geriatrician and pharmacist transcripts were initially coded separately 
and grouped into categories as appropriate. Categories for both professional groups 
were then combined to form overarching themes. At all times of data abstraction, 
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constant referral back to transcripts, demographics and inductive codes was 
undertaken to ensure that the analysis remained true to, and reflected appropriately, 
the developing themes. 
 
5.5.6.2 Phase 2: Mapping of all determinants of deprescribing to the TDF 
SS and DB re-read the transcripts and mapped all inductive codes from the phase 1 
thematic analysis to the relevant TDF domain(s). The TDF domain definitions (table 
5, chapter 2) were used to guide this mapping and organised the coded data within 
each domain into barriers and enablers to deprescribing(157). Mapping was 
compared and any disagreements resolved through discussion and referral to a 
third researcher experienced in health psychology and qualitative research (JT). 
 
5.5.6.3 Phase 3: Prioritising TDF domains for targeting in a deprescribing 
intervention 
The phase 1 thematic analysis provided a contextualised understanding of the 
barriers and enablers most important to participants for effecting deprescribing 
behaviour change. This information was used to prioritise the TDF domains most 
relevant for a deprescribing intervention. Relevant TDF domains were identified 
through consensus discussion between the three researchers (SS, MJT, DB) and 
confirmed by a health psychologist (JT). 
For each theme, all barriers and enablers expressed by the collective as exerting a 
strong impact on deprescribing behaviour and no significant conflicting views were 
collated(233). The mapped domain for each of these barriers was prioritised. For 
the enablers, if participants expressed that a change in the status quo was required, 
then the associated domain was prioritised, whilst those enablers already present 
by virtue of implementing the intervention in the hospital setting did not lead to 
domain prioritisation. 
 
5.6 Results 
 
5.6.1 Sample 
All geriatricians and pharmacists who were purposively sampled participated in the 
focus groups. Fifty-four participants; 28 geriatricians and 26 pharmacists, 
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participated across the eight focus groups. Table 13 provides participant 
characteristics. The mean (SD) focus group duration was 55 (5) minutes. 
Table 13 Focus group characteristics 
Hospital 
Professional 
group 
Number of 
participants 
Number with 
prescribing 
authority 
Hospital 1a Pharmacists 8 (4 female 4 male) 3 
Hospital 1a Geriatricians 7 (5 female 2 male) 7 
Hospital 2a Pharmacists 7 (7 female) 1 
Hospital 2a Geriatricians 8 (3 female 5 male) 8 
Hospital 3b Pharmacists 6 (3 female 3 male) 1 
Hospital 3b Geriatricians 7 (4 female 3 male) 7 
Hospital 4b Pharmacists 5 (2 female 3 male) 1 
Hospital 4b Geriatricians 6 (1 female 5 male) 6 
aTeaching hospital bDistrict general hospital 
 
5.6.2 Phase 1: Thematic analysis 
 
Four themes were identified: 
1. Role of different professionals 
2. The inpatient environment 
3. Consideration of outcomes 
4. Attitudes towards medicines 
 
Themes were recurring after the third focus group and no new themes emerged 
after the sixth focus group. There were no discernible differences between 
participants from teaching and district general hospitals or prescribing and non-
prescribing pharmacists. 
 
Role of different professionals 
There was high motivation to increase deprescribing in hospital, with both 
geriatrician and pharmacist participants recognising that existing deprescribing 
practice in hospital was limited and dominated by reactive behaviour. 
“I think we do a lot more reactive deprescribing probably and a lot less proactive 
deprescribing than we should.” (Pharmacist 2, Hospital 2) 
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Geriatricians and pharmacists acknowledged that increasing deprescribing practice 
aligned with the generalist nature of their professions’ roles and responsibilities. 
They indicated that this generalist nature meant that they could assume key roles in 
the deprescribing process. There was also agreed scope for other healthcare 
practitioners such as nurses and physiotherapists to support deprescribing in 
hospital. However, the role of practitioners with a restricted focus, such as 
therapeutic area specialists (for example cardiology, infectious diseases and 
surgery), was described as potentially incompatible with deprescribing for older 
people. 
Participants indicated that junior healthcare practitioners, including junior 
geriatricians and pharmacists, lacked the required competencies to lead 
deprescribing. This was a recognised consequence of insufficient trainee healthcare 
practitioner experience and limited education regarding deprescribing within training 
programmes. 
Whilst the scope for several professional groups working in hospital to contribute to 
deprescribing was recognised, there was consensus that overall responsibility for 
deprescribing in hospital rested with one nominated professional group. Participants 
from both professional groups agreed that geriatricians should be the professional 
group nominated to assume overall responsibility for deprescribing decision-making 
in hospital. Furthermore, in the geriatrician focus groups, many participants 
expressed confidence in their ability to weigh up the risks and benefits of 
deprescribing to inform decision-making. For geriatricians therefore, the principal 
barriers to deprescribing were the environmental and resource factors in the 
hospital setting. 
“It’s interesting how all of the barriers to deprescribing are practical rather than I just 
don’t know whether I should stop it. So we’re extremely competent in our ability to 
decide this is why this is what we should do.” (Geriatrician 5, Hospital 2) 
 
Pharmacist participants suggested their skill set better aligns with identifying 
potentially inappropriate medication and advising on deprescribing, which was 
endorsed by geriatrician participants. Pharmacist participants were reluctant to 
assume overall responsibility for deprescribing because of an expressed lack of 
confidence in decision-making. 
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“And then it’s just the difficulty of clinical relevance of these medications and the 
context of the patient that maybe pharmacists wouldn’t be happy with. It would have 
to be somebody who’s feeling happy enough to do it” (Pharmacist 2, Hospital 3) 
 
However, existing working patterns and priorities in hospital was reported to limit 
pharmacists’ capacity to assume any role in deprescribing and was a significant 
barrier to them supporting deprescribing in hospital. 
“The time that we have on the ward as pharmacists is well so it’s basically 
discharges, missed doses if you can do a medication reconciliation great and that’s 
about it. The actual clinical review of charts is so squeezed … before you know it 
you’ve been on the ward four hours and you’ve not really clinically reviewed 
anything you’ve just been a [discharge prescription] machine, ordered the missed 
doses and that’s it so it’s it can be difficult to clinically review stuff” (Pharmacist 5, 
Hospital 4) 
 
The inpatient environment 
The influence of the inpatient environment on deprescribing was discussed in 
relation to the interacting dynamics of the clinical picture, communication and 
access to resources. Both geriatrician and pharmacist participants acknowledged 
that there was significant scope to increase deprescribing in hospital, however at 
present these opportunities were not being seized. The scope to increase 
deprescribing was complemented by the necessary resources and capacity 
available in the hospital environment to safely trial deprescribing and monitor 
patients’ responses to medication withdrawal. 
“… if they’re in hospital they can be monitored more closely when you do stop the 
more riskier medication and if they’re in for a length of time like you say then there’s 
the time to stop medication if they can be and you can essentially ensure the 
patients concordance if you have to titrate it down.” (Pharmacist 5, Hospital 3) 
 
Furthermore, participants were reassured by the network of other specialist 
healthcare practitioners working in the hospital setting available to support the 
deprescribing process. 
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Conversely, significant challenges to deprescribing in the hospital setting were 
acknowledged. Limited information available to hospital practitioners regarding 
patients’ medications was raised as a barrier. Strength, dose and formulation of 
patients’ usual medications were routinely ascertained by pharmacists on admission 
using various sources such as discussion with patients/family or accessing 
electronic medication records. However, hospital practitioners reported that key 
information required to determine whether deprescribing was appropriate, such as 
the reason why the medication was prescribed and for how long were rarely known. 
“You don’t always have all the information in hospital. So it’s very difficult to as we 
said make that decision… there’s always the risk you might end up stopping 
something they really do need. And it might not be obvious that they really do need 
it from the information you’ve got in front of you.” (Pharmacist 7, Hospital 1) 
 
Some participants thought that a potential solution to this problem is recent 
advances in communication with some hospitals gaining access to primary care-
held comprehensive medication records. However, both professional groups were 
sceptical about navigating records to find the required information. This was 
described as a time consuming, impractical and often unsuccessful exercise. 
A barrier to deprescribing was the acute nature of a hospital admission requiring 
prioritisation of the patients’ problems requiring immediate action. 
I think we’re also under huge pressures to just get people out of hospital so 
sometimes the for ourselves and for other specialities actually let’s just deal with the 
infection and lets concentrate on getting them out of hospital back home to a care 
home to rehab and certainly during the winter I think there was huge pressure there 
that we didn’t have that opportunity so much to take a step back and think what else 
can we do to think about making the holistic care of the patient better… 
(Geriatricians 3, Hospital 2) 
 
This was confounded by patients’ artificial lifestyle whilst in hospital, including acute 
immobility, scheduled meals and medications being managed by healthcare 
practitioners. These factors were perceived to potentially distort the assessments 
undertaken in hospital to inform long-term deprescribing decisions. 
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“…things might change so dramatically when they leave hospital, either they’ve 
recovered from their sepsis and they need their antihypertensives or they’ve started 
eating again and they need more of their gliclazide...” (Geriatrician 5, Hospital 2) 
 
Participants asserted a clear need to establish a safety net through sharing 
information with primary care providers responsible for ongoing care after patients 
are discharged from hospital. It was suggested that such correspondence could 
include directions for monitoring for changes that may indicate re-prescribing was 
necessary. However, participants agreed that the existing transfer of information 
between care settings is poor and may undermine deprescribing efforts. 
“I think we’re very bad at relaying changes to the [primary care practitioners]. I don’t 
know about you but I get a lot of letters from [primary care practitioners] saying this 
person was discharged and you stopped this list of medications and then you look 
at the discharge letter and there’s no reason why, or sometimes it doesn't mention it 
was stopped at all. So I think I can see how it’s frustrating for [primary care 
practitioners] that long term medications are stopped without a rationale.” 
(Geriatrician 5, Hospital 4) 
 
Similarly, pharmacist participants voiced concerns regarding communicating 
medication changes with patients in hospital. Barriers identified included patients 
being unable to participate in decision-making because of ill health and 
deprescribing being regarded by patients as a low priority relative to the acute 
condition responsible for the admission. However, the availability of family members 
as both sources of medication information and participants in decision-making were 
facilitators identified by pharmacists and geriatricians. 
“I think often as well patients, some patients don’t take information on board quite as 
well because they’re worried about the surgery they’ve got to have or you know 
they’re kept awake all night by what’s it over the ward. You know and then so 
actually they’re just kind of nodding and but when you’ve got someone in their home 
environment they feel much more empowered perhaps and you know.” (Pharmacist 
2, Hospital 2) 
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Participants expressed disappointment about not receiving feedback on positive 
outcomes resulting from hospital-initiated deprescribing once patients were 
discharged. Both professional groups recognised the successes of schemes to 
incentivise changes in antimicrobial prescribing practice in the UK hospital setting. 
This led to suggestions that similar approaches may also be enablers of 
deprescribing. 
“…incentives C. Diff years and years no one cared financial incentive it was sorted... 
Somehow that seems to be what works in community with treating and monitoring 
with blood pressures that seems to be working with our infection control that seems 
to be working with our antimicrobial deprescribing so if there is a way to measurably 
make this work then maybe financial incentives” (Pharmacist 7, Hospital 2) 
 
Consideration of outcomes 
The perceived risks and potential benefits of deprescribing versus continuing to 
prescribe were identified by participants as key factors influencing deprescribing 
behaviours, with decisions predicated on finely balancing the medication, the 
patient’s clinical condition and their preferences. Potential patient orientated positive 
outcomes arising from deprescribing were reduced medication burden and 
incidence of adverse drug events leading to improved quality of life. 
“They have got to try and swallow each one and they’ve got to read what one to 
take and then they’ve got to take them a different times and it just takes a lot out of 
their day. So actually if you’re deprescribing and that frees up and improves their 
quality of life then that’s our main goal.” (Pharmacist 5, Hospital 2) 
 
A reduction in unnecessary medication expenditure, reduced treatment costs 
associated with adverse drug events and rationalising use of health resources were 
suggested as potential benefits to healthcare systems. In turn, patient and health 
system benefits were proposed to lead to individual practitioner benefits, with 
geriatrician and pharmacist participants suggesting deprescribing may lead to 
reduced workload. 
“Exactly, I mean to be honest that work life balance which we are all craving for 
might come back if we have prescribed just four medications rather than you know 
20 that would be an advantage.” (Geriatrician 2, Hospital 1) 
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The perceived risks of deprescribing were associated with the consequences of 
discontinuing a medication rather than the process itself. Potential adverse clinical 
outcomes were predominantly discussed, such as adverse drug withdrawal events 
leading to hospital readmissions and increased workload. The potential for adverse 
deprescribing outcomes to lead to a negative response from patients and family was 
recognised as comparable to any healthcare intervention. However, concerns were 
expressed that unrelated adverse events may be incorrectly attributed to 
deprescribing by patients and family. 
“And all the patients I’ve stopped statins and then they’ve had heart attacks and 
been acute you know.” (Geriatrician 1, Hospital 1) 
“Even though you’ve stopped their statin you’re like the statin is not why they’ve had 
a heart attack.” (Geriatrician 6, Hospital 1) 
“Exactly but there is a sort of perception.” (Geriatrician 1, Hospital 1) 
“That perception that can be quite a negative impact that if something then does 
happen to that patient that they feel it was the medication alone that was the reason 
not the fact that they’re extremely elderly.” (Geriatrician 6, Hospital 1) 
“Yes.” (Geriatrician 1, Hospital 1) 
 
The potential adverse outcomes of deprescribing were balanced with those 
associated with medication use in older people. Deprescribing was perceived as a 
necessary intervention to prevent the harms associated with inappropriate 
medication. 
“It is pretty short sighted when it comes to medication we just reap the whirlwind 
later on if you don’t think about it [deprescribing] now.” (Geriatrician 5, Hospital 2) 
 
The absence of evidence supporting both deprescribing and prescribing of many 
medicines for older people contributed to the challenge of balancing the risks and 
potential benefits of deprescribing: 
“… I mean our patients if they’re on so many drugs we have really no research 
background to suggest what’s actually happening within their body. Most of the trials 
are mono therapy single disease based so a lot of the evidence for 
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antihypertensives, statins and all of this are in not in our patient groups so the 
evidence base is lacking…” (Geriatrician 4, Hospital 2) 
 
There was divergence in views between geriatrician and pharmacist participants 
regarding whether deprescribing was perceived to carry greater risk than continuing 
potentially inappropriate medicines. Pharmacist participants felt that on balance, 
passively continuing to prescribe a medication in the absence of an immediate need 
to deprescribe was safer than proactively deprescribing. 
“… but we all sort of feel more comfortable because we didn’t do anything 
[deprescribing] as opposed to I did do something [deprescribing].” (Pharmacist 2, 
Hospital 2) 
 
Conversely, geriatricians felt that both deprescribing and continuing to prescribe 
were active decisions, with no inherent differences in the risks between the two 
decisions. 
“I would feel better if thought has gone into either the prescribing or the 
deprescribing episode. Because that’s on your mind when you’re making those 
decisions you are thinking of both scenarios.” (Geriatrician 4, Hospital 2) 
 
Attitudes towards medicines 
Geriatrician and pharmacist participants’ deprescribing behaviour were influenced 
by patient, family, healthcare provider, and wider societal attitudes towards 
medicines. Participants felt that patients and carers were resistant to deprescribing 
because of their attachment to their long-term medication, which was a significant 
barrier to deprescribing. 
“Yes sometimes patients who have been on a medication for a long long time they 
don’t want to stop it because if we stop that one it might affect them adversely or 
something like that they just totally don’t want to stop it.” (Geriatrician 7, Hospital 1) 
 
Conversely, participants also characterised a significant proportion of older people 
who disliked taking medication and are amenable to deprescribing. 
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Healthcare culture’s attitudes towards medication use was acknowledged as 
changing in favour of deprescribing efforts, with the burden of inappropriate 
medication use increasingly recognised in calls for medicines optimisation 
initiatives. 
“… generally medical expertise with deprescribing has improved. I think that all the 
sort of national drives around polypharmacy have really helped support them…” 
(Pharmacist 6, Hospital 2) 
 
Nevertheless, healthcare culture’s positive attitudes towards deprescribing were not 
perceived by participants to be reflected in treatment guidelines, which were 
described as overemphasising commencing pharmacological treatment in the 
absence of considering opportunities for deprescribing. However, geriatricians noted 
that deviation from treatment guidelines was a characteristic of their generalist 
speciality. 
“Do you not think that a lot of other specialities are guideline driven the fact that they 
don’t feel as empowered to stop it … if the patient has got something, diabetes and, 
they’re not on those drugs and they’re at risk of heart failure and it has to be quite a 
sort of a brave and empowered doctor to go against that. Of course we 
[geriatricians] don’t work in a guideline driven speciality but if you are a cardiologist 
and somebody comes in with a myocardial infarction, they have to go home on 
those medications” (Geriatrician 6, Hospital 1) 
 
5.6.3 Phase 2: Mapping to the TDF 
All of the inductive codes within the four themes were mapped to nine TDF 
domains. These codes are presented within their respective domains, according to 
whether they were barriers or enablers to deprescribing (i.e. influencers of 
deprescribing behaviours), in table 14. Codes in the theme ‘Attitudes towards 
medicines’ were only mapped to one TDF domain, whilst the remaining three 
themes incorporated multiple domains
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Table 14 Thematic analysis barrier and enabler inductive codes mapped to nine TDF domains 
Barrier inductive code Enabler inductive code Theoretical domain 
Theme: Attitudes towards medicines 
Patient resistance to deprescribing G, P Patients dislike medication G, P Social influence 
Carer resistance to deprescribing G, P Patient informed deprescribing decision-making G, P 
Patients perceive medications are primary care's remit G Patient and carer deprescribing endorsement G, P 
Societal perception that medications are always good G Patient trust in deprescribing practitioner G 
Prescribing guidelines hinder deprescribing G Medical team appreciation of pharmacists P 
Patients are passive to medication decision-making G Hospital support network P 
Primary care attachment to medication G Primary care respect of hospital decision-making P 
Reactive health system culture G National campaigns P 
Deprescribing is not part of the culture outside geriatrics G  
Medical team unwillingness to engage with pharmacists' 
deprescribing recommendations P 
 
Patients perceive deprescribing is a cost-cutting measure P  
Historic labelling of medication as 'long term' P  
Carer may perceive deprescribing as palliation P  
Lack of confidence to approach others about deprescribing 
P 
 
Prescribing by therapeutic area specialists hinders 
deprescribing P 
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Table 14 (continued) 
Barrier inductive code Enabler inductive code Theoretical domain 
Theme: Consideration of outcomes 
Deprescribing not followed-up in primary care G, P No perceived difference in risk between deprescribing 
and continuing a medication G 
Beliefs about 
consequences 
Deprescribing may lead to patient or carer complaints G Deprescribing leads to reduced medication expenditure 
G, P 
Adverse drug withdrawal events G, P Failing to deprescribe may lead to adverse drug events 
G, P 
Perceived continuing medication presents less risk than 
deprescribing P 
Deprescribing may improve patients' quality of life G, P 
Patients may incorrectly attribute future adverse events to 
deprescribing G, P 
Deprescribing may lead to reduced workload G, P 
Deprescribing may cause readmissions G, P Deprescribing may prevent readmissions G, P 
Primary care may not adhere to hospital deprescribing P Deprescribing may reduce the need for acute 
interventions G, P 
Patients may not adhere to deprescribing P Patient involvement in deprescribing decision-making 
absolves prescriber G 
Deprescribing is risky P Deprescribing may lead to improved medication 
adherence G, P 
Poor deprescribing outcomes negatively impact on 
relationships with patients P 
Deprescribing reduces medication burden G 
Deprescribing may lead to increased workload P Deprescribing is a vehicle for setting realistic patient 
expectations G 
 Deprescribing leads to benefits (general) P 
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Table 14 (continued) 
Barrier inductive code Enabler inductive code Theoretical domain 
 Deprescribing means patients are prescribed only 
necessary medication P 
 
Fear of deprescribing consequences P Deprescribing is rewarding emotionally G Emotion 
Fear of assuming responsibility for deprescribing P  
Theme: Role of different healthcare professionals 
Pharmacists lack confidence in ability to make 
deprescribing decisions G, P 
Confidence in ability to deprescribe G Beliefs about 
capabilities 
 Pharmacists can make deprescribing recommendations 
G, P 
Other's awareness of deprescribing G Educational sessions G, P Knowledge 
Lack of guidance to support deprescribing G, P Adverse outcomes of drugs in older people G 
Lack of evidence to support deprescribing G, P Lack of evidence to support use of medication in older 
people G, P 
Deprescribing education is poor G, P Provision of evidence to support deprescribing G 
Junior practitioners lack the required knowledge to 
deprescribe P 
Generalists’ knowledge G, P 
 Deprescribing practice in Geriatrics is greater 
compared to other specialities P 
 Awareness that deprescribing practice is limited P 
 Knowledge and awareness of medicines requiring 
deprescribing P 
 Senior and specialist pharmacists have the required 
knowledge to recommend deprescribing P 
 Broad experience has fostered the required knowledge 
to deprescribe G 
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Table 14 (continued) 
Barrier inductive code Enabler inductive code Theoretical domain 
Deprescribing perceived to be primary care's remit G, P Seniors to lead deprescribing G, P Social/professional 
Role and Identity Hospital's remit is currently to address acute problems P Pharmacists have a potential role in deprescribing G, P 
Pharmacist role is currently to advise and check other's 
work P 
Geriatrician's role is to deprescribe G 
Therapeutic area specialisation hinders deprescribing P Geriatricians to oversee deprescribing G, P 
Junior practitioners not to deprescribe P Deprescribing is not primary care's role G 
Deprescribing is not part of current practice P Someone needs to take ownership of deprescribing G 
Deprescribing is a doctor's responsibility G, P Primary care responsible for ongoing monitoring G 
 Empowering pharmacists to assume deprescribing 
roles P 
 Generalist care facilitates deprescribing P 
 Deprescribing is perceived to be the hospital's role P 
 Pharmacists to advise on deprescribing P 
 Pharmacists' role currently includes deprescribing P 
 Therapeutic area specialists can advise on 
deprescribing P 
Pharmacists working patterns limits capacity to support 
deprescribing G, P 
Changing pharmacists working patterns to support 
deprescribing P 
Environmental 
context and 
resources 
 
 
Theme: The inpatient environment 
Deprescribing is lower priority than treating acute patient 
problems G, P 
Setting deprescribing goals G, P Goals 
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Table 14 (continued) 
Barrier inductive code Enabler inductive code Theoretical domain 
Lack of feedback on positive outcomes of deprescribing P ‘Checkbox’ for deprescribing review G Reinforcement 
 Geriatric prescribing not guided by national payment 
structures G 
 Incentives to deprescribe G, P 
 Feedback on outcomes of deprescribing P 
Poor communication both within the hospital and between 
the hospital and primary care G, P 
Primary care is not well resources to deprescribe G, P Environmental 
context and 
resources Patients are not their usual selves in hospital G, P Patients present to hospital with medications requiring 
deprescribing G 
Hospital is an artificial clinical environment G Opportunity to trial deprescribing G, P 
Multiple specialities managing patients hinders 
deprescribing G 
Hospital is well resourced to deprescribe G, P 
Insufficient time G, P Deprescribing clinic G, P 
Incomplete medication history G, P Community of healthcare professionals to support 
deprescribing G, P 
Unable to monitor medium-term effects P Carers accessible in hospital G, P 
Lack of relationship with patients P Opportunity to discuss deprescribing with patients P 
 Improved communication with primary care P 
G Geriatrician expressed barrier or enabler P Pharmacist expressed barrier or enabler
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5.6.4 Phase 3: Prioritising TDF domains for targeting in a 
deprescribing behaviour change intervention 
Figure 11 provides the five TDF domains prioritised for behaviour change targeting 
in a practitioner deprescribing intervention. 
 
Figure 11 Themes (inner four quadrants) linked to five prioritised TDF domains 
(outer ring) 
 
‘Social professional role and identity’ and ‘Knowledge’ are not prioritised domains 
because whilst these represented strong enablers, both geriatricians and 
pharmacists asserted that deprescribing aligns with existing perceptions of their 
complementary roles and knowledge. Similarly, ‘Beliefs about capabilities’ is not 
represented because both professions had confidence in their ability to undertake 
the roles that they had defined for themselves. It can be seen that the ‘Emotion’ 
domain, which was exclusively expressed with barriers by pharmacists being fearful 
of assuming responsibility for any negative consequences of deprescribing, is not 
represented. This is in recognition of participants across both professional groups 
agreeing that the geriatrician should be the professional assuming overall 
responsibility for deprescribing in hospital. 
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The three TDF domains of ‘Social influence’, ‘Environmental Context and 
Resources’ and ‘Goals’ represented strong barriers to both geriatricians and 
pharmacists deprescribing behaviour and therefore are prioritised for targeting. 
Additionally, for pharmacists the ‘Beliefs about consequences’ domain is prioritised 
in recognition of their perception that continuing to prescribe a medication presents 
less risk than deprescribing. 
The ‘Reinforcement’ domain is prioritised because participants expressed a strong 
desire for feedback on their behaviour and patient outcomes in order to facilitate 
deprescribing. 
 
5.7 Discussion 
Geriatricians and pharmacists perceive that deprescribing in hospital is a part of 
their generalist role. The hospital setting therefore potentially offers a significant 
advantage over primary care for implementing deprescribing, as primary care 
physicians are ambivalent to undertaking this role(116). A hospital deprescribing 
intervention for older people led by geriatricians and supported by pharmacists was 
the preferred configuration with incentivisation as an enabler. The four strong 
barriers to address are the misconception that patients and carers are resistant to 
deprescribing, pharmacists’ negative beliefs about deprescribing consequences, 
pharmacists’ working patterns limiting their capacity to support deprescribing and 
deprescribing not being a hospital priority. 
Key drivers emerging for implementing a hospital deprescribing intervention for 
older people are that both geriatricians and pharmacists perceive it to align with 
their ‘Social/professional role and identity’(25). They are also confident in their 
existing ‘Knowledge’ and ‘Beliefs about capabilities’ to undertake their identified 
roles. For geriatricians, this was leading deprescribing, and for pharmacists it was 
supporting through opportunities to deprescribe. For pharmacists to adopt this 
supportive role, the ‘Environmental Context and Resources’ domain needs targeting 
to facilitate pharmacists’ working patterns aligning with active participation in core 
clinical team activity(235,236). 
In accordance with the primary care literature(116), pharmacists’ discussions in the 
consideration of outcomes theme reported numerous risks which they perceived 
outweigh the potential benefits of deprescribing. This may provide some explanation 
for the limited deprescribing activity observed in pharmacist-led hospital 
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deprescribing interventions(84), and indicates the importance of the ‘Beliefs about 
consequences’ domain to pharmacists’ deprescribing activity. Unlike geriatricians, 
pharmacists reported numerous risks that they perceived outweigh the potential 
benefits of deprescribing. An intervention enlisting the support of pharmacists 
should therefore include components to recalibrate their perceptions of the relative 
risks and benefits of deprescribing. A notable distinction between geriatricians and, 
pharmacists and primary care physicians is that geriatricians expressed less 
concern about the risks and described numerous potential benefits. ‘Beliefs about 
consequences’ for geriatricians therefore favoured deprescribing. A further contrast 
between the primary care and hospital settings is that primary care practitioners 
perceive medicines as rarely causing adverse events(116). Geriatricians and 
pharmacists in this study however consistently questioned the appropriateness of 
medicines commonly prescribed for older people due to their potential for causing 
adverse drug events and limited evidence for use in this population. 
The evidence presented in Chapter 4 and the wider literature suggests that 
deprescribing is widely acceptable to patients and carers(52,237,238), yet 
geriatricians and pharmacists believe there to be resistance. An intervention should 
therefore target pharmacists’ ‘Beliefs about consequences’ to recalibrate their 
perceptions of the relative risks and benefits of deprescribing. 
Encouragingly, participants felt that deprescribing is not only acceptable but 
desirable within the wider healthcare community(239). A restriction for primary care 
and therapeutic area specialist practitioners in realising this aspiration is that the 
national UK guidelines driving practice recommend initiation of several medications 
for a single health condition(116), whilst none discuss when and how to stop 
medication(52). Contrary to prescribing guidelines being a recognised barrier to 
deprescribing(52,116), geriatricians perceived deviation from guidelines as a 
characteristic of their speciality. However, for practitioners reticent to deviate from 
guidelines, emerging deprescribing guidelines are potentially relevant intervention 
components(65,66,71,72,240). 
The inpatient environment offered enablers to deprescribing such as routine 
monitoring and access to multi-disciplinary teams. It also presented the barrier of 
prioritising acute patient problems over deprescribing. Targeting the ‘Goals’ domain 
to raise the priority of deprescribing in hospital may therefore be an appropriate 
solution. Encouragingly, participants acknowledged that there is significant scope to 
increase deprescribing in hospital(190). The proposed enabler of incentivisation 
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mapped to the ‘Reinforcement’ domain may be an appropriate intervention 
component given that it has demonstrated efficacy in influencing hospital 
prescribing behaviours(241).  
The influencers of whether geriatricians and pharmacists deprescribe in the hospital 
setting have been identified and may now be mapped to the Behaviour Change 
Technique Taxonomy version 1 (BCTTv1)(172,220) to enable identification of 
evidence-based Behaviour Change Techniques (BCTs). This will provide a theory 
informed framework for developing and implementing a hospital deprescribing 
intervention targeting practitioner behaviour. Emerging patient focussed 
interventions such as the Eliminating Medications through Patient OWnership of 
End Results (EMPOWER) brochure, which is an interactive knowledge transfer tool 
that provides the risks associated with benzodiazepines, safer alternatives and 
steps for tapering(242). The theory underpinning EMPOWER is that providing the 
aforementioned knowledge is hypothesised to trigger patients’ motivation, capacity 
and opportunity to initiate deprescribing discussion with practitioners(243). Results 
from a cluster-RCT demonstrated a 22% increase in the rate of benzodiazepine 
deprescribing with EMPOWER compared to usual care in the community pharmacy 
setting(244). Ongoing research to evaluate the feasibility and acceptability of patient 
focussed interventions in the hospital setting(245) may therefore complement the 
programme of work in this thesis through encouraging patient engagement in 
practitioner-led deprescribing(221). 
Data triangulation arising from intra and inter-professional convergence around the 
key issues was frequently observed, affording confidence in the reliability of these 
findings(246,247). Furthermore, the transferability of barriers and enablers between 
district general and teaching hospitals indicates that an intervention based on the 
results from this study may be applicable to multiple hospital contexts(248). 
Capturing the perspectives of the two professions primarily responsible for 
prescribing decisions for older people in the UK hospital context has allowed 
exploration of a wide range of barriers and enablers.  
Confining the study to the UK hospital population may limit the international 
transferability of these findings, particularly where roles and resource factors differ 
from this sample. For example, in some contexts geriatricians and pharmacists may 
not be available to lead deprescribing, and other practitioners such as nurses may 
undertake the deprescribing activities of geriatricians and pharmacists described in 
this study. Additionally, given that even geriatricians and pharmacists in the UK 
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context work within a multidisciplinary team, a potential limitation of this study may 
be that the views of the wider team have not been fully considered. The required 
specificity when developing behaviour change interventions focussed this study on 
geriatricians and pharmacists, therefore the views of other potentially relevant 
professionals have intentionally not been captured. Accordingly, the adopted 
methodological approach could be duplicated in other countries and other 
professional groups, particularly where the deprescribing role is less likely to be 
assumed by geriatricians and pharmacists. 
The results from this chapter suggest that the deprescribing research agenda to 
change hospital practitioner behaviour should recognise the five TDF domains of 
‘Social influence’, ‘Beliefs about consequences’, ‘Environmental context and 
resources’, ‘Goals’ and ‘Reinforcement’. A hospital deprescribing intervention for 
older people should focus on geriatricians’ and pharmacists’ behaviour within the 
prioritised TDF domains. Future work should identify intervention components with 
evidence for changing behaviour within the prioritised TDF domains, and seek to 
select those components that are most likely to be appropriate for operationalising 
in the hospital setting. 
In Chapter 6, the evidence-based BCTs that are mapped to the five prioritised TDF 
domains will be identified and presented. Tailored selection of these BCTs 
according to the UK hospital context will be undertaken by geriatricians and 
pharmacists representative of this study sample according to whether they are likely 
to be affordable, practical, effective and cost-effective, acceptable, safe and 
equitable(249).
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Chapter 6 Selecting Behaviour Change 
Techniques for a hospital 
deprescribing intervention: An expert 
consensus study with geriatricians and 
pharmacists 
 
This chapter is in part derived from the publication: 
Scott, S., Twigg, M. J., Clark, A., Farrow, C., May, H., Patel, M., … Bhattacharya, D. 
Development of a deprescribing implementation framework for the hospital setting: 
A focus group study with geriatricians and pharmacists. Age and Ageing. 2019. 
Accepted in press.
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6.1 Introduction 
Chapter 5 presented empirical research addressing a gap in the existing literature 
regarding the views of geriatricians and pharmacists towards deprescribing in 
hospital. Both professional groups expressed a strong desire to increase 
deprescribing activity in hospital, and that this aligned with their roles and 
responsibilities. A hospital deprescribing intervention for older people led by 
geriatricians and supported by pharmacists was the preferred configuration with 
incentivisation as an enabler. The four strong barriers to address are the 
misconception that patients and carers are resistant to deprescribing, pharmacists’ 
perceptions that deprescribing is riskier than continuing to prescribe, pharmacists’ 
working patterns limiting capacity to support deprescribing and deprescribing not a 
being a hospital priority 
Chapter 2 provided the rationale for underpinning the development of interventions 
with theory. The Theoretical Domains Framework (TDF), was introduced and is an 
integrative framework of behaviour change theories for developing and 
implementing interventions(157). It comprises 14 domains representing 
determinants of behaviour. Collectively, the 14 TDF domains are linked to a 
taxonomy of Behaviour Change Techniques (BCTs)(220), which are the ‘building 
blocks’ of interventions that lead to behaviour change. The TDF has been applied 
extensively to develop interventions targeting practitioners’ behaviours including 
promoting uptake of a screening tool in geriatric oncology(250). 
The one enabler and four barriers to deprescribing identified in Chapter 5 were 
mapped to the TDF, and five domains were prioritised for behaviour change: Social 
influence; Beliefs about consequences; Environmental context and resources; 
Goals; Reinforcement. For these five domains, the mapping table developed by 
Cane et al.(220) provides a total of 44 linked evidence-based BCTs. Figure 12 
provides the barriers and enabler to deprescribing, five prioritised TDF domains and 
the 44-linked BCTs as a ‘hospital Deprescribing Implementation Framework 
(hDIF)(251).
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Figure 12 hospital Deprescribing Implementation Framework (hDIF) 
TDF: Theoretical Domains Framework, BCTs: Behaviour Change Techniques
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Selection of BCTs from the hDIF should be according to health system contexts 
using criteria such as APEASE (affordability, practicability, effectiveness, 
acceptability, safety and equity) (97), which was introduced in Chapter 2. This 
should be achieved through engagement with the practitioners whose behaviour 
requires changing using consensus methods. 
 
6.2 Aim 
To develop a theory and evidence-based intervention for geriatricians and 
pharmacists to implement deprescribing in the UK hospital context. 
 
6.3 Objectives 
1. To select geriatricians’ and pharmacists’ preferred BCTs from the hDIF (figure 
12) for inclusion in a hospital deprescribing intervention 
2. To characterise how selected BCTs may be operationalised in the hospital 
setting 
 
6.4 Ethics approval 
Ethical approval was obtained from the University of East Anglia Faculty of Medicine 
and Health Sciences Research Ethics Committee (Reference 2018/19 - 009). The 
study protocol and ethical approval letter are provided in appendices 13 and 14 
respectively. 
 
6.5 Methods 
This project was overseen by the project management group described in Chapter 
3. 
 
6.5.1 Study design 
Consensus methods are used in research to problem solve, generate ideas or 
determine priorities, and ultimately achieve agreement or convergence of opinion 
amongst a group or groups of stakeholders(252). These stakeholder groups are 
usually an expert panel, defined in this context as ‘a panel of informed 
individuals'(253). How consensus is defined and operationalised varies 
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significantly(254), and is guided by the research question and methodological 
approach applied to achieve consensus. The two consensus methods most 
frequently applied in health services research are the Delphi technique and the 
Nominal Group Technique (NGT). These methods share characteristics with focus 
groups, such as generation of ideas through group interaction. However, a key 
difference is that whilst focus groups explore in-depth the thoughts and ideas of 
participants towards the subject matter, consensus methods aim to generate 
solutions or answers to a question. 
The Delphi technique is a highly structured process involving participants 
responding to several iterations of a survey in ‘rounds’ to achieve 
consensus(253,255). The first round survey invites responses to statements, such 
as on a Likert scale with supporting extended responses. These responses are then 
analysed and collated, and inform the second round survey. Here, participants are 
provided with the first round statements, their original response and the median 
group response along with any extended responses. Participants are then asked to 
re-respond to the statements after considering the group responses; they may or 
may not provide a different response to round one. The number of rounds is usually 
determined a priori, with two rounds being most frequently selected. There are no 
rules regarding how many participants are required for a Delphi technique, and 
samples vary from 15 to over 60(253). 
The Delphi technique it useful when working with a geographically diverse group of 
respondents and surveys are usually administered online for added convenience. 
Participants are also afforded the flexibility of asynchronous responding, however 
this can prolong a Delphi technique if multiple reminders are required to facilitate 
engagement. There is minimal interaction between respondents to Delphi surveys, 
which may present a disadvantage of this methodological approach depending on 
the study aims. Whilst respondents will be exposed to the group’s responses in 
subsequent rounds, there is no generation of novel concepts or iteration of the 
presented concepts. This is likely to be a disadvantage for studies whose aim 
extends further than merely achieving consensus regarding concepts prescribed by 
those who are facilitating the Delphi technique. 
NGT is another consensus method used to generate potential solutions to research 
questions through idea generation, problem solving, prioritisation and agreement. 
NGT is a highly structured and facilitated face-to-face group interaction of between 
two and 14 participants designed to enable presentation, listening and discussion of 
152 
 
thoughts and ideas through a five step cycle (figure 13)(252). Participants are 
usually provided with questions to consider in advance of the session. 
 
Figure 13 The five steps of Nominal Group Technique (adapted from Tully et 
al.(252)) 
 
Each round is allocated approximately 30 minutes. For silent generation, 
participants are allowed approximately 30 minutes to silently reflect and record their 
individual thoughts and ideas about the questions provided beforehand. One 
participant at a time is then asked to propose a single idea to the group during the 
‘round robin’ step this is recorded verbatim. Participants are encouraged to think of 
new ideas during this process, however they must wait their turn before sharing with 
the group and no discussion of ideas occurs. The round robin stage continues until 
no new ideas are generated. Clarification follows, where participants are 
encouraged to discuss ideas and ensure understanding to enable informed 
decision-making. Participants are encouraged to group similar ideas together and 
modify or exclude ideas as necessary. Participants are then asked to select their top 
ideas from the previous stages and rank these in order of preference by assigning a 
number to each item, with a larger number indicating greater importance. The 
facilitator asserts the number of ideas to be ranked, with five ideas being commonly 
specified in the literature. Finally, the scores for each idea are summed and 
presented to the group for discussion. The cycle may or may not repeat depending 
on whether consensus was achieved via voting and/or discussion. 
1. Silent 
generation
2. Round 
robin
3. 
Clarification
4. Voting
5. 
Discussion
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NGT encourages group discussion and interaction. Whilst prescribed concepts are 
provided to participants in advance for consideration, the first three NGT steps may 
result in significant interaction regarding these concepts or generation of novel 
concepts. This is particularly useful when concepts may not necessarily be 
presented in their final refined forms or where there is need to explore whether 
additional concepts not presented to participants should be considered. Given the 
face-to-face nature of the NGT, sample sizes are generally smaller than for the 
Delphi technique, thus findings may be less representative of a wider defined 
population, which is a disadvantage if generalisability is an objective. The face-to-
face nature also presents the logistical challenges associated with convening 
sessions of approximately three hours in duration with geographically diverse 
participants and thus must be considered in terms of feasibility. 
Some NGT studies adopt a modified approach, often borrowing elements of the 
Delphi technique, such as administration of a pre-NGT survey(256). In this form of 
modified NGT, participants complete a pre-session consensus survey and the 
results of which inform the latter face-to-face NGT session. An advantage of this 
adaptation to NGT is that an early indication of participants’ views towards the 
research problem and the magnitude of consensus is obtained prior to the face-to-
face meeting. This allows the NGT facilitator to guide the face-to-face discussion to 
focus on areas of non-consensus amongst participants, as informed by the survey. 
Removal of concepts prior to the time and resource intensive face-to-face NGT 
session if there is clear consensus that the concepts are not relevant to the 
research questions may occur. 
There is a need for a consensus approach to achieve the two objectives of selecting 
BCTs from the hDIF and characterising the selection for inclusion in a hospital 
deprescribing intervention. Whilst the Delphi technique may facilitate the former 
objective, it will not enable the respondent group to generate and agree through 
discussion, characterisations of how BCTs may be operationalised. NGT would 
facilitate both selection of BCTs through the voting step and characterisation of 
BCTs, it is not feasible to discuss all 44 BCTs from the hDIF in a face-to-face NGT 
session. This modified NGT previously described(256) enables participants to 
appraise the 44 BCTs before the face-to-face meeting, allowing only those BCTs 
which may be appropriate for inclusion in the intervention proceeding to the formal 
NGT. The consensus survey would therefore likely remove a substantial number of 
BCTs from the process, making the face-to-face NGT session feasible. 
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Accordingly, an expert panel was convened to select and characterise BCTs for a 
hospital deprescribing intervention using a modified NGT to facilitate consensus in 
two stages: 
Stage 1: Initial voting round (online survey) 
Stage 2: Face-to-face NGT 
 
6.5.1.1 Initial appraisal of Behaviour Change Techniques by the research team 
In order to eliminate unnecessary burden on the expert panel, an initial appraisal of 
the 47 BCTs from the hDIF by the research team was deemed necessary to remove 
any which were clearly inappropriate for a United Kingdom (UK) hospital 
deprescribing intervention. This was achieved through an initial discussion between 
SS and DB which was guided by but not restricted to the APEASE criteria. The 19 
BCTs proposed for exclusion plus rationale were presented to the study 
management group of geriatricians, pharmacists, patient and carer representatives, 
academic pharmacists and medical statistician, and are provided in table 15. The 
remaining 28 BCTs were deemed to conservatively meet the APEASE criteria.
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Table 15 Behaviour Change Techniques excluded from the study through research team appraisal 
Behaviour Change Technique 
Definition(172) 
Rationale for exclusion 
Misconception that patients and carers are resistant to deprescribing (barrier) 
Social support or encouragement (general) 
Advise on, arrange or provide social support (e.g. from friends, relatives, 
colleagues,’ buddies’ or staff) or non-contingent praise or reward for performance 
of the behaviour. It includes encouragement and counselling, but only when it is 
directed at the behaviour. 
General social support/encouragement covered by the 
BCTs ‘Social support emotional’ and ‘Social support 
practical’. 
Pharmacists’ negative beliefs about deprescribing consequences (barrier) 
Anticipated regret 
Induce or raise awareness of expectations of future regret about performance of 
the unwanted behaviour. 
Pharmacists do not currently perceive failure to 
deprescribe as an unwanted behaviour (chapter 5) thus 
will not regret failing to deprescribe. Thus other BCTs 
require prioritisation above and beyond anticipated 
regret. 
Comparative imagining of future outcomes 
Prompt or advise the imagining and comparing of future outcomes of changed 
versus unchanged behaviour. 
Pharmacists think that the risks of deprescribing 
outweigh the benefits (chapter 5), therefore this BCT 
may reinforce failing to deprescribe. 
Threat 
Inform that future punishment or removal of reward will be a consequence of 
performance of an unwanted behaviour (may include fear arousal). 
Threatening a healthcare practitioner is very unlikely to 
be deemed acceptable and may precipitate 
demoralisation if presented to the expert panel in this 
study. Undesirable consequences may include 
unmotivated workforce/inappropriate deprescribing for 
fear of threat. 
Covert conditioning 
Advise to imagine performing the wanted behaviour in a real-life situation followed 
by imagining a pleasant consequence. 
Pharmacists are sceptical about the benefits of 
deprescribing relative to the risks (chapter 5) thus 
unlikely to imagine performing the behaviour. 
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Table 15 (continued) 
Behaviour Change Technique 
Definition(172) 
Rationale for exclusion 
Pharmacists’ working patterns limits capacity to support deprescribing (barrier) 
Discriminative (learned cue) 
Identify an environmental stimulus that reliably predicts that reward will follow the 
behaviour. 
Pharmacists’ dictated working patterns cannot be 
altered by pharmacists responding to a cue reward. 
Prompts/cues 
Introduce or define environmental or social stimulus with the purpose of 
prompting or cueing the behaviour. The prompt or cue would normally occur at the 
time or place of performance. 
Pharmacists’ dictated working patterns cannot be 
altered by pharmacists responding to a cue. 
Restructuring the social environment 
Change, or advise to change the social environment in order to facilitate 
performance of the wanted behaviour or create barriers to the unwanted 
behaviour (other than prompts/cues, rewards and punishments). 
Pharmacists’ working patterns e.g. limited or no time 
allocated to supporting deprescribing cannot be altered 
by a change in the social environment. 
Avoidance/changing exposure to cues for the behaviour 
Advise on how to avoid exposure to specific social and contextual/physical cues 
for the behaviour, including changing daily or weekly routines. 
Pharmacists’ working patterns e.g. limited or no time 
allocated to supporting deprescribing cannot be altered 
by a change in exposure to deprescribing cues. 
Deprescribing is not a hospital priority (barrier) 
Goal setting (outcome) 
Set or agree on a goal defined in terms of a positive outcome of wanted 
behaviour. 
The target behaviour is deprescribing inappropriate 
medication; it is not appropriate to set a target of the 
number of medications deprescribed as this is 
dependent on several factors external to the prescriber 
e.g. presence of inappropriate medication, patient 
willingness to engage etc. 
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Table 15 (continued) 
Behaviour Change Technique 
Definition(172) 
Rationale for exclusion 
Review of outcome goals 
Review outcome goal(s) jointly with the person and consider modifying goal(s) in 
light of achievement. This may lead to resetting the same goal, a small change in 
that goal or setting a new goal instead of, or in addition to the first. 
The target behaviour is deprescribing inappropriate 
medication; it is not appropriate to review a target of the 
number of medications deprescribed as this is 
dependent on several factors external to the prescriber 
e.g. presence of inappropriate medication, patient 
willingness to engage etc. 
Incentivising deprescribing (enabler) 
Threat 
Inform that future punishment or removal of reward will be a consequence of 
performance of an unwanted behaviour (may include fear arousal). 
Threatening a healthcare practitioner is very unlikely to 
be deemed acceptable and may precipitate 
demoralisation if presented to the expert panel in this 
study. Undesirable consequences may include 
unmotivated workforce/inappropriate deprescribing for 
fear of threat. 
Differential reinforcement 
Arrange reward for performance of an alternative to the unwanted behavior. 
Not applicable as the target behaviour (deprescribing 
inappropriate medication) is the only alternative to the 
undesirable behaviour (failing to stop inappropriate 
medication). 
Discrimination training 
Arrange for reward following the behavior in one situation but not in another. 
There are no situations in which failing to appropriately 
deprescribe is acceptable. 
Social reward 
Arrange verbal or non-verbal reward if and only if there has been effort and/or 
progress in performing the behavior. 
It cannot be guaranteed that deprescribing will always 
lead to a positive social response 
Non-specific reward 
Arrange delivery of a reward if and only if there has been effort and/or progress in 
performing the behavior. 
Excluded as generic rewards already covered by 
material and social rewards. 
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Table 15 (continued) 
Behaviour Change Technique 
Definition(172) 
Rationale for exclusion 
Response cost 
Arrange for withdrawal of something valued if and only if an unwanted behavior is 
performed. 
This variation of threatening a healthcare practitioner is 
very unlikely to be deemed acceptable and may 
precipitate demoralisation if presented to the expert 
panel in this study. Undesirable consequences may 
include unmotivated workforce/inappropriate 
deprescribing for fear of threat. 
 
Anticipation of future rewards or removal of punishment 
Arrange for future rewards or removal of punishments will be a consequence of 
undertaking the desired behaviour. 
Significant overlap with incentive and threat BCTs 
Punishment 
Arrange for aversive consequence contingent on the performance of the 
unwanted behavior. 
Punishing a healthcare practitioner is very unlikely to be 
deemed acceptable and may precipitate demoralisation 
if presented to the expert panel in this study. 
Undesirable consequences may include unmotivated 
workforce/inappropriate deprescribing for fear of threat. 
A: Affordable, P: Practical, E: Effective/cost-Effective, A: Acceptable, S: Safe, E: Equitable
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All proposed BCTs for exclusion were accepted by the wider research team and 
thus the BCTs indicated in table 15 were excluded from the study. 
 
6.5.1.2 Sample 
A purposive sample of senior hospital geriatricians and pharmacists representative 
of the target audience for the deprescribing behaviour change intervention were 
eligible and formed the expert panel. Participants were recruited from five acute 
teaching and district general hospitals across three English counties to represent a 
range of context and resource provision.  
 
6.5.1.3 Recruitment 
An invitation email describing the study was sent to eligible potential participants via 
nominated gatekeepers at each of the five hospitals. The gatekeepers were 
members of the University of East Anglia Health Partners Medicines Optimisation 
Group which has representation from the five hospitals. Participants provided 
written, informed consent for participation in the two-stage consensus study and 
provided demographic information including age, gender and professional group 
(geriatrician or pharmacist) via the stage 1 online survey (initial voting round) 
described below. 
 
6.5.2 Data collection 
 
6.5.2.1 Stage 1: Initial voting round 
 
6.5.2.1.1 Procedure 
A survey was developed by four members of the research team with experience in 
the field of behavioural science (SS, DB, AD and JT), provided in appendix 15. The 
survey was designed to facilitate the expert panel’s selection of BCTs for inclusion 
in the deprescribing intervention using the APEASE criteria. 
The definitions provided in the Behaviour Change Technique Taxonomy version 1 
(BCTTv1)(172) for each of the 28 BCTs from the hDIF retained by the research 
team (see 6.5.1.1) were used as a foundation for the survey statements. To enable 
full participation by the expert panel who were not behavioural scientists, the BCT 
160 
 
definitions(172) were modified into plain English statements. Additionally, for the 
prioritised barriers, enabler and each of the six APEASE criteria, a brief plain 
English statement was also prepared. 
The survey therefore comprised the five sections of four barriers and one enabler, 
each presenting BCTs requiring a response to statements representing the six 
APEASE criteria. Participants were asked to rate their level of agreement with each 
of the APEASE criteria in relation to BCTs on a four-point Likert scale from strongly 
disagree to strongly agree. An optional extended response answer box was also 
provided for each BCT section to allow respondents to expand on their answers. 
The survey was piloted and refined with the wider research group, which included 
senior clinical pharmacists and consultant geriatricians representative of the target 
audience. As the wider research group did not have experience in behavioural 
science, this piloting/refinement enabled identification of any difficulties with 
interpreting survey statements and selecting informed responses. The consensus 
survey was refined iteratively based on the wider research team’s feedback until no 
further adaptations were deemed necessary. 
Table 16 illustrates the presentation of the BCT ‘Information about others’ approval’ 
for APEASE appraisal regarding the barrier of ‘misconception that patients and 
carers are resistant to deprescribing’ in the final survey. 
Table 16 Example appraisal question for the BCT ‘Information about others’ 
approval’ 
Information about others’ approval 
Tell geriatricians and pharmacists that the vast majority of patients and carers are 
willing to have one or more of their medications deprescribed if this is proposed 
by a practitioner 
 Strongly 
disagree 
Disagree Agree Strongly 
agree 
Affordable for my hospital     
Practical to deliver as intended     
Likely to be effective and cost-
effective in addressing the 
barrier 
    
Acceptable to patients, carers 
and practitioners in my hospital 
    
Likely to be safe and free of 
undesirable consequences 
    
Equitable in that it is unlikely to 
increase disparities between 
different sectors of society e.g. 
different ethnicities and gender 
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The final survey was hosted on the Online surveys® platform and a link to complete 
emailed to participants by their gatekeeper. 
 
6.5.2.1.2 Data analysis 
Descriptive statistics were reported for ratings across the APEASE criteria for each 
BCT using Microsoft® Excel. Consensus was defined as 80% of the expert panel 
agreeing or strongly agreeing that a BCT met all six of the APEASE criteria. A 
systematic review of methodological criteria for consensus studies reported a 
median threshold of 75% definition for consensus, ranging from 50-97%(254). A 
stringent threshold of 80% was adopted for the present study due to the anticipated 
relatively small number of participants and the large number of items requiring a 
response (six APEASE criteria for 37 BCTs). Additionally, BCTs which fail to meet 
the consensus threshold would not be retained, thus allowing discussions to focus 
on the BCTs with the greatest support. 
Partial consensus was defined as 80% of experts agreeing or strongly agreeing that 
a BCT met at least three of the APEASE criteria; these BCTs required consensus 
discussions by the expert panel in stage 2. All other BCTs not achieving consensus 
or patient consensus were excluded from the study. Additionally, BCTs achieving 
partial consensus where one or more other BCTs achieved consensus for the same 
barrier or enabler were excluded. 
Extended responses were collated for each BCT progressing to stage 2 for use 
during the discussions. 
 
6.5.2.2 Stage 2: Face-to-face NGT 
 
6.5.2.2.1 Procedure 
The aims of stage 2 were to facilitate: 
1. Discussion regarding BCTs achieving partial consensus during stage 1 and 
then re-voting to achieve consensus to include or exclude. 
2. Discussion regarding characterising BCTs for operationalising in the hospital 
setting. 
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Aim 1 
One NGT cycle per BCT that achieved partial consensus in stage 1 was undertaken 
to determine whether to include or exclude in the deprescribing intervention. 
Quantitative and extended responses to the online survey regarding these BCTs 
with partial consensus were presented. The voting round mirrored the online survey 
APEASE criteria appraisal. Turning Point® electronic voting system facilitated the 
NGT voting stages. All BCTs not achieving consensus were excluded. 
 
Aim 2 
One NGT cycle per BCT selected for inclusion in the deprescribing intervention 
(from stages 1 and 2) was undertaken to characterise BCTs for operationalising in 
the hospital setting. Participants reached consensus regarding the agreed idea or 
combination of ideas through the discussion step. SS and DB facilitating the 
discussions synthesised the agreed BCT characterisation statements in real-time. 
 
6.5.2.2.2 Data analysis 
For aim 1, real-time analysis of voting mirrored the online consensus survey 
analysis, facilitated by the Turning Point platform. For aim 2, generated and agreed 
BCT characterisation statements were recorded and validated by participants 
through discussions. 
 
6.6 Results 
Four geriatricians and five pharmacists were recruited, six were male and the mean 
(standard deviation) age of the participants was 40 (9) years. 
 
6.6.1 Stage 1: Initial voting round 
Tables 17 and 18 provide the quantitative and extended responses to the initial 
voting round survey respectively.
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Table 17 Expert panel quantitative responses to the initial voting round survey and consensus decision regarding the 28 Behaviour Change 
Techniques 
Barrier or enabler 
Prioritised TDF 
domain 
Behaviour Change 
Technique 
A P E A S E 
Consensus 
Decision 
   % agreement  
Misconception that patients and 
carers are resistant to 
deprescribing (barrier) 
Social influence 
Social comparison 100.0 88.9 88.9 88.9 100.0 88.9 Include 
Information about 
others’ approval 
100.0 88.9 77.8 77.8 100.0 88.9 Partial 
consensus 
Social support 
emotional 
77.8 33.3 33.3 66.7 100.0 100.0 Reject 
Social support practical 66.7 66.7 88.9 88.9 100.0 100.0 Partial 
consensus 
Vicarious reinforcement 100.0 88.9 77.8 88.9 100.0 100.0 Partial 
consensus 
Restructuring the social 
environment 
66.7 44.4 77.8 100.0 100.0 100.0 Partial 
consensus 
Modelling or 
demonstrating the 
behaviour 
77.8 66.7 88.9 88.9 100.0 100.0 Partial 
consensus 
Identification of self as 
role model 
100.0 88.9 77.8 88.9 88.9 100.0 Partial 
consensus 
Social reward 88.9 77.8 77.8 77.8 100.0 88.9 Partial 
consensus 
Pharmacists’ negative beliefs 
about deprescribing 
consequences (barrier) 
Beliefs about 
consequences 
Emotional 
consequences 
100.0 77.8 100.0 88.9 100.0 100.0 Partial 
consensus 
Salience of 
consequences 
100.0 88.9 100.0 88.9 100.0 100.0 Include 
Covert sensitisation 77.8 77.8 66.7 77.8 88.9 100.0 Reject 
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Table 17 (continued) 
Barrier or enabler 
Prioritised TDF 
domain 
Behaviour Change 
Technique 
A P E A S E 
Consensus 
Decision 
   % agreement  
  Social and 
environmental 
consequences 
77.8 88.9 88.9 100.0 88.9 100.0 Partial 
consensus 
Vicarious reinforcement 100.0 77.8 66.7 88.9 100.0 100.0 Partial 
consensus 
Pros and cons 100.0 88.9 88.9 100.0 100.0 100.0 Include 
Pharmacists’ working patterns 
limits capacity to support 
deprescribing (barrier) 
Environmental 
context and 
resources 
Restructure the physical 
environment 
 
 
11.1 22.2 88.9 100.0 88.9 100.0 Partial 
consensus 
Deprescribing is not a hospital 
priority (barrier) 
Goals 
Goal setting (behaviour) 66.7 33.3 66.7 66.7 77.8 88.9 Reject 
Review behaviour goals 66.7 44.4 55.6 66.7 77.8 88.9 Reject 
Action planning 
(implementation 
intention) 
77.8 77.8 100.0 100.0 100.0 100.0 Partial 
consensus 
Incentivising deprescribing 
(enabler) 
Reinforcement 
Self-reward 88.9 77.8 66.7 77.8 77.8 77.8 Reject 
Material incentive 22.2 44.4 33.3 44.4 55.6 77.8 Reject 
Thinning 22.2 33.3 55.6 44.4 66.7 66.7 Reject 
Negative reinforcement 77.8 22.2 11.1 11.1 22.2 66.7 Reject 
Shaping 66.7 33.3 66.7 66.7 66.7 77.8 Reject 
Counter conditioning 55.6 44.4 44.4 55.6 55.6 77.8 Reject 
Material reward 0 44.4 22.2 33.3 55.6 77.8 Reject 
Extinction 55.6 44.4 22.2 22.2 44.4 77.8 Reject 
Classical conditioning 66.7 55.6 88.9 88.9 100.0 100.0 Partial 
consensus 
A: Affordable, P: Practical, E: Effective/cost-Effective, A: Acceptable, S: Safe, E: Equitable
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Table 18 Expert panel extended responses to the initial voting round survey 
Barrier or enabler 
Prioritised 
TDF domain 
Behaviour 
Change 
Technique 
Extended responses 
Misconception that 
patients and carers 
are resistant to 
deprescribing (barrier) 
Social 
influence 
Social 
comparison 
Not sure how you'd draw attention to other practitioners and audit what they're 
actually doing 
 
Requires real life examples, with information about follow up as the key is 
deprescribing safely so its necessary to demonstrate the lack of harm. Ideally at 
an individual patient level as well as a health economy level. Would be more 
useful if built on the top of evidence based tools and lists of high risk / low value 
drugs too target. Perhaps patient stories on how they felt and how to 
successfully explain this to patients and family. 
 
Would like examples from comparable trusts 
 
The other practitioners who are successfully deprescribing should work in a 
comparable environment, within similar constraints of the job as those being 
shown 
 
By inviting successful de prescribers to local education meetings in the trust 
Information 
about others’ 
approval 
Is this true? What's the vast majority? Often some are quite attached to things. 
This could be published but wouldn't be that effective I feel 
 
This presumes we have the evidence to support this statement. Knowing that it’s 
acceptable to patients to initiate the conversation will build confidence in 
professionals to broach the topic. Real examples and patient stories e.g. videos 
of patient interviews demonstrating the benefit would be useful, ideally in 
different clinical / social scenarios. 
 
The geriatricians/pharmacists would want to see evidence of this claim 
166 
 
Table 18 (continued) 
Barrier or enabler 
Prioritised 
TDF domain 
Behaviour 
Change 
Technique 
Extended responses 
  
Social support 
emotional 
What sort of emotional support - not sure this helps in any way 
 
Most likely to be achievable through clinical supervision or coaching style 
sessions. Could be effective if flexible and supported by the organisation to pair 
up supervisor and supervisee. Time and people's busy days are likely to make 
this hard to deliver in practice. May need to target who would benefit and at what 
point, or for what length of time. E.g. is this most effective if provided for the first 
3 months of implementing a programmed intervention or change programme? 
 
Will be dependent on the nature of the support required 
 
I don't feel like a lack of emotional support for potential deprescribers is 
necessarily a barrier to deprescribing... the term 'emotional support' requires 
clarification 
 
I'm not sure about the practicability , acceptability or cost efficacy of this 
intervention 
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Table 18 (continued) 
Barrier or enabler 
Prioritised 
TDF domain 
Behaviour 
Change 
Technique 
Extended responses 
  
Social support 
practical 
Probably best idea so far - a geriatrician as lead, with a pharmacist as support 
may help. They need job planning time to lead education, review cases etc. 
 
If training and underpinning knowledge is sufficient and toolkit with tools provided 
I'm not sure what practical help would be required in person. A third person 
being asked to attend for this discussion may undermine the clinician-patient 
relationship and risks escalating the concern over why this conversation is being 
managed in this way. May risk development of deprescribing 'experts' being 
called upon to support when patients identified rather than a culture spreading 
through clinical staff that deprescribing is business as usual. 
 
Again dependent upon the nature of the support required 
 
I feel this is probably the most powerful intervention put forward for this barrier 
Vicarious 
reinforcement 
Not sure how effective this would be - seems very vague 
 
Positive reinforcement, particularly if it can be kept local, could be effective. 
Especially if this take the form of a social movement to promote working towards 
a joint goal. 
 
Good examples - on line learning? Evidence base to be shared. 
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Table 18 (continued) 
Barrier or enabler 
Prioritised 
TDF domain 
Behaviour 
Change 
Technique 
Extended responses 
  
Restructuring 
the social 
environment 
Agree is a good idea but finding the time may be tricky 
 
On a wide scale this is likely to be expensive and therefore unaffordable. 
Perhaps may work for nominated leads in each Trust. Perhaps by creating a 
inter-Trust network of deprescribing leads. 
 
Again would be useful if this provides practical support, is relevant to my trust - 
could be delivered by e-learning or conference call to make this more practical to 
deliver 
 
They would need to be working in a similar environment to get the best results 
Modelling or 
demonstrating 
the behaviour 
Acceptability will depend on the experience of practitioners - suspect less likely 
to be well received by experienced clinicians but could be an effective method 
for early years practitioners. 
 
This would be excellent - within our trust you would need a lead for this who 
could then set this example with colleagues. 
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Table 18 (continued) 
Barrier or enabler 
Prioritised 
TDF domain 
Behaviour 
Change 
Technique 
Extended responses 
  
Identification of 
self as role 
model 
Again is a bit vague - not sure this would encourage me - seems a bit 
sycophantic 
 
As part of a wider package this might be useful, but not sufficient alone to make 
an impact. 
Social reward Gift Vouchers? Not sure this would be effective, could be abused – avoid 
 
Sounds like incentives for deprescribing. How would 'successfully engaging' be 
defined? Could possibly work as an award or recognition for individuals or teams 
that have implemented good projects or had good results through publishing 
audit or project writ up. 
Pharmacists’ negative 
beliefs about 
deprescribing 
consequences 
(barrier) 
Beliefs about 
consequences 
Emotional 
consequences 
Not clear how this would be achieved beyond good mentoring 
 
I don’t personally agree with this statement, so think it should be effective to 
provide the evidence of the overall benefits of deprescribing and pharmacists 
should then be vocal advocates. 
Salience of 
consequences 
Is negative reinforcement better than positive? Probably not in my eyes 
 
Include in the training package as part of generating a behaviour change 
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Table 18 (continued) 
Barrier or enabler 
Prioritised 
TDF domain 
Behaviour 
Change 
Technique 
Extended responses 
  Covert 
sensitisation 
Not sure this role pay aspect works in a busy real life situation - maybe in a 
classroom 
 
Happy to support if there's evidence this works as part of the behaviour change 
training programme. would work well with real life patient stories 
 
Real life examples of actual case studies where there was an opportunity to 
deprescribe that wasn't taken, and harm then occurred - appreciate that these 
may be difficult to find! 
Social and 
environmental 
consequences 
More evidenced based may have more effect - making pricing comparisons of 
drugs on prescription systems (e.g. EPMA) I've always wondered if that makes a 
difference - would need to be integrated into existing digital systems 
 
I'd query including the financial consequences - may prove a disincentive for 
some if motives appear to be non-clinical 
 
I feel like the risk-focused comparison would be more effective than 
health/financial benefit comparison 
Vicarious 
reinforcement 
Draw attention how? Too vague 
 
Would be interested in understanding how this could be achieved 
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Table 18 (continued) 
Barrier or enabler 
Prioritised 
TDF domain 
Behaviour 
Change 
Technique 
Extended responses 
  Pros and cons Good idea given time - often the best way of deciding but is this practical for 
multi-drugs? 
 
Could be useful as part of a wider training package 
 
Pharmacists are aware of the pros of deprescribing, yet still are often averse to 
it, so I don't necessarily feel like listing them out will improve deprescribing rates 
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Table 18 (continued) 
Barrier or enabler 
Prioritised 
TDF domain 
Behaviour 
Change 
Technique 
Extended responses 
Pharmacists’ working 
patterns limits 
capacity to support 
deprescribing (barrier) 
Environmental 
context and 
resources 
Restructure the 
physical 
environment 
Good idea - I'd love more MDT ward rounds and have had pharmacists on ward 
rounds - is it practical - more time should be given to ward rounds in general - 
can be intimidating for pharmacists - need experience (perhaps part of training?) 
 
Changing what clinical activities pharmacists are working on is not about working 
patterns as much as about use of resource. Taking time for advising on 
deprescribing and getting involved in MDTs is a change of focus and existing 
workload needs to be rearranged or delegated. Needs a whole team approach 
and agreed model for provision of clinical pharmacy, as well as increased 
involvement of pharmacy technicians in meds rec etc. 
 
This is what we should be doing but currently lack the staffing to do so 
 
In my opinion, it not necessary the fact that working patterns can't allow it, but it 
is purely for reasoning of priority. Pharmacists are on the ward at the time of the 
ward round, but aren't able to join due to missed doses/discharges/MRs that 
unfortunately take priority 
 
This intervention will require increased number of pharmacists to provide ward 
pharmacy services and actively support deprescribing 
 
Not practical - no where near enough pharmacists for this to work 
 
A pharmacist on the ward rounds would be brilliant in terms of working together 
and deprescribing. 
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Table 18 (continued) 
Barrier or enabler 
Prioritised 
TDF domain 
Behaviour 
Change 
Technique 
Extended responses 
Deprescribing is not a 
hospital priority 
Goals 
Goal setting 
(behaviour) 
Somewhat arbitrary and who decides the target - can see national guidelines 
would do anything other than ENCOURAGE prescriptions not DISCOURAGE 
them. May encourage rogue deprescribing (I've not hit my 50% warfarin 
deprescribing target) 
 
Setting targets may be the wrong approach unless very specific and evidence 
based. Getting a confirmed indication if a target may become tick box and not as 
effective as intended. There may not be the appropriate records in secondary 
care to even answer this question. Needs a whole system approach not setting 
expectations that this can be solved in any one sector of the NHS. The priority in 
hospital is medical stabilisation and discharge. Changing meds can result in 
destabilising the patient - need evidence this is not the case. Or agreement with 
GPs that they will act on advice to stop certain medicines if deprescribing 
identified in hospital but not acted upon. 
 
There would be a massive data collection/audit burden associated with this 
which I believe would make it impractical to deliver. Also, during this data 
collection, if you find a drug without a known indication would it be ‘unethical’ to 
leave it? 
 
Would be useful is setting aside a number of patients on the ward round that you 
then select for deprescribing. 
Review 
behaviour goals 
Again who sets the targets - this isn't holistic medicine surely? 
 
Likely to be effective if implemented as part of an ongoing implementation and 
support programme 
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Table 18 (continued) 
Barrier or enabler 
Prioritised 
TDF domain 
Behaviour 
Change 
Technique 
Extended responses 
  Action planning 
(implementation 
intention)? 
Action plans are always good - more joined up working with pharmacy and geris 
together has to be a good thing 
 
Likely to be effective if implemented as part of an ongoing implementation and 
support programme. Would like to see this as a team/trust action plan rather 
than for individuals - joint action and support 
 
I think this would work on a targeted basis - like the antibiotic guardian pledge - 
for example, "I pledge to look further into any patient prescribed a PPI where 
there is no clear indication for it, with a view to potentially stopping that 
medication." 
Incentivising 
deprescribing 
Reinforcement 
Self-reward Not sure this will work. Not what CPD points are for! The motivation should be 
for the good of the patient not the good of the doctor! 
 
Not convinced this will be effective or there are currently effective systems to 
measure this 
 
Not sure I agree with this approach 
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Table 18 (continued) 
Barrier or enabler 
Prioritised 
TDF domain 
Behaviour 
Change 
Technique 
Extended responses 
  Material 
incentive 
Material incentive? At best QOF points type system. At worst Daily Mail Headline 
"Doctors denying drugs for Prizes!" Wouldn't motivate me - may others! Cost 
also an issue 
 
Would need good evidence that proxy measures result in clinical impact. Would 
prefer to see specific targets for deprescribing and good system wide measures 
etc. opiate prescribing, antipsychotics in dementia 
 
Difficult. It would have to be clear that the reward was for initiating the 
conversation, not the actual deprescribing of a drug.  Also, although practitioners 
would welcome this I think patients would not necessarily appreciate knowing a 
practitioner is getting material reward out of their healthcare. 
Thinning As long as the measures are sensible and make sense otherwise will be a tick 
box exercise 
 
I wouldn’t be convinced that my trust would take this on if we were talking 
financial incentives 
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Table 18 (continued) 
Barrier or enabler 
Prioritised 
TDF domain 
Behaviour 
Change 
Technique 
Extended responses 
  Negative 
reinforcement 
This is the stick rather than the carrot? Rarely works 
 
Eventually the culture may change to such an extent that continuing to prescribe 
something that is inappropriate is clinically unacceptable and is an 'incident' but I 
think we are a way off that at the moment. More likely to work on an 
organisational level if Trusts are required to demonstrate that have training and 
systems in place to support this work. System wide data on specific clinical 
targets showing poor performance may also work, just not sure this works on the 
individual level. 
 
Who is going to do this 
 
Not a reasonable intervention, and would not be seen positively by practitioners. 
Potentially unsafe as practitioners essentially forced. 
Shaping Deprescribing Champions is a good concept but can be lost with all the other 
champions in a hospital. Again not keen on the reward idea 
 
Works well in other areas e.g. CQUIN projects to start with easy goals and 
gradually make them harder as organisations improve. 
 
Not sure how this would work 
 
I feel like this would be a more effective intervention than 'thinning' 
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Table 18 (continued) 
Barrier or enabler 
Prioritised 
TDF domain 
Behaviour 
Change 
Technique 
Extended responses 
  Counter 
conditioning 
If we can identify the prompts and measure the % acted upon this could work 
well. 
 
These more measured approaches to rewards I feel are likely to be more 
reasonable and effective than a blanket ‘material incentive/reward’ intervention. 
Material reward Rife for bad headlines and abuse sorry! 
 
If we want deprescribing to be seen as normal behaviour and to be adopted 
widely, this may disincentives uptake or embedding. Rewards for doing what 
some patients could be seen as the prescribers 'job' e.g. prescribing safety could 
be poorly received by the public. Could encourage inappropriate deprescribing 
Extinction Not holistic - won't work 
 
Akin to CQUIN projects as long as measures realistic and were achievable. 
Rewards have to be worth the effort required to implement or will not be take up 
 
Once the promised rewards have been permanently discontinued, there would 
be no drive to even attempt the remaining targets from a rewards point of view - 
in fact, it may push deprescribing interventions down afterwards. 
Classical 
conditioning 
Much more interesting - coloured digital prompts perhaps have some merit with 
a ‘champion’ designing, running and auditing it  May not be practical dependant 
on which digital prescription system is used. The person needs job planned time 
to do this 
 
A mixed approach like this is most likely to be effective 
 
Would be interested in this approach 
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6.6.2 Stage 2: Face-to-face NGT 
The following BCTs achieved partial consensus and thus proceeded to stage 2 for 
consensus discussions and re-voting: 
• Restructure the physical environment (Barrier: Pharmacists’ working 
patterns limits capacity to support deprescribing). 
• Action planning (Barrier: Deprescribing is not a hospital priority). 
• Classical conditioning (Enabler: Incentivising deprescribing). 
 
The following BCTs achieved consensus at stage 1 thus proceeded to stage 2 for 
discussion regarding characterisation for operationalising in the hospital setting (in 
addition to any of the three BCTs above achieving consensus at stage 2 regarding 
inclusion in the intervention): 
• Social comparison (Barrier: Misconception that patients and carers are 
resistant to deprescribing). 
• Salience of consequences (Barrier: Pharmacists’ negative beliefs about 
deprescribing consequences). 
• Pros and cons (Barrier: Pharmacists’ negative beliefs about deprescribing 
consequences). 
 
NGT cycles for ‘Restructure the physical environment’ and ‘Action planning’ resulted 
in consensus to include these BCTs in the deprescribing intervention. The expert 
panel failed to achieve the 80% consensus threshold when voting for the practicality 
criterion for the BCT ‘Classical conditioning’ to address the enabler of incentivising 
deprescribing. Following the discussion NGT round, the panel suggested that this 
enabler would be addressed instead by ‘measuring, reporting and sharing levels of 
deprescribing opportunities between team such as wards or hospitals’. This aligns 
with the BCT ‘social comparison’, defined as to ‘draw attention to others’ 
performance to allow comparison with the person’s own performance’. The panel 
agreed that this newly proposed BCT met the APEASE criteria to address the 
aforementioned enabler, and it was selected for inclusion in the deprescribing 
intervention. 
The characterised BCTs are provided in table 19. For the BCTs of ‘Social 
comparison’, ‘Salience of consequences’ and ‘Pros and cons’, the characterisation 
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statements are unchanged from the plain English descriptions synthesised by the 
research team in stage 1. 
Table 19 Six Behaviour Change Techniques selected and characterised for 
operationalisation in a hospital deprescribing intervention 
Behaviour Change Technique Characterisation 
Misconception that patients and carers are resistant to deprescribing (barrier) 
Social comparison 
Draw attention to practitioners through 
weekly departmental bulletins who are 
successfully deprescribing by navigating 
any challenges of patients and carer 
resistance to deprescribing 
Pharmacists’ negative beliefs about deprescribing consequences (barrier) 
Salience of consequences 
Emphasise the benefits of deprescribing 
and harmful consequences of failing to 
deprescribe in terms which will resonate 
with pharmacists e.g. a 30 minute online 
training session 
Pros and cons 
Advise pharmacists to list and compare the 
advantages and disadvantages of actively 
supporting deprescribing of inappropriate 
medication e.g. a 30 minute online training 
session 
Pharmacists’ working patterns limits capacity to support deprescribing (barrier) 
Restructure the physical 
environment 
Pharmacists to attend short multi-
disciplinary team meeting e.g. 30 minute 
geriatrician-led multidisciplinary team 
meeting to enable them to actively support 
deprescribing 
Deprescribing is not a hospital priority (barrier) 
Action planning 
A senior geriatrician and pharmacist to 
engage with senior managers such as the 
medical and nursing directors to develop 
an organisational-level action plan. The 
action plan is to comprise of setting 
deprescribing as a high organisational 
priority goal and specifying locally relevant 
steps to achieving the goal and specifying 
who is responsible within the organisation 
for contributing towards the goal. 
Incentivising deprescribing (enabler) 
Social comparison 
 
Measuring, reporting and sharing the 
proportion of patients screened for 
deprescribing opportunities between 
hospital wards, hospitals and regions. 
 
6.7 Discussion 
This study demonstrates the methodological approach by which the hDIF is 
operationalised to develop a theory and evidence-based hospital deprescribing 
intervention tailored to contextual factors, using the UK setting as an exemplar. 
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Engagement with the practitioners whose behaviour requires changing has led to 
selection and characterisation of six BCTs to support implementation of 
deprescribing in the UK hospital context.  
The action plan and training elements of the deprescribing intervention are designed 
to create an environment that promotes engagement with deprescribing. 
Restructuring pharmacist working patterns and the sharing of practice are designed 
to perpetuate deprescribing activity. The dual-nature of the resultant intervention 
departs from previous trials that report a focus purely on perpetuation of activity, for 
example by providing a guide for identifying deprescribing opportunities. The 
absence of components within these interventions to support initial engagement 
with deprescribing may provide some explanation for their lack of efficacy, even 
within a resource intensive trial environment which may in itself support 
perpetuation(84). 
Selection of ‘Action planning’ at the organisational level aims to establish 
deprescribing as a priority through specifying where, when and how the hospital’s 
deprescribing goals will be achieved. “Action plans specify where, when and how a 
goal will be implemented and help individuals plan the specific actions they will take 
to achieve their overarching goal”(257). Action plans have been frequently used to 
promote behaviour change in the healthcare setting. An intervention comprising 
action planning alone resulted in 53% of patients with coronary heart disease 
adopting healthier health related behaviours such as improvements in diet and 
increasing regular exercise(258). 
The two BCTs selected to address the barrier of pharmacists’ beliefs about negative 
deprescribing consequences recognise the findings from Chapter 5 that senior 
pharmacists have appropriate knowledge regarding the risks and benefits of 
prescribing and not deprescribing. The ‘Salience of consequences’ and ‘Pros and 
cons’ BCTs therefore request pharmacists to cognitively appraise deprescribing 
opportunities, focussing on the likelihood and evaluation of the consequences of 
deprescribing versus failing to deprescribe(259). These BCTs may be delivered 
through training, which could be online or face-to-face. It may be possible to 
combine these BCTs with a recently developed survey to measure practitioners’ 
deprescribing self-efficacy (240). The survey may serve as a ‘readiness test’ 
undertaken after training to ensure pharmacists are prepared for deprescribing 
activities. 
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The ‘Social comparison’ BCT was selected to address both the barrier of 
misconception that patients and carers are resistant to deprescribing and enabler of 
deprescribing incentivisation, with distinct characterisations for both. For the barrier, 
selection of alternative BCTs such as providing evidence to align practitioners’ 
views with the evidence that patients/family endorse deprescribing in hospital(260), 
via the BCT ‘Information about others’ approval’, may have been expected. 
However, practitioners rated ‘Social comparison’ more favourably in terms of 
effectiveness, suggesting that observing a peer successfully agreeing deprescribing 
with a patient/family member resonates more with practitioners than simply being 
told this is possible. 
The expert panel’s decision to address the enabler of reinforcing deprescribing with 
a BCT not presented in the implementation framework is of interest. Given that the 
BCTs for reinforcement in the implementation framework relate either to 
incentivisation or punishment, it is likely that neither were acceptable due to both 
being perceived as unethical. This is supported by the extended responses and low 
agreement with the ‘acceptability’ criterion regarding reward BCTs. Whilst 
incentivisation to change practitioners’ prescribing behaviour is common practice, 
for example promoting appropriate antimicrobial prescribing(241), rewards are 
usually provided to the organisation and not practitioner(241). The hDIF does not 
stipulate that rewards should be at the practitioner level, however, the plain English 
description of each linked BCT provided in the online survey did contextualise 
reward BCTs at the practitioner level to aid interpretation. This may have influenced 
the panel’s decision-making, and future applications of the hDIF should therefore 
avoid prescribing BCTs with this degree of specificity where possible. Alternatively, 
practitioners may have simply perceived ‘Social comparison’ which they proposed in 
preference to incentives and punishments as a superior BCT for reinforcing 
deprescribing behaviour. 
This study has applied a modification of a structured and widely used consensus 
method in order to support an expert panel of geriatricians and pharmacists to 
select BCTs for inclusion in a novel deprescribing intervention. The modified NGT 
drew on key elements of the Delphi technique in terms of the initial voting round, 
which informed a traditional NGT. This hybrid approach ensured that appraisal of a 
large number of BCTs by an expert panel was feasible, whilst also enabling the 
panel to focus on certain BCTs for further discussion and characterisation. 
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Initial appraisal of the 44 BCTs included in the hDIF by two members of the 
research team resulted in the exclusion of BCTs which were deemed inappropriate 
for a UK hospital deprescribing intervention. This was undertaken in order to 
increase the feasibility of the study by removing BCTs which experts clearly did not 
need to spend time appraising. However, there is a risk that this process resulted in 
the removal of BCTs that the expert panel may have deemed appropriate for the 
deprescribing intervention. Efforts were made to minimise this risk, including the 
initial appraisal being undertaken by two pharmacists with an understanding of the 
UK hospital context and subsequent validation of the decision-making by the wider 
research team, which included geriatricians and pharmacists representative of the 
expert panel members. 
Whilst the number of expert panel members was relatively small for a survey study, 
a high consensus threshold of 80% across all six APEASE criteria was set in order 
to minimise the uncertainty introduced by the small sample size. The aim of this 
study was to develop an intervention bespoke to the English setting and thus 
international transferability was not intended. However limiting the study to 
geriatricians and pharmacists representing hospitals from three East of England 
counties may limit transferability of the resultant intervention nationally, particularly 
to hospital contexts differing significantly to the included sample. Efforts were made 
to minimise this, such as representation of both district general and teaching 
hospitals which differ in terms of resources and patient acuity(222–224). During the 
NGT BCT characterisation discussions, the panel alluded to some of these 
differences at their own hospitals such as whether medicines were prescribed using 
electronic or paper-based systems. 
Engagement from the target audience of a behaviour change intervention in the 
development process is pivotal to intervention success(96,97). The development of 
the hDIF was informed by the barriers and enablers to deprescribing in hospital from 
the perspectives of geriatricians and pharmacists, as described in Chapter 5. The 
present study adds a further layer of engagement to the development of a novel 
deprescribing intervention by going back to the target audience for selection of 
BCTs from the hDIF. 
Five of the six BCTs selected by the expert panel were options provided by the hDIF 
for the prioritised TDF domains and related barriers to deprescribing. This 
triangulation between BCTs provided by the hDIF and what the expert panel 
perceive as appropriate for inclusion in a deprescribing intervention affords some 
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confidence that the hDIFs is a valid framework for application for this purpose. 
However, further exploration regarding selection of a non-mapped BCT to address 
the enabler of ‘Incentivising deprescribing’ in warranted. As discussed above, this 
may be a limitation of the stage 1 plain English descriptions synthesised for the 
online survey unduly influencing the expert panel’s interpretation of relevant BCTs. 
Whist the online survey was informally piloted with non-experts in behavioural 
science and no issues were identified, these were members of the research team 
who may not have been sufficiently naïve to the programme of work. Accordingly, 
future studies applying the hDIF using a similar methodological approach should 
consider formal piloting using appropriate methods such as the ‘think aloud’ applied 
in Chapter 4. 
Hospital deprescribing interventions should attend both to the barriers of initiating 
deprescribing activity and strategies to perpetuate. The hDIF has been successfully 
applied in a consensus study with the practitioners whose behaviour requires 
changing to select six intervention components to address the barriers and enabler 
to deprescribing in hospital. The selected intervention components have been 
characterised and are the active ingredients of a novel deprescribing intervention for 
the UK context.
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Chapter 7 Discussion
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7.1 Overall thesis discussion 
This is the first programme of work developed using behaviour change theory to 
develop a deprescribing intervention to address inappropriate polypharmacy in the 
hospital setting. Reactive and proactive deprescribing have been conceptualised 
and it was identified that the latter does not routinely occur in the hospital setting. 
Older patients and their carers expressed that deprescribing in the hospital setting 
was acceptable to them. Patients and carers were also clear that deprescribing 
must be initiated by their doctor thus it was established geriatricians are the target 
audience for behaviour change. Furthermore, the availability of pharmacists in the 
hospital setting provides a unique opportunity to identify inappropriate medicines 
and make deprescribing suggestions to geriatricians caring for older people. 
Accordingly, pharmacists were also established as the target audience for 
behaviour change. Unlike GPs, geriatricians and pharmacists identify that they have 
the required knowledge and skills to undertake their defined roles. Moreover, the 
hospital setting offers existing enablers to deprescribing such as provision of routine 
patient monitoring and access to the wider multidisciplinary team of healthcare 
practitioners. However, several barriers to deprescribing by geriatricians and 
pharmacists were identified which required addressing including it being a low 
organisational priority, a misconception that patients and carers are resistant to 
deprescribing and a negative belief about the consequences of deprescribing. 
Finally, the Behaviour Change Techniques (BCTs) to address the barriers and 
enablers to deprescribing in the hospital setting which are most likely to be 
acceptable, effective and practical to implement in this environment have been 
identified and are the active ingredients for a novel intervention. 
During the course of this PhD, there have been significant developments to the 
wider deprescribing landscape globally. ’Deprescribing networks’ have evolved 
through bringing together healthcare professionals, researchers and policy makers 
to collaboratively formulate strategies to address inappropriate polypharmacy. As of 
2019, five networks have been established: United States National Network on 
Deprescribing; Canadian Deprescribing Network; English Deprescribing Network; 
Northern European Researchers in Deprescribing; Australian Deprescribing 
Network. A key objective of the English Deprescribing Network is to “improve 
communication between patients and clinicians and shape the national strategy 
around appropriate prescribing and the avoidance of medicines-related harm.” The 
network hopes to achieve this through facilitating work which will “support the… 
behavioural change required to ensure people are taking the right medicines”(261). 
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Whilst deprescribing networks have led to the development of evidence-based 
deprescribing guidelines(65,66,71,72) which support decision making, particularly 
where knowledge and skills deficits are a barrier to deprescribing, they do not 
consider how to operationalise deprescribing. The research in this thesis provides 
the evidence-base and theory required to operationalise deprescribing in the 
hospital setting. 
Prior to commencing this PhD, the existing body of research had focussed on 
practitioners and patients in the primary care setting; a 2014 systematic review of 
prescribers’ barriers and enablers to deprescribing demonstrated this trend, with 20 
out of the 21 eligible studies being in primary care(116). This focus is 
understandable given that the vast majority of medicines are prescribed by primary 
care practitioners. For example, in England 98% of prescriptions are generated by 
general practitioners (GPs). There is therefore a clear need for primary care 
interventions targeting GPs’ deprescribing behaviour. Accordingly, in May 2018 the 
UK National Institute for Health Research funded the ‘Improving Medicines use in 
People with Polypharmacy in Primary Care’ project through its Health Services and 
Delivery Research programme(262). The project aims to develop and test an 
intervention to improve how polypharmacy is managed, including deprescribing, 
through the development of a novel intervention. 
There is acknowledgement that tackling inappropriate polypharmacy requires 
interventions in primary care, hospital and at the interface between the two 
settings(38). This is reinforced by Health Education England through its ‘Making 
Every Contact Count’ initiative, which encourages practitioners to use every 
opportunity arising from interactions with patients to make positive improvements on 
health and wellbeing(263). Over half of older people in hospital are prescribed at 
least one pre-admission medicine that is potentially inappropriate and thus requires 
review to determine suitability for deprescribing(34). An admission to hospital is an 
opportunity for a holistic review of a patient’s medication, which has led to calls for 
practitioners to undertake a generalist review of patients’ medications(38) to tackle 
inappropriate polypharmacy. However, the evaluation of deprescribing in Chapter 3 
identified that this rarely happens in the one hospital where activity was 
explored(190). Whilst there are deprescribing networks and guidelines rapidly being 
generated and tools available to inform the process, they do not seem to have 
translated into hospital deprescribing practice locally. There is no reason to suggest 
that this is likely to be different elsewhere. Contrary to the calls for addressing 
inappropriate polypharmacy in hospital, an Irish longitudinal study including 38,299 
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older patients found that for patients admitted to hospital, the likelihood of being 
prescribed a PIM at discharge was higher than before the admission (adjusted 
odds=1.72 (95% confidence interval 1.63 to 1.84) (37). It is unsurprising therefore 
that GPs are amongst those leading calls for the hospital setting to assume a role in 
deprescribing(264). The resounding acceptability of deprescribing in hospital 
indicated by the patients and carers surveyed in Chapter 4 further endorses a 
research focus on hospital deprescribing(260). Finally, the exploratory focus groups 
undertaken with hospital practitioners in Chapter 5 confirmed that several of the key 
components for safe and effective deprescribing such as medication history and 
routine monitoring were already available to them in hospital(60). 
Polypharmacy often spans multiple therapeutic areas therefore requires generalist 
strategies to address the problem at scale. Generalist practitioners such as 
pharmacists and geriatricians are described by GPs as best placed to provide a 
generalist review of polypharmacy and deprescribe accordingly(264). Conversely, 
specialists in hospitals with a restricted therapeutic focus may not feel able to 
provide this generalist review, particularly those who’s prescribing is driven by 
guidelines which rarely advise on deprescribing(50,52). 
Successful deprescribing within a restricted therapeutic focus has been 
demonstrated to be safe and feasible in the ECSTATIC cluster randomised non-
inferiority trial of deprescribing preventative cardiovascular medication in primary 
care(265). Whilst the development of the ECSTATIC intervention has not been 
comprehensively reported, it appears to have been designed cognisant of the 
known barriers to deprescribing in the primary care context. Briefly, the intervention 
comprises providing knowledge to GPs and nurses in a two hour workshop led by a 
GP with a special interest in cardiology. The difference in the primary outcome of 
predicted cardiovascular risk between the intervention and control groups fell within 
the non-inferiority margin, and the authors concluded that deprescribing 
preventative cardiovascular medication is safe. ECSTATIC has clearly made a 
valuable contribution to the literature by establishing the safety and feasibility of 
deprescribing with a restricted therapeutic focus in primary care. As intervention 
efficacy is specific to both the setting and the nature of the behaviour(249), the 
ECSTATIC intervention is unlikely to be directly transferable to the hospital 
polypharmacy context. 
Akin to prescribing, deprescribing is a patient-centred process(60) and the 
importance of understanding the views of patients and carers has been emphasised 
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in the literature(98) and is reflected in the patient and public involvement from 
inception to completion of the programme of research included in this thesis(260).  
In addition to the primary care focussed practitioner literature, there has been 
substantial research internationally exploring the views of patients towards 
deprescribing. For example, the rPATD has been used in studies across several 
countries and in various care settings including the United States of America(266), 
Australia(267) and Malaysia(207), all reporting similar results to those in Chapter 4. 
This high agreement with deprescribing has led researchers and practitioners to 
focus on targeting patients’ behaviour in order to increase deprescribing activity. 
The EMPOWER (Eliminating Medications through Patient Ownership of End 
Results) is a patient-educational intervention booklet providing knowledge about 
benzodiazepine deprescribing which aims to encourage patients to initiate 
deprescribing discussions with practitioners. The EMPOWER booklet was tested in 
2019 in a feasibility study of a randomised controlled trial (RCT) in the Australian 
hospital setting(245). Delivering the booklet to patients was feasible, however there 
did not appear to be a trend towards more deprescribing discussions being initiated 
by intervention participants and the rates of deprescribing at one-month post 
discharge were comparable. This was a feasibility study and therefore not designed 
to detect a difference, the authors concluded that definitive trials were indicated in 
order to determine whether EMPOWER is effective in the hospital setting. 
Whilst the delivery of a patient-centred deprescribing intervention may be desirable 
under certain circumstances(245), two key considerations mean that it deviates 
from the programme of work described in this thesis. Firstly, as described above, a 
focus on polypharmacy, rather than medicines within a specific therapeutic area 
may yield greater benefits(268). Secondly, the results presented in Chapter 4 
suggest that patients and carers in the hospital context want practitioners to initiate 
deprescribing discussions, rather than this being their responsibility. This finding 
was replicated in a recent administration of the rPATD in the Australian primary care 
context(267). The gap in the literature addressed by this thesis was therefore the 
development of a hospital intervention targeting the behaviour of geriatricians and 
pharmacists. 
The majority of existing deprescribing intervention studies report deprescribing of 
PIMs as defined by criteria such as STOPP(84). The Chapter 3 evaluation of 
existing deprescribing activity in hospital identified that deprescribing in response to 
an adverse clinical trigger such as suspected medication related kidney damage, 
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dominated deprescribing activity(190). In contrast, deprescribing medicines if future 
gains were unlikely to outweigh future harms was infrequent. This led to coining of 
the terms ‘reactive deprescribing’ and ‘proactive deprescribing’. This 
characterisation of the observed deprescribing activity in the hospital setting 
indicates that these are two discrete behaviours with different behavioural 
determinants and therefore likely different intervention components to effect 
behaviour change and therefore should not be reported as an amalgam. 
The Medical Research Council’s (MRC) guidance on developing and evaluating 
complex interventions emphasises the importance of ‘Identifying the evidence base’ 
and ‘Identifying/developing theory’(96). The Theoretical Domains Framework (TDF) 
underpinned focus groups with geriatricians and pharmacists in Chapter 5 fulfilled 
both the requirement of ‘Identifying the evidence base’ and ‘Identifying/developing 
theory’. The existing work by Cane et al. which maps each TDF domain to a 
taxonomy of 96 Behaviour Change techniques (BCTs)(220) enabled progression 
from characterising deprescribing behavioural determinants in Chapter 5 to 
selecting BCTs in Chapter 6. 
The richness of data generated from the qualitative approach adopted was essential 
to the application of the TDF for understanding behaviour change mechanisms. 
Mapping of qualitative data to the TDF often results in the full range of domains 
being ‘active’ in the data(159). This is unsurprising given that researchers 
undertaking qualitative studies using the TDF aim to explore all potential barriers 
and enablers within each domain, therefore topic guides and interview schedules 
are structured accordingly. Previous studies have then reported that most or all TDF 
domains should be targeted for behaviour change in a subsequent intervention, with 
all 96 BCTs being intervention candidates(159). Reporting most or all TDF domains 
as requiring targeting in an intervention indicates that the precise mechanism by 
which behaviour change may occur has not been established. Instead, TDF 
domains which may be of little relevance are likely to have been captured and 
proceed to be targeted using BCTs within an intervention. This inefficiency adds 
unnecessary complexity to what is already a complex intervention. For interventions 
intended for implementation in contexts with scope for provision of limited or no 
additional resources, inclusion of BCTs that are not necessary is counterproductive 
and limits the likely feasibility and potential efficacy of the intervention(269). There 
should therefore be a focus on targeting TDF domains that are essential for 
behaviour change. Accordingly, there was a need in this thesis to prioritise TDF 
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domains in terms of their relative importance to geriatricians’ and pharmacists’ 
deprescribing behaviour. 
New guidance for using the TDF emerged in 2017, which included references to 
more recent studies which have attempted to prioritise TDF domains(159). Unlike 
the novel approach adopted in Chapter 6, the majority of these studies resorted to 
counting utterances of qualitative data mapped to TDF domains, with domains 
containing more mapped data being prioritised. The limitation of this approach is 
that it does not accurately capture the extent to which participants express the 
relative importance of a barrier or enabler within the mapped text. It may be that 
participants spent little time discussing a fundamental barrier, for example because 
they felt it could not be addressed. In contrast, inductive thematic analysis enabled 
barriers and enablers expressed by the collective as having a strong impact on 
deprescribing behaviour in the absence of conflicting views to be identified and the 
TDF domains prioritised. 
Chapter 5 demonstrated that some of the barriers and enablers to deprescribing 
span both the primary care and hospital settings. The barrier of practitioner 
perception that patients are resistant to deprescribing cited by GPs(116) was 
echoed by geriatricians and pharmacists in Chapter 5. The conclusion from Chapter 
4 that patients and carers are amenable to deprescribing in hospital suggests that 
the aforementioned barrier is in fact a misconception by geriatricians and 
pharmacists in the UK hospital context. The extent to which this barrier is a 
misconception by GPs, rather than genuine patient resistance in the primary care 
context, is unclear given that the revised Patients’ Attitudes Towards Deprescribing 
(rPATD) questionnaire has not been used in the UK primary care setting. Research 
in the primary care setting to establish patient attitude towards practitioner initiated 
deprescribing discussions is therefore warranted. Such research will guide selection 
of intervention components according to whether or not perceived patient and carer 
resistance is a misconception by GPs or whether it is an accurate representation of 
patient and carer attitudes towards deprescribing in the primary care setting. Clear 
distinctions were also identified in Chapter 5 between the primary care and hospital 
settings in terms of the barriers and enablers to deprescribing. This reinforces the 
need to develop deprescribing interventions which are context specific and 
endorses the methodological approach adopted for the research in this thesis. 
Given the global appetite for all care settings to contribute to deprescribing(38,270), 
the findings from this thesis demonstrate a need to develop interventions that are 
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tailored to the barriers and enablers of specific contexts. The ‘Improving Medicines 
use in People with Polypharmacy in Primary Care’ programme of work is focussing 
on developing an intervention which achieves this for the primary care context, for 
example the intervention is likely to include training to address the barrier of lack of 
knowledge and skills regarding how and when to deprescribe(116,271). 
The limited success of previously reported hospital interventions may be attributable 
to their incorrect focus on addressing lack of knowledge and skills through providing 
PIM screening tools such as FORTA(69) and STOPP(31). This is unsurprising given 
that the literature available prior to this thesis designated a lack of knowledge and 
skills as a key barrier, notwithstanding that this is derived from a primary care 
perspective. However, this contradicts the hospital context work undertaken in 
Chapter 5, which identified that geriatricians and pharmacists perceive themselves 
to already have the required knowledge and skills to deprescribe. Failure to identify 
and address a gap in the evidence base has led to previous hospital deprescribing 
interventions not addressing the determinants of deprescribing identified in Chapter 
5. Moreover, previous intervention have included components which are redundant 
via targeting a barrier that does not apply to the hospital setting. As discussed 
earlier in this chapter, redundant components may impede the feasibility and 
potential efficacy of interventions by detracting from target audience engagement 
with components which are essential(269). Nonetheless, PIM screening tools are 
likely to be useful in trials of hospital deprescribing interventions for research 
purposes to evaluate the extent to which deprescribing opportunities are addressed, 
or where BCTs involving monitoring and/or feedback on behaviour are indicated. 
The hospital Deprescribing Implementation Framework (hDIF) introduced in Chapter 
6, provided a framework of 44 BCTs corresponding to five prioritised TDF domains 
for developing a hospital deprescribing intervention. Selecting BCTs from the hDIF 
should be informed by the context in which the intervention is intended to be 
delivered. For example, whilst the barrier of misconception of patient and carer 
resistance to deprescribing may apply to both primary care and hospital 
practitioners, the most appropriate BCT is likely to differ. There is variation in 
practice for selecting BCTs for inclusion in an intervention. Historically, BCTs have 
been selected by the research team developing the intervention(175,272,273). This 
may be due to researchers considering that context has been fully considered by 
engaging with the target audience during the process of exploring the barriers and 
enablers to the behaviour in a similar manner to Chapter 5. The limitation of this 
methodological approach is that the research team may have less contextual insight 
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than the target audience in terms of a BCT’s affordability, practicability, 
effectiveness, acceptability, safety and equity (APEASE)(97).  
The added value of working with the target audience to select BCTs was 
demonstrated in Chapter 6 for the enabler of ‘incentivising deprescribing’. The target 
audience emphatically rejected ‘reward’ related BCTs, describing these as 
incompatible with the behaviour of deprescribing. Since rewards have been 
successfully used in the hospital setting previously to change antimicrobial 
prescribing behaviour, it is possible that researcher-led selection of BCTs may have 
resulted in inclusion of similar BCTs in a hospital deprescribing intervention(241). 
The resultant intervention would likely have been highly unacceptable to the target 
audience. 
Whilst the barriers and enablers and TDF domains included in the hDIF were 
derived from empirical work in the English hospital context, there are several BCTs 
available for each prioritised TDF domain which may be selected from. The 
implications of this is that the hDIF may be appropriate for developing practitioner 
behaviour change interventions for hospitals beyond the English context, providing 
the barriers and enabler that require addressing align with those included in the 
hDIF. Contextual factors will then influence which BCTs are selected to include in 
the intervention to address the barriers and enabler. 
The evidence base, underpinning theory and intervention components (i.e. BCTs) 
relating to the development of complex interventions are often represented as logic 
models(96). These describe an intervention, its causal assumptions and the process 
and clinical outcomes. This provides a diagrammatic representation of the 
hypothesised mechanism by which an intervention is intended to produce its 
effects(274). Arrows are used to represent the causal mechanisms between key 
aspects of the logic model. Figure 14 provides a logic model for the behaviour 
change intervention developed in this thesis. The ‘problem’ and ‘context’ 
components of the logic model have been informed through identifying the evidence 
base via the empirical work undertaken in Chapters 3, 4 and 5. Chapter 2 identified 
the most appropriate theory to underpin the programme of research whilst Chapters 
5 and 6 populated the theoretical determinants and behaviour change techniques 
respectively. Figure 14 does not provide the intended outcomes for the intervention, 
as defining definitive trial outcomes was beyond the scope of the early 
developmental work undertaken in this thesis. Section 7.3 Implications for research 
and future research plans provides recommendations accordingly. 
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Logic models are useful because they inform the evaluation of complex 
interventions by informing the structure and prioritisation of data collection. The 
causal mechanisms described in a logic model should be tested prior to a definitive 
trial to determine whether the intervention works as intended, with potential 
refinements made to the logic model as necessary. Recommendations for 
refinement and testing of the intervention developed in this thesis are discussed in 
section 7.3 Implications for research and future research plans. 
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Figure 14 Logic model for the development of a practitioner behaviour change intervention for deprescribing in the hospital setting
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7.2 Implications for practice 
A hospital deprescribing intervention should therefore include components to 
address the barriers of a misconception that patients and carers are resistant to 
deprescribing, pharmacists’ negative beliefs about deprescribing consequences, 
pharmacists’ working patterns limits capacity to support deprescribing and 
deprescribing is not being a hospital priority. A component(s) should also be 
included which addresses the enabler of incentivising deprescribing. The most 
appropriate configuration for the intervention is inclusion of the following BCTs: 
• Social comparison: Draw attention to practitioners who are successfully 
navigating the challenges of patient/carer attachment to medication 
• Salience of consequences: Emphasise the benefits of deprescribing and 
harmful consequences of failing to deprescribe 
• Pros and cons: List and compare the advantages and disadvantages of 
deprescribing 
• Social comparison: Measuring and sharing of deprescribing practice 
between teams 
• Restructure the physical environment: Pharmacists to attend short multi-
disciplinary team meetings 
• Action planning: Setting deprescribing as a high priority goal at the 
organisational level and specifying who within the organisation is responsible 
for contributing towards this goal 
 
Chapter 6 described selection and characterisation of these BCTs according to the 
English hospital setting. Granular detail regarding the characterisation is 
intentionally not provided for the BCTs in terms of how they will be operationalised 
in practice. This scope for adaptation is necessary when developing behaviour 
change interventions in terms of implementation at scale, as it provides scope for 
local adaptation at the individual hospital or ward level. Adaptation is an essential 
process to align the intervention with the needs of the target audience, organisation 
resources and to gain trust and ownership by the target audience(275). Adaptation 
of the intervention to ‘fit’ the local context facilitates successful implementation and 
sustainability(275). 
Positive results from a definitive trial testing the practitioner behaviour change 
intervention will have significant implications for practice. Widespread 
implementation across English hospitals will hopefully lead to an increase in 
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deprescribing of inappropriate medication and associated positive outcomes for 
patients, practitioners and the NHS(190). There are, however, further indirect 
implications for practice arising from this programme of work. 
The focus groups in Chapter 5 identified the barrier of insufficient deprescribing 
education for trainee doctors and pharmacists. Whilst the geriatrician and 
pharmacist participants were able to circumvent this barrier through post 
qualification education, and peer and experiential learning, this lack of education 
and training precluded junior practitioners from actively participating in 
deprescribing. This same barrier has been expressed by GPs(116), and may also 
extend to therapeutic area specialists in hospital who may not have the enabling 
knowledge and experience described by the focus group participants. Ultimately, 
medicines optimisation(7) and good prescribing practice(20) is the responsibility of 
all practitioners involved in medicines management for patients. With deprescribing 
being a core component of both, practitioners beyond those specialising in geriatrics 
and pharmacy should contribute to deprescribing. Accordingly, deprescribing should 
be included in the education and training of healthcare practitioners in order to equip 
the healthcare workforce to routinely support deprescribing. 
The calls from GPs for hospitals to assume a greater role in deprescribing are 
contingent on effective communication of deprescribing decisions by hospitals to 
primary care(264). This includes conveying why a medication has been 
discontinued and clear instructions regarding the monitoring GPs are expected to 
undertake. Whilst not prioritised as a key barrier in Chapter 5 as it does not 
independently hinder hospital deprescribing, poor communication between hospitals 
and primary care was acknowledged as requiring improvement to ensure that 
deprescribing is safely monitored long-term post-discharge. A key requirement to 
comprehensive communication of medication changes at discharge is effective 
recording of the changes during the admission. The data form the evaluation of 
deprescribing activity in hospital from Chapter 3 suggests that this requirement is 
not met for a substantial proportion of medication discontinuations in hospital(190). 
Hospitals need to develop strategies to effectively document medication changes, 
preferably in real time. Systems for automatic transfer of this information into 
discharge letters may help address the concerns regarding poor communication of 
deprescribing between hospital and primary care. 
The government-commissioned independent review of ‘Operational productivity and 
performance in English NHS acute hospitals’ by Lord Carter of Coles published in 
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2016 made several key recommendations relating to the role of pharmacists(230). 
Pharmacists’ time being spent undertaking clinical rather than operational services 
has a positive impact on medicine optimisation(230). Lord Carter reported 
significant variation in the average proportion of pharmacists’ time undertaking 
clinical services (2.5-71%), and recommended that “80% of pharmacist resource is 
utilised for direct medicines optimisation activities”(230), of which deprescribing is a 
core component(7). How hospitals are performing against this benchmark has yet to 
be evaluated. 
Pharmacists recruited into the Chapter 5 focus group study identified as having a 
principally clinical role at recruitment and the discussions regarding their activities 
supported this. However, both geriatricians and pharmacists identified that 
pharmacists’ lack of integration into the multi-disciplinary team was a barrier to 
deprescribing. Pharmacists explained that their activities focussed on medication 
histories and processing discharge prescriptions across several wards, limiting their 
capacity to integrate into the multi-disciplinary team. In turn, this limited their 
capacity to support deprescribing. Whilst pharmacists appear to be spending a 
substantial proportion of their time working on hospital wards, the activities they are 
performing are not necessarily contributing to medicines optimisation as Lord Carter 
suggests. Pharmacists’ lack of integration into the multi-disciplinary team is a long 
established challenge and it is unlikely that the profession will be able to contribute 
to medicines optimisation to its full potential without addressing this(235,236). The 
intervention developed in this programme of work includes a component to 
restructure the physical environment to facilitate pharmacists attending multi-
disciplinary meetings to support deprescribing. This change in working patterns is 
on a relatively small scale (attending short meetings e.g. attending a geriatrician-led 
multidisciplinary team meeting for 30 minutes), however it was deemed appropriate 
to support deprescribing by the expert panel in Chapter 6. The precedent set by 
Lord Carter’s review(230) and the results from this thesis indicate a clear need for 
further work to embed pharmacists into multi-disciplinary teams. Whilst research is 
required to identify and address the barriers and enablers to pharmacist multi-
disciplinary team working, this is firstly and foremost an implication for the 
profession itself and NHS organisations, both of which should provide leadership in 
order to address the issue. 
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7.3 Implications for research and future research plans 
The implications for research closely associated with each empirical project are 
discussed within the relevant chapters of this thesis (Chapters 3-6). Implications 
associated with the overall programme of work are discussed below. 
Coining of the terms ‘reactive deprescribing’ and ‘proactive deprescribing’ has 
implications for future studies which aim to characterise deprescribing practice, 
including those applying PIM screening tools such as FORTA(69) and STOPP(31). 
Researchers should apply the published definitions(190) in studies characterising 
existing deprescribing practice and those testing new interventions to determine 
which deprescribing behaviour is being changed. 
The evaluation of hospital deprescribing activity undertaken in Chapter 3 aimed to 
identify the scope for developing a novel intervention. An evaluation of 
deprescribing activity in the primary care setting is also warranted to fulfil the same 
aim. Characterisation of this activity into reactive and proactive deprescribing should 
also be included in the evaluation to determine the nature of the change in 
deprescribing behaviour to be targeted by primary care interventions. 
The programme of work described in this thesis to develop a practitioner behaviour 
change intervention for deprescribing in the hospital setting has completed the 
‘Identifying the evidence base’ and ‘Identifying/developing theory’ components of 
the MRC complex intervention ‘Development’ phase(96). The final goal for a 
behaviour change intervention is evaluation of efficacy within a definitive trial, which 
then informs whether wide scale implementation into practice is appropriate. 
However, according to MRC guidance, prior to evaluation there remains a need to 
complete the ‘Development’ phase and undertake the ‘Feasibility/piloting’ 
phase(96). 
 
Future research plan 1: Development of a Core Outcome Set for hospital 
deprescribing trials 
As discussed earlier in this chapter, intervention outcomes are an important 
component of intervention logic models which have not been included in figure 14. 
As a behaviour change intervention, an essential process outcome measure is the 
extent to which the target behaviour (deprescribing) has changed(249), thus a priori 
the number of pre-admission medicines discontinued will likely be a primary 
outcome. However, suitable patient, practitioner and commissioner orientated 
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outcome measures are also important. There are currently no universally accepted 
outcomes for hospital deprescribing trials (Core Outcome Set (COS)). 
This developmental work may be facilitated by building on the foundations of a 
primary care COS for appropriate polypharmacy trials(276) and a medication review 
trials COS(277). Both existing COSs are pertinent to deprescribing in hospital but 
neither can be adopted for testing the intervention developed in this thesis in a trial 
without refinement. The former COS(276) omits relevant hospital specific outcomes 
such as readmissions, despite patients prescribed inappropriate medications being 
significantly more likely to be readmitted relative to those with no inappropriate 
medications(278). The broad focus of the latter COS(277) to include all aspects of 
medication review such as prescribing, deprescribing, dose and formulation 
changes was not intended to prioritise deprescribing related outcomes. For 
example, it considers prescribing related outcomes such as improved pain control 
but not potentially relevant deprescribing outcomes such as frailty. A longitudinal 
non-randomised, researcher delivered deprescribing intervention reported “less 
deterioration in functional, mental and cognitive status, sleep quality, appetite and 
sphincter control”(279). These effects were observed within 3 months after de-
prescribing and are therefore potentially appropriate co-primary outcome measures 
for a hospital deprescribing trial. Prioritisation of outcomes from a future hospital 
deprescribing COS may then be added to the logic model (figure 14). 
 
Future research plan 2: Modelling intervention processes and outcomes 
The design and testing of complex interventions is time and resource intensive, thus 
there has been a call for efficient trial design(96). ‘Modelling processes and 
outcomes’ is the final step of the MRC’s ‘Development’ phase(96), and evaluates 
how core intervention components, such as BCTs, perform individually and when 
combined to determine which are active or inactive within the intervention and at 
what level (‘dose’) best outcomes are achieved(143,280). The best performing 
components and their optimal doses can then be combined to generate the optimal 
intervention deliverable within predetermined constraints such as time allowed. 
Modelling also enables testing of the causal assumptions described in the logic 
model (figure 14). This is achieved by selecting an outcome which measures the 
proposed mechanism by which a BCT being tested is hypothesised to act, rather 
than a global outcome measure such as change in deprescribing practice which 
would be appropriate for a definitive trial. The Multiphase Optimization Strategy 
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(MOST) is one such approach to modelling which involves undertaking a series of 
fractional factorial experiments which has been successfully applied to the 
development of complex behaviour change interventions including smoking 
cessation(143) and weight loss(281). Modelling the practitioner behaviour change 
intervention for deprescribing in hospital developed in this thesis using a 
methodological approach such as MOST should therefore follow in order to refine 
the intervention. 
 
Future research plan 4: Feasibility trial of the intervention 
After modelling and incorporating any refinements necessary, the intervention may 
proceed to ‘Piloting/feasibility testing’ in order to test the intervention and trial 
procedures in terms of acceptability, recruitment and retention of participants and 
selection of an appropriate primary outcome and inform the subsequent sample size 
calculation(96). The feasibility testing is also an opportunity to evaluate the reliability 
and validity of intervention implementation, termed intervention fidelity. This may 
include evaluating whether the intervention was delivered to the target audience as 
intended, whether it was received by the target audience as intended and whether 
the target audience enacted elements of the intervention (i.e. BCTs) as 
intended(282). Assessing intervention fidelity is an essential component of a 
feasibility study because it allows for adaptations to address poor intervention 
implementation prior to conducting a time and resource intensive definitive trial. 
 
Future research plan 5: Definitive trial of the intervention 
Post-successful feasibility testing, a definitive trial may proceed in order to 
determine whether the intervention changes practitioner behaviour and results in an 
increase in the number of patients receiving deprescribing on Older People’s 
Medicine wards in hospital(190). Moreover, as discussed above, the intervention will 
also need to demonstrate that it leads to improvements in other outcomes such as 
those which are patient orientated. 
Testing of any intervention requires a trial design which ensures a robust 
assessment of the intervention(96). Randomisation within the trial design is 
recommended because it is the most robust method of preventing selection bias. 
This arises when participants who receive the intervention (intervention group) differ 
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significantly from participants who do not receive the intervention (control 
group)(96). 
A randomised-controlled trial (RCT) is the preferred method to test healthcare 
interventions such as the efficacy of a medication(96). An RCT involves participants 
being individually randomised to either the intervention or control group. A 
conventional RCT is not an appropriate trial design to test a behaviour change 
intervention due to the high probability of contamination between the care received 
by intervention and control group patients(96). This is because once practitioners 
receive the intervention, they are not suitable to deliver ‘usual care’ to control group 
patients, because their deprescribing behaviour is likely to have changed as a 
result. Accordingly, there is a need to select a trial design which avoids 
contamination between groups. 
A cluster randomised trial is a potential solution to contamination of interventions to 
change behaviour and are widely used in health services research(96). In these 
trials, groups of patients (clusters), rather than individual patients, are randomised to 
receive either the intervention or control. For the intervention developed in this 
thesis, the cluster could be the hospital itself. This would significantly reduce the 
likelihood of contamination given that the practitioners who receive the intervention 
will be in contact only with patients in the intervention group, and vice versa(96). 
An alternative to the cluster randomised trial is a stepped wedge design, which 
involves “random and sequential crossover of clusters from control to intervention 
until all clusters are exposed”(283). Accordingly, in a stepped wedge design, all 
patients eventually receive care delivered as a result of phased implementation of 
the deprescribing behaviour change intervention(96). One advantage of a stepped 
wedge design over a cluster randomised trial is there are a greater number of 
clusters exposed to the intervention in the former (i.e. all clusters are exposed 
eventually)(283). This results in a smaller sample size being required to test the 
intervention which means a trial may be more feasible. Moreover, stepped wedge 
trials are advantageous where not offering the intervention to a group of participants 
may be deemed unethical(283). However, a disadvantage of the stepped wedge 
design relates to the phased implementation. Because more clusters are exposed to 
the intervention towards the end of the trial, the effect of the intervention may be 
confounded by any temporal effects(283). 
Given the unpredictable nature of interventions to change behaviour(97,148), a 
cluster randomised trial which is not vulnerable to temporal confounding is the most 
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appropriate trial design to test the intervention developed in this thesis. The sample 
size required to test the intervention in the definitive trial will depend on the primary 
outcome selected. 
 
Future research plan 6: Widespread intervention implementation 
Finally, if the intervention is deemed effective, the process of widespread 
implementation can commence. Whilst this will be heavily informed by the learning 
from the aforementioned phases, an implementation theory, such as Normalisation 
Process Theory (NPT)(284), which was discussed in Chapter 2, may support this 
process. 
 
Engagement with a wide group of stakeholders in future research 
The future research recommendations outlined above should also involve 
engagement with stakeholders beyond those included in the programme of work 
described in this thesis. For example, other members of the OPM multi-disciplinary 
team such as nurses, physiotherapists and occupational therapists who are likely to 
be working with geriatricians and pharmacists whilst they are deprescribing. This will 
provide an opportunity to evaluate the acceptability of the intervention to these 
stakeholders and address any barriers through refinement as necessary. Similarly, 
GPs and primary care pharmacists should be invited to comment on the 
intervention, particularly as communication with primary care to facilitate ongoing 
monitoring of deprescribing was identified in Chapter 5 as important by geriatricians 
and pharmacists. Engaging with these stakeholders will also provide an opportunity 
to address some the limitations discussed earlier in this chapter as a result of 
focussing on geriatricians and pharmacists only in this programme of work. 
 
7.4 Strengths and limitations 
The strengths and limitations associated with each empirical project are discussed 
within the relevant chapters of this thesis (Chapters 3-6). The strengths and 
limitations associated with the overall programme of work are discussed below. 
The collaborative nature of the programme of work underpinning the intervention 
has enhanced the transparency of findings and maximised the feasibility of both the 
studies undertaken and likely implementation of the intervention. Engaging with key 
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stakeholders is a core requirement in the development of strategies to change 
behaviour because it enables tailoring of intervention components to address the 
key barrier. Securing external funding from Pharmacy Research UK made the 
studies in Chapters 4 and 5 eligible for adoption on to the national portfolio of the 
National Institute for Health Research. The portfolio adoption provided access to 
support from the Ageing Clinical Research Network which enabled recruitment of 
patient, carer and practitioner participants across multiple hospital sites. The 
Pharmacy Research UK funding also facilitated meaningful patient and carer 
involvement throughout the programme of work through funding NN (patient 
prescribed polypharmacy) and JG (carer of a patient prescribed polypharmacy) to 
join the research management group described in Chapter 3. NN and JG had 
significant impact on key decision taken throughout the studies described in this 
thesis. For example, NN and JG provided leadership in the interpretations of the 
views of patients’ and carers’ towards deprescribing captured in Chapter 4(260) 
which was highly influential in aligning the programme of work with the development 
of a practitioner-focussed intervention. NN and JG continued to ensure that the 
voices of patients and carers shaped the resultant deprescribing intervention 
through guiding our interpretation of the subsequent intervention developmental 
work with geriatricians and pharmacists. 
Furthermore, application of behavioural science theory to understand the barriers 
and enablers to deprescribing in hospital from the perspectives of geriatricians and 
pharmacists enabled an understanding of the likely mechanism by which behaviour 
change may occur in terms of increasing deprescribing activity(96). This was a key 
distinguishing characteristic of this programme of work versus the atheoretical 
approach taken to develop previously reported hospital deprescribing interventions, 
achieving little or no effect on deprescribing activity(84). Additionally, undertaking 
the empirical work described in Chapters 5 and 6 enabled exploration of the barriers 
and enablers to deprescribing which provided an understanding of what was 
missing from the existing interventions in terms of content which may have been 
responsible for the limited efficacies achieved. This in turn enabled identification and 
selection of BCTs by the target audience of geriatricians and pharmacists. 
Successful selection of BCTs by the target audience via the modified Nominal 
Group Technique study in Chapter 6 validates the exploratory work in the focus 
group study in Chapter 5, importantly the outcome of TDF domain prioritisation and 
the associated novel approach adopted. 
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When developing interventions to change behaviour, there is a need for high 
specificity in terms of what the behaviour is and who is the target(249). Lack of 
specificity in terms of the practitioner group an intervention targets may result in an 
insurmountable number of key barriers and enablers pertinent to each practitioner 
group of interest being identified as requiring addressing. This adds further 
complexity to a system which by its very nature of targeting human behaviour is 
already complex. It is therefore impractical to develop a hospital deprescribing 
intervention targeting all practitioners. Rather than developing an intervention to 
target the behaviours of all practitioner groups within the multidisciplinary team, 
resources should focus on changing the behaviour(s) of a small number of 
practitioner groups who are most likely to deprescribe with the support of an 
intervention. The programme of work described in this thesis specified geriatricians 
and pharmacists as the target audience of a behaviour change intervention. The 
research then focussed on developing an intervention tailored to the determinants of 
these professional groups’ deprescribing behaviour(249). 
The mixed method approach to the programme of work in this thesis provided a 
broad lens for generating evidence and developing the intervention, which is also a 
strength. This allowed triangulation of key findings between empirical research 
projects and their associated differences in terms of methods, context and 
participants. This provides assurances in terms of validity, strength and the 
interpretative potential of the overall programme of work(285). For example, the 
finding from the retrospective quantitative analysis described in Chapter 3 that 
proactive deprescribing practice in hospital was limited was validated by geriatrician 
and pharmacist focus group participants in Chapter 5. 
The peer review process afforded by the Pharmacy Research UK and publication of 
Chapter 3(190), 4(260) and 5(251) enabled refinement of the research methods, 
analysis and interpretation of key findings and is a core strength in the work 
included in this thesis. 
There are two key limitations associated with the programme as a whole. 
The first is the focus on exploring barriers and enablers to deprescribing from the 
perspectives of geriatricians and pharmacists at the expense of other professional 
groups working on OPM wards as discussed earlier in this chapter. Related to this is 
that the acceptability of deprescribing and the intervention developed here has not 
been evaluated from the perspectives of other professional groups. The significance 
of this is that even if an intervention is not intended to target a group of professions, 
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its implementation should nonetheless be acceptable to all actors within a 
community of practice(286). This is of particular significance because both 
geriatricians and pharmacists cited access to other professional groups in hospital 
for advice as a deprescribing enabler. Moreover, any resistance the intervention 
content or a change in geriatricians’ and pharmacists’ behaviour could introduce a 
new barrier within the social influence TDF domain(157). 
A related limitation is the absence of engagement with primary care practitioners, 
particularly General Practitioners (GPs). Any hospital initiated deprescribing will 
inevitably require colleagues in primary care to assume ongoing monitoring. This 
was described by geriatricians and pharmacists in Chapter 5 as an enabler. GPs 
have expressed that geriatricians and pharmacists are well suited to initiate 
deprescribing in hospital(116) and that there is an expectation that patients’ 
medicines are reviewed and appropriate deprescribing is initiated during the 
admission where necessary(264). Accordingly, there is evidence that the concept of 
deprescribing in hospital is acceptable to GPs. However, as discussed above, the 
extent to which the intervention content and the manner by which it promotes 
deprescribing is acceptable to GPs remains unknown. 
The second limitation associated with the programme of work as a whole is the 
likely limited generalisability of the findings and thus potentially the intervention. The 
empirical studies described in Chapters 3 to 6 were undertaken in hospitals across 
the East of England only (n=1 to 5 hospitals across the studies). Whilst district 
general and larger teaching hospitals were included to capture any variation arising 
from difference resources and patient populations(222–224), there may be 
differences between hospitals in English regions which were not captured and thus 
reflected in the intervention. These factors are also likely to impact on the 
international generalisability of the findings and intervention, particularly in countries 
where geriatricians and pharmacists are unlikely to be the professional groups 
assuming responsibility for deprescribing. For example, a reviewer for the 
manuscript corresponding to Chapter 5(251) commented that a shortage of 
geriatricians in Canada may limit widespread adoption of the intervention. 
Similarly, there is much debate regarding the generalisability of qualitative research, 
and it is often cited as a limitation. This is of particular relevance to this programme 
of work given that the findings from the focus group study (Chapter 5) form the 
foundation of the intervention. Smith suggests that judging generalisability from a 
statistical perspective is inappropriate for judging the value of qualitative 
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research(248). Moreover, Smith argues that qualitative research can be 
generalisable but from a different perspective to quantitative research. For example, 
in Chapter 5 we discuss the transferability of barriers and enablers between district 
general and teaching hospitals, which is generalisability from case-to-case within a 
study. Smith also discusses the concept of theoretical generalisation, which is 
where qualitative findings are used to establish a concept of theory(248). By 
underpinning the qualitative data analysis (Chapter 5) with the TDF and thus 
establishing the theoretical determinants of geriatricians’ and pharmacists’ 
deprescribing behaviour, we have achieved theoretical generalisation as described 
by Smith(248). Accordingly, whilst there are some limitations to the qualitative 
methodological approach underpinning the intervention development process, there 
are also key strengths to acknowledge. Moreover, given the absence of exploration 
of the barriers and enablers to deprescribing in hospital captured in the existing 
literature(116) to develop a survey, an alternative quantitative approach was not 
possible. 
 
7.5 Conclusion 
• Studies evaluating deprescribing practice should characterise any activity 
identified according to whether it was reactive or proactive in nature. 
• The hospital deprescribing intervention developed in this thesis requires 
optimisation through modelling the selected Behaviour Change Techniques. 
This will enable determination of whether all of the selected Behaviour Change 
Techniques are active and at what ‘dose’ the optimal outcome is achieved. 
• A Core Outcome Set for hospital deprescribing trials requires development to 
enable selection of appropriate outcomes when testing deprescribing 
interventions. 
• The optimised intervention requires testing in a feasibility study and then 
definitive trial to ultimately determine whether it is effective and cost-effective in 
changing practitioner deprescribing behaviour. 
• Large-scale implementation of the intervention may follow if the intervention is 
found to be effective in a definitive trial. This will require adaptation of the 
intervention to support implementation and sustainability at the local context 
level.
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Appendix 3 Data extrapolation calculations for Chapter 3 
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Sampled Extrapolation
e-Prescribing reason for medication discontinuation All data Sampled % sampled Proactive % proactive Reactive % reactive Neither % neither Unclear % unclear Not stopped % not stopped Total proactive % total proactive Total reactive % total reactive Total neither % total neither Total unclear % total unclear Total not stopped % total not stopped
Acute kidney injury 2 2 100 0 0 2 100 0 0 0 0 0 0 0 0 2 100 0 0 0 0 0 0
Biochemistry derranged 14 2 14.28571429 0 0 2 100 0 0 0 0 0 0 0 0 14 100 0 0 0 0 0 0
Blood dyscrasia 3 3 100 0 0 2 66.66666667 1 33.33333333 0 0 0 0 0 0 2 66.66666667 1 33.33333333 0 0 0 0
Drowsy 2 2 100 0 0 0 0 1 50 0 0 1 50 0 0 0 0 1 50 0 0 1 50
Formulation no longer appropriate 64 11 17.1875 0 0 1 9.090909091 0 0 0 0 10 90.90909091 0 0 5.818181818 9.090909091 0 0 0 0 58.18181818 90.90909091
Haemodynamically unstable 6 1 16.66666667 0 0 0 0 1 100 0 0 0 0 0 0 0 0 6 100 0 0 0 0
Interaction with other treatment 20 3 15 0 0 1 33.33333333 0 0 0 0 2 66.66666667 0 0 6.666666667 33.33333333 0 0 0 0 13.33333333 66.66666667
No longer clinically necessary 328 79 24.08536585 7 8.860759494 12 15.18987342 17 21.51898734 7 8.860759494 36 45.56962025 29.06329114 8.860759494 49.82278481 15.18987342 70.58227848 21.51898734 29.06329114 8.860759494 149.4683544 45.56962025
No reason documented 138 79 57.24637681 0 0 14 17.72151899 24 30.37974684 5 6.329113924 36 45.56962025 0 0 24.4556962 17.72151899 41.92405063 30.37974684 8.734177215 6.329113924 62.88607595 45.56962025
Patient refusing to take 7 1 14.28571429 0 0 0 0 0 0 1 100 0 0 0 0 0 0 0 0 7 100 0 0
Renal impairment 7 1 14.28571429 0 0 1 100 0 0 0 0 0 0 0 0 7 100 0 0 0 0 0 0
Route no longer appropriate 87 15 17.24137931 0 0 1 6.666666667 6 40 0 0 8 53.33333333 0 0 5.8 6.666666667 34.8 40 0 0 46.4 53.33333333
Suspected toxicity/high levels 4 1 25 0 0 1 100 0 0 0 0 0 0 0 0 4 100 0 0 0 0 0 0
Total 682 200 29.3255132 7 37 50 13 93
Sampled No %
Reactive 37 84.09090909
Proactve 7 15.90909091
Total 44 100
Extrapolation No % of all discontinued
Reactive 121.5633295 17.82453512
Proactive 29.06329114 4.261479639
Neither 155.3063291 22.77218902
Not stopped 331.2695819 48.57325248
Unclear 44.79746835 6.568543747
Total 682 100
Overall totals N % of confirmed deprescribing
Reactive 121.5633295 80.70507656
Proactive 29.06329114 19.29492344
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Sampled Extrapolation
e-Prescribing reason for medication discontinuation All data Sampled % sampled Proactive % proactive Reactive % reactive Neither % neither Unclear % unclear Not stopped % not stopped Total proactive % total proactive Total reactive % total reactive Total neither % total neither Total unclear % total unclear Total not stopped % total not stopped
Acute kidney injury 2 2 =SUM(C3/B3)*100 0 =SUM(E3/C3)*100 2 =SUM(G3/C3)*100 0 =SUM(I3/C3)*100 0 =SUM(K3/C3)*100 0 =SUM(M3/C3)*100 =SUM(B3*(F3/100)) =SUM((O3/B3)*100) =SUM(B3*(H3/100)) =SUM((Q3/B3)*100) =SUM(B3*(J3/100)) =SUM((S3/B3)*100) =SUM(B3*(L3/100)) =SUM((U3/B3)*100) =SUM(B3*(N3/100)) =SUM(W3/B3)*100
Biochemistry derranged 14 2 =SUM(C4/B4)*100 0 =SUM(E4/C4)*100 2 =SUM(G4/C4)*100 0 =SUM(I4/C4)*100 0 =SUM(K4/C4)*100 0 =SUM(M4/C4)*100 =SUM(B4*(F4/100)) =SUM((O4/B4)*100) =SUM(B4*(H4/100)) =SUM((Q4/B4)*100) =SUM(B4*(J4/100)) =SUM((S4/B4)*100) =SUM(B4*(L4/100)) =SUM((U4/B4)*100) =SUM(B4*(N4/100)) =SUM(W4/B4)*100
Blood dyscrasia 3 3 =SUM(C5/B5)*100 0 =SUM(E5/C5)*100 2 =SUM(G5/C5)*100 1 =SUM(I5/C5)*100 0 =SUM(K5/C5)*100 0 =SUM(M5/C5)*100 =SUM(B5*(F5/100)) =SUM((O5/B5)*100) =SUM(B5*(H5/100)) =SUM((Q5/B5)*100) =SUM(B5*(J5/100)) =SUM((S5/B5)*100) =SUM(B5*(L5/100)) =SUM((U5/B5)*100) =SUM(B5*(N5/100)) =SUM(W5/B5)*100
Drowsy 2 2 =SUM(C6/B6)*100 0 =SUM(E6/C6)*100 0 =SUM(G6/C6)*100 1 =SUM(I6/C6)*100 0 =SUM(K6/C6)*100 1 =SUM(M6/C6)*100 =SUM(B6*(F6/100)) =SUM((O6/B6)*100) =SUM(B6*(H6/100)) =SUM((Q6/B6)*100) =SUM(B6*(J6/100)) =SUM((S6/B6)*100) =SUM(B6*(L6/100)) =SUM((U6/B6)*100) =SUM(B6*(N6/100)) =SUM(W6/B6)*100
Formulation no longer appropriate 64 11 =SUM(C7/B7)*100 0 =SUM(E7/C7)*100 1 =SUM(G7/C7)*100 0 =SUM(I7/C7)*100 0 =SUM(K7/C7)*100 10 =SUM(M7/C7)*100 =SUM(B7*(F7/100)) =SUM((O7/B7)*100) =SUM(B7*(H7/100)) =SUM((Q7/B7)*100) =SUM(B7*(J7/100)) =SUM((S7/B7)*100) =SUM(B7*(L7/100)) =SUM((U7/B7)*100) =SUM(B7*(N7/100)) =SUM(W7/B7)*100
Haemodynamically unstable 6 1 =SUM(C8/B8)*100 0 =SUM(E8/C8)*100 0 =SUM(G8/C8)*100 1 =SUM(I8/C8)*100 0 =SUM(K8/C8)*100 0 =SUM(M8/C8)*100 =SUM(B8*(F8/100)) =SUM((O8/B8)*100) =SUM(B8*(H8/100)) =SUM((Q8/B8)*100) =SUM(B8*(J8/100)) =SUM((S8/B8)*100) =SUM(B8*(L8/100)) =SUM((U8/B8)*100) =SUM(B8*(N8/100)) =SUM(W8/B8)*100
Interaction with other treatment 20 3 =SUM(C9/B9)*100 0 =SUM(E9/C9)*100 1 =SUM(G9/C9)*100 0 =SUM(I9/C9)*100 0 =SUM(K9/C9)*100 2 =SUM(M9/C9)*100 =SUM(B9*(F9/100)) =SUM((O9/B9)*100) =SUM(B9*(H9/100)) =SUM((Q9/B9)*100) =SUM(B9*(J9/100)) =SUM((S9/B9)*100) =SUM(B9*(L9/100)) =SUM((U9/B9)*100) =SUM(B9*(N9/100)) =SUM(W9/B9)*100
No longer clinically necessary 328 79 =SUM(C10/B10)*100 7 =SUM(E10/C10)*100 12 =SUM(G10/C10)*100 17 =SUM(I10/C10)*100 7 =SUM(K10/C10)*100 36 =SUM(M10/C10)*100 =SUM(B10*(F10/100)) =SUM((O10/B10)*100) =SUM(B10*(H10/100)) =SUM((Q10/B10)*100) =SUM(B10*(J10/100)) =SUM((S10/B10)*100) =SUM(B10*(L10/100)) =SUM((U10/B10)*100) =SUM(B10*(N10/100)) =SUM(W10/B10)*100
No reason documented 138 79 =SUM(C11/B11)*100 0 =SUM(E11/C11)*100 14 =SUM(G11/C11)*100 24 =SUM(I11/C11)*100 5 =SUM(K11/C11)*100 36 =SUM(M11/C11)*100 =SUM(B11*(F11/100)) =SUM((O11/B11)*100) =SUM(B11*(H11/100)) =SUM((Q11/B11)*100) =SUM(B11*(J11/100)) =SUM((S11/B11)*100) =SUM(B11*(L11/100)) =SUM((U11/B11)*100) =SUM(B11*(N11/100)) =SUM(W11/B11)*100
Patient refusing to take 7 1 =SUM(C12/B12)*100 0 =SUM(E12/C12)*100 0 =SUM(G12/C12)*100 0 =SUM(I12/C12)*100 1 =SUM(K12/C12)*100 0 =SUM(M12/C12)*100 =SUM(B12*(F12/100)) =SUM((O12/B12)*100) =SUM(B12*(H12/100)) =SUM((Q12/B12)*100) =SUM(B12*(J12/100)) =SUM((S12/B12)*100) =SUM(B12*(L12/100)) =SUM((U12/B12)*100) =SUM(B12*(N12/100)) =SUM(W12/B12)*100
Renal impairment 7 1 =SUM(C13/B13)*100 0 =SUM(E13/C13)*100 1 =SUM(G13/C13)*100 0 =SUM(I13/C13)*100 0 =SUM(K13/C13)*100 0 =SUM(M13/C13)*100 =SUM(B13*(F13/100)) =SUM((O13/B13)*100) =SUM(B13*(H13/100)) =SUM((Q13/B13)*100) =SUM(B13*(J13/100)) =SUM((S13/B13)*100) =SUM(B13*(L13/100)) =SUM((U13/B13)*100) =SUM(B13*(N13/100)) =SUM(W13/B13)*100
Route no longer appropriate 87 15 =SUM(C14/B14)*100 0 =SUM(E14/C14)*100 1 =SUM(G14/C14)*100 6 =SUM(I14/C14)*100 0 =SUM(K14/C14)*100 8 =SUM(M14/C14)*100 =SUM(B14*(F14/100)) =SUM((O14/B14)*100) =SUM(B14*(H14/100)) =SUM((Q14/B14)*100) =SUM(B14*(J14/100)) =SUM((S14/B14)*100) =SUM(B14*(L14/100)) =SUM((U14/B14)*100) =SUM(B14*(N14/100)) =SUM(W14/B14)*100
Suspected toxicity/high levels 4 1 =SUM(C15/B15)*100 0 =SUM(E15/C15)*100 1 =SUM(G15/C15)*100 0 =SUM(I15/C15)*100 0 =SUM(K15/C15)*100 0 =SUM(M15/C15)*100 =SUM(B15*(F15/100)) =SUM((O15/B15)*100) =SUM(B15*(H15/100)) =SUM((Q15/B15)*100) =SUM(B15*(J15/100)) =SUM((S15/B15)*100) =SUM(B15*(L15/100)) =SUM((U15/B15)*100) =SUM(B15*(N15/100)) =SUM(W15/B15)*100
Total 682 200 =SUM(C16/B16)*100 =SUM(E3:E15) =SUM(G3:G15) =SUM(I3:I15) =SUM(K3:K15) =SUM(M3:M15)
Sampled No %
Reactive =SUM(G3:G15) =SUM(B19/B21)*100
Proactve =SUM(E3:E15) =SUM(B20/B21)*100
Total =SUM(B19:B20) =SUM(C19:C20)
Extrapolation No % of all discontinued
Reactive =SUM(Q3:Q16) =SUM((B24/$B$29)*100)
Proactive =SUM(O3:O16) =SUM((B25/$B$29)*100)
Neither =SUM(S3:S15) =SUM((B26/$B$29)*100)
Not stopped =SUM(W3:W15) =SUM((B27/$B$29)*100)
Unclear =SUM(U3:U15) =SUM((B28/$B$29)*100)
Total =SUM(B24:B28) =SUM(C24:C28)
Total confirmed deprescribing =SUM(B24:B25)
% of all recorded stopped medicines deprescribed =SUM(B31/B16)*100
% prescribed meds deprescribed =SUM(B31/24552)*100
Overall totals N % of confirmed deprescribing
Reactive =B24 =SUM(B36/B31)*100
Proactive =B25 =SUM(B37/B31)*100
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Appendix 8 Distribution in patient rPATD responses when cross-tabulated 
with the primary outcome for Chapter 4 
311 
 
 
B1.d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
B1.d No Count 3 2 5 
% within 
Outcome_A2d 
6.8% 6.5% 6.7% 
Yes Count 41 29 70 
% within 
Outcome_A2d 
93.2% 93.5% 93.3% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
B2d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
B2d No Count 37 22 59 
% within 
Outcome_A2d 
84.1% 71.0% 78.7% 
Yes Count 7 9 16 
% within 
Outcome_A2d 
15.9% 29.0% 21.3% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
B3d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
B3d No Count 24 8 32 
% within 
Outcome_A2d 
54.5% 25.8% 42.7% 
Yes Count 20 23 43 
% within 
Outcome_A2d 
45.5% 74.2% 57.3% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
B4d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
B4d No Count 39 20 59 
% within 
Outcome_A2d 
88.6% 64.5% 78.7% 
Yes Count 5 11 16 
% within 
Outcome_A2d 
11.4% 35.5% 21.3% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
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B5d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
B5d No Count 32 5 37 
% within 
Outcome_A2d 
72.7% 16.1% 49.3% 
Yes Count 12 26 38 
% within 
Outcome_A2d 
27.3% 83.9% 50.7% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
A1d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
A1d No Count 35 7 42 
% within 
Outcome_A2d 
79.5% 22.6% 56.0% 
Yes Count 9 24 33 
% within 
Outcome_A2d 
20.5% 77.4% 44.0% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
 
A3d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
A3d No Count 37 8 45 
% within 
Outcome_A2d 
84.1% 25.8% 60.0% 
Yes Count 7 23 30 
% within 
Outcome_A2d 
15.9% 74.2% 40.0% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
A4d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
A4d No Count 30 8 38 
% within 
Outcome_A2d 
68.2% 25.8% 50.7% 
Yes Count 14 23 37 
% within 
Outcome_A2d 
31.8% 74.2% 49.3% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
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A5d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
A5d No Count 33 17 50 
% within 
Outcome_A2d 
75.0% 54.8% 66.7% 
Yes Count 11 14 25 
% within 
Outcome_A2d 
25.0% 45.2% 33.3% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
C1d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
C1d No Count 25 17 42 
% within 
Outcome_A2d 
56.8% 54.8% 56.0% 
Yes Count 19 14 33 
% within 
Outcome_A2d 
43.2% 45.2% 44.0% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
C2d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
C2d No Count 24 18 42 
% within 
Outcome_A2d 
54.5% 58.1% 56.0% 
Yes Count 20 13 33 
% within 
Outcome_A2d 
45.5% 41.9% 44.0% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
C3d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
C3d No Count 35 21 56 
% within 
Outcome_A2d 
79.5% 67.7% 74.7% 
Yes Count 9 10 19 
% within 
Outcome_A2d 
20.5% 32.3% 25.3% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
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C4d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
C4d No Count 36 25 61 
% within 
Outcome_A2d 
81.8% 80.6% 81.3% 
Yes Count 8 6 14 
% within 
Outcome_A2d 
18.2% 19.4% 18.7% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
C5d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
C6d No Count 37 27 64 
% within 
Outcome_A2d 
84.1% 87.1% 85.3% 
Yes Count 7 4 11 
% within 
Outcome_A2d 
15.9% 12.9% 14.7% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
I1d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
I1d No Count 1 8 9 
% within 
Outcome_A2d 
2.3% 25.8% 12.0% 
Yes Count 43 23 66 
% within 
Outcome_A2d 
97.7% 74.2% 88.0% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
I2d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
I2d No Count 6 9 15 
% within 
Outcome_A2d 
13.6% 29.0% 20.0% 
Yes Count 38 22 60 
% within 
Outcome_A2d 
86.4% 71.0% 80.0% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
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I3d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
I3d No Count 8 5 13 
% within 
Outcome_A2d 
18.2% 16.1% 17.3% 
Yes Count 36 26 62 
% within 
Outcome_A2d 
81.8% 83.9% 82.7% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
I4d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
I4d No Count 15 10 25 
% within 
Outcome_A2d 
34.1% 32.3% 33.3% 
Yes Count 29 21 50 
% within 
Outcome_A2d 
65.9% 67.7% 66.7% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
 
I5d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 No 
I5d No Count 9 5 14 
% within 
Outcome_A2d 
20.5% 16.1% 18.7% 
Yes Count 35 26 61 
% within 
Outcome_A2d 
79.5% 83.9% 81.3% 
Total Count 44 31 75 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
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Key 
Reference Corresponding rPATD item 
Outcome_A2d I would like to try stopping one of my 
medicines to see how I feel without it 
B1d I feel the National Health Service (NHS) 
spends a lot of money on my medicines 
B2d Taking my medicines every day is very 
inconvenient 
B3d I feel that I am taking a large number of 
medicines 
B5d I feel that my medicines are a burden to 
me 
B6d Sometimes I think I take too many 
medicines 
A1d I feel that I may be taking one or more 
medicines that I no longer need 
A3d I would like my doctor to reduce the 
dose of one or more of my medicines 
A4d I think one or more of my medicines 
may not be working 
A5d I believe one or more of my medicines 
may be currently giving me side effects 
C1d I would be reluctant to stop a medicine 
that I had been taking for a long time 
C2d If one of my medicines was stopped, I 
would be worried about missing out on 
future benefits 
C3d I get stressed whenever changes are 
made to my medicines 
C4d If my doctor recommended stopping a 
medicine, I would feel that he/she was 
giving up on me 
C5d I have had a bad experience when 
stopping a medicine before 
I1d I have a good understanding of the 
reasons I was prescribed each of my 
medicines 
I2d I know exactly what medicines I am 
currently taking, and/or I keep an up-to-
date list of my medicines 
I3d I like to know as much as possible 
about my medicines 
I4d I like to be involved in making decisions 
about my medicines with my doctors 
I5d I always ask my doctor, pharmacist or 
other healthcare professional if there is 
something I don’t understand about my 
medicines 
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Appendix 9 Distribution in carer rPATD responses when cross-tabulated 
with the primary outcome for Chapter 4 
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B1d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 1.00 
B1d .00 Count 4 1 5 
% within 
Outcome_A2d 
13.8% 
2.1% 
6.6% 
1.00 Count 25 46 71 
% within 
Outcome_A2d 
86.2% 97.9% 93.4% 
Total Count 29 47 76 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
B2d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 1.00 
B2d .00 Count 9 9 18 
% within 
Outcome_A2d 
31.0% 19.1% 23.7% 
1.00 Count 20 38 58 
% within 
Outcome_A2d 
69.0% 80.9% 76.3% 
Total Count 29 47 76 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
B3d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 1.00 
B3d .00 Count 22 23 45 
% within 
Outcome_A2d 
75.9% 48.9% 59.2% 
1.00 Count 7 24 31 
% within 
Outcome_A2d 
24.1% 51.1% 40.8% 
Total Count 29 47 76 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
 
B4d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 1.00 
B4d .00 Count 19 10 29 
% within 
Outcome_A2d 
65.5% 21.3% 38.2% 
1.00 Count 10 37 47 
% within 
Outcome_A2d 
34.5% 78.7% 61.8% 
Total Count 29 47 76 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
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A1d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 1.00 
A1d .00 Count 19 7 26 
% within 
Outcome_A2d 
65.5% 14.9% 34.2% 
1.00 Count 10 40 50 
% within 
Outcome_A2d 
34.5% 85.1% 65.8% 
Total Count 29 47 76 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
A3d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 1.00 
A3d .00 Count 24 5 29 
% within 
Outcome_A2d 
82.8% 10.6% 38.2% 
1.00 Count 5 42 47 
% within 
Outcome_A2d 
17.2% 89.4% 61.8% 
Total Count 29 47 76 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
A4d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 1.00 
A4d .00 Count 18 9 27 
% within 
Outcome_A2d 
62.1% 19.1% 35.5% 
1.00 Count 11 38 49 
% within 
Outcome_A2d 
37.9% 80.9% 64.5% 
Total Count 29 47 76 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
A5d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 1.00 
A5d .00 Count 18 13 31 
% within 
Outcome_A2d 
62.1% 27.7% 40.8% 
1.00 Count 11 34 45 
% within 
Outcome_A2d 
37.9% 72.3% 59.2% 
Total Count 29 47 76 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
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C1d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 1.00 
C1d .00 Count 5 17 22 
% within 
Outcome_A2d 
17.2% 36.2% 28.9% 
1.00 Count 24 30 54 
% within 
Outcome_A2d 
82.8% 63.8% 71.1% 
Total Count 29 47 76 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
C2d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 1.00 
C2d .00 Count 16 28 44 
% within 
Outcome_A2d 
55.2% 59.6% 57.9% 
1.00 Count 13 19 32 
% within 
Outcome_A2d 
44.8% 40.4% 42.1% 
Total Count 29 47 76 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
C3d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 1.00 
C3d .00 Count 15 29 44 
% within 
Outcome_A2d 
51.7% 61.7% 57.9% 
1.00 Count 14 18 32 
% within 
Outcome_A2d 
48.3% 38.3% 42.1% 
Total Count 29 47 76 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
C4d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 1.00 
C5d .00 Count 27 38 65 
% within 
Outcome_A2d 
93.1% 80.9% 85.5% 
1.00 Count 2 9 11 
% within 
Outcome_A2d 
6.9% 19.1% 14.5% 
Total Count 29 47 76 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
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I1d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 1.00 
I1d .00 Count 3 9 12 
% within 
Outcome_A2d 
10.7% 20.5% 16.7% 
1.00 Count 25 35 60 
% within 
Outcome_A2d 
89.3% 79.5% 83.3% 
Total Count 28 44 72 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
I2d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 1.00 
I2d .00 Count 1 2 3 
% within 
Outcome_A2d 
3.6% 4.5% 
4.2% 
1.00 Count 27 42 69 
% within 
Outcome_A2d 
96.4% 95.5% 95.8% 
Total Count 28 44 72 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
I3d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 1.00 
I3d .00 Count 4 8 12 
% within 
Outcome_A2d 
14.3% 18.2% 16.7% 
1.00 Count 24 36 60 
% within 
Outcome_A2d 
85.7% 81.8% 83.3% 
Total Count 28 44 72 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
 
I4d * Outcome_A2d Crosstabulation 
 
Outcome_A2d 
Total .00 1.00 
I4d .00 Count 2 9 11 
% within 
Outcome_A2d 
7.1% 20.5% 15.3% 
1.00 Count 26 35 61 
% within 
Outcome_A2d 
92.9% 79.5% 84.7% 
Total Count 28 44 72 
% within 
Outcome_A2d 
100.0% 100.0% 100.0% 
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Key 
Reference Corresponding rPATD item 
Outcome_A2d I would like the doctor to try stopping 
one of my care recipient’s medicines to 
see how they feel without it 
B1d I feel the National Health Service (NHS) 
spends a lot of money on my care 
recipient’s medicines 
B2d I feel that the person I care for is taking 
a large number of medicines 
B3d I feel that my care recipient’s medicines 
are a burden to them 
B4d Sometimes I think the person I care for 
takes too many medicines 
A1d I feel that the person that I care for may 
be taking one or more medicines that 
they no longer need 
A3d I would like the doctor to reduce the 
dose of one or more of my care 
recipient’s medicines 
A4d I think one or more of my care 
recipient’s medicines may not be 
working 
A5d I believe one or more of my care 
recipient’s medicines may be currently 
giving them side effects 
C1d I would be reluctant to stop one of my 
care recipient’s medicines that they had 
been taking for a long time 
C2d I get stressed whenever changes are 
made to my care recipient’s medicines 
C3d I feel that if I agreed to stopping one of 
my care recipient’s medicines then this 
is giving up on them 
C4d The person that I care for has had a 
bad experience when stopping a 
medicine before 
I1d I know exactly what medicines the 
person that I care for is currently taking 
and/or I have an up-to-date list of their 
medicines 
I2d I like to know as much as possible 
about my care recipient’s medicines 
I3d I like to be involved in making decisions 
about my care recipients medicines 
with their doctors 
I4d I always ask the doctor, pharmacist or 
other healthcare professional if there is 
something I don’t understand about my 
care recipient’s medicines 
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Appendix 10 Study protocol for Chapter 5 
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Appendix 12 Consolidated criteria for reporting qualitative research (COREQ) 
checklist for Chapter 5 
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Item 
No. 
Topic Guide Questions/Description Response / reported on Page No. 
Domains 1: Research team and reflexivity 
Personal characteristics 
1 Interviewer/facilitator Which author/s conducted the interview or 
focus group? 
SS and DB / Page 4 
2 Credentials What were the researcher’s credentials? E.g. 
PhD, MD 
SS’s credentials were ‘MPharm’ and DB’s 
credentials were ‘BPharm, PhD’ / Not reported in 
manuscript 
3 Occupation What was their occupation at the time of the 
study? 
SS was a UK registered pharmacist who was 
undertaking a PhD in pharmacy practice and DB 
was a UK registered pharmacist and Senior 
Lecturer in Health Services Research / Page 4 
4 Gender Was the researcher male or female? SS (male) and DB (female) / Not reported in 
manuscript 
5 Experience and training What experience or training did the 
researcher have? 
SS completed training in qualitative research 
methodology and the principles and practice of 
behaviour change research / Not reported in 
manuscript 
Relationship with participants 
6 Relationship established Was a relationship established prior to study 
commencement? 
There were no established relationships between 
the researchers and the focus group participants. 
A relationship was established between the 
researchers and gatekeepers for each group of 
participants for the purposes of recruitment / 
Page 3 
7 Participant knowledge of the 
interviewer 
What did the participants know about the 
researcher? e.g. personal goals, reasons for 
doing the research 
Participants were informed that the researchers 
(SS/DB) were pharmacists and they were 
informed of the research aims / Pages 3&4 
8 Interviewer characteristics What characteristics were reported about the 
inter viewer/facilitator? e.g. Bias, 
Participants were informed that the researchers 
(SS/DB) were pharmacists, of the research aims 
 382 
 
assumptions, reasons and interests in the 
research topic 
and that the research was being undertaken as 
part of SS’s PhD / Not reported in manuscript 
Domain 2: Study design 
Theoretical framework 
9 Methodological orientation and 
Theory 
What methodological orientation was stated 
to underpin the study? e.g. grounded theory, 
discourse analysis, ethnography, 
phenomenology, content analysis 
Thematic analysis as described by Braun and 
Clark underpinned by the Theoretical Domains 
Framework / Pages 4&5 
Participant selection 
10 Sampling How were participants selected? e.g. 
purposive, convenience, consecutive, 
snowball 
Participants were purposively sampled across 
four UK hospitals to maximise variation in 
demographic and practitioner seniority grade / 
Page 3 
11 Method of approach How were participants approached? e.g. 
face-to-face, telephone, mail, email 
All potentially eligible participants at the hospital 
sites were invited by email from a nominated 
gatekeeper of their respective specialities / Page 
3 
12 Sample size How many participants were in the study? 54 participants (28 geriatricians and 26 
pharmacists) / Page 5 
13 Non-participation How many people refused to participate or 
dropped out? Reasons? 
All geriatricians and pharmacists who were 
purposively sampled agreed to participate in the 
focus groups. No participants dropped out. / 
Page 5 
Setting 
14 Setting of data collection Where was the data collected? e.g. home, 
clinic, workplace 
All focus groups were convened in meeting 
rooms and the respective hospital sites / Page 4 
15 Presence of non- participants Was anyone else present besides the 
participants and researchers? 
No / Not explicitly reported in manuscript 
16 Description of sample  What are the important characteristics of the 
sample? e.g. demographic data, date 
Refer to table 1 for demographic data and data 
were collected between February and May 2018 
/ Pages 4&5 
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Data collection 
17 Interview guide Were questions, prompts, guides provided by 
the authors? Was it pilot tested? 
A semi-structured topic guide was designed to 
illicit participants’ views regarding the following: 
Perception of existing deprescribing practice 
Barriers to increasing deprescribing practice 
Enablers for increasing deprescribing practice 
 
Probes to explore the 14 TDF domains were also 
included and used where necessary. See 
supplementary file 2 for the full topic guide / 
Pages 3&4 
18 Repeat interviews  Were repeat inter views carried out? If yes, 
how many?  
No / Not explicitly reported in manuscript 
19 Audio/visual recording Did the research use audio or visual 
recording to collect the data? 
Focus groups discussions were audio recorded / 
Page 4 
20 Field notes Were field notes made during and/or after the 
interview or focus group? 
Field notes were made during the focus groups 
and referred to during analysis / Page 4 
21 Duration What was the duration of the interviews or 
focus group? 
The mean (SD) focus group duration was 55 (5) 
minutes / Page 5 
22 Data saturation Was data saturation discussed? To determine whether data saturation had been 
achieved, the principles for deciding saturation in 
theory-based qualitative studies outlined by 
Francis et al. were followed. Themes were 
recurring after the third focus group and no new 
themes emerged after the sixth focus group. / 
Pages 3&6 
23 Transcripts returned Were transcripts returned to participants for 
comment and/or correction 
No / Not explicitly reported in manuscript 
Domain 3: Analysis and findings 
Data analysis 
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24 Number of data coders How many data coders coded the data? SS inductively coded for the thematic analysis 
which was checked by MJT (qualitative research 
expert). SS and DB mapped codes to the TDF 
which was checked by JT (health psychologist). / 
Pages 4&5 
25 Description of the coding tree Did authors provide a description of the 
coding tree? 
The TDF was used as a basis for the coding tree 
(refer to table 2) / Pages 11-15 
26 Derivation of themes Were themes identified in advance or derived 
from the data? 
Inductive and deductive approaches were 
utilised to identify the key themes relating to 
deprescribing for older people in hospital. The 
phase 1 thematic analysis involved inductive 
coding of data and thus no pre-determined 
themes were applied. For the phase 2 mapping 
to the TDF, the pre-defined domains were 
deductively applied to the phase 1 data. / Pages 
4&5 
27 Software  What software, if applicable, was used to 
manage the data? 
Data were managed using NVivo 11 (QSR 
International, Melbourne, Australia) / Page 4 
28 Participant checking  Did participants provide feedback on the 
findings? 
No / Not explicitly reported in manuscript 
Reporting 
29 Quotations presented Were participant quotations presented to 
illustrate the themes/findings? Was each 
quotation identified? e.g. participant number 
Quotations are provided to contextualise novel 
concepts and participant/hospital numbers are 
provided. / Pages 6-9 
30 Data and findings consistent Was there consistency between the data 
presented and the findings? 
Data including quotations are provided in a 
manner consistent with the findings / Refer to 
results and discussion 
31 Clarity of major themes Were major themes clearly presented in the 
findings? 
The four major themes are presented and 
explained in the results section / Pages 6-9 
32 Clarity of minor themes Is there a description of diverse cases or 
discussion of minor themes? 
Divergence between geriatricians and 
pharmacists are reported and explained in the 
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results and discussed in the discussion. The 
TDF domains which were mapped onto the four 
major themes and the constituent inductive 
codes (and the relationships between the three) 
are presented in table 2. / Refer to results and 
dicsussion 
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